data_6kg8_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6kg8 _Structure_validation_residue.Date_analyzed 2020-07-03 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.449 -0.489 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.42 ' HZ1' ' CG ' ' A' ' 102' ' ' ASP . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.537 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.453 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.418 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.418 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 36.4 m-80 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.665 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.665 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.453 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.42 ' CG ' ' HZ1' ' A' ' 22' ' ' LYS . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HB3' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.516 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.534 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.513 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.534 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.527 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p . . . . . 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 . . . . . 0 N--CA 1.45 -0.443 0 CA-C-O 120.713 0.292 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.552 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.451 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.439 ' HZ1' ' HB2' ' A' ' 47' ' ' LYS . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.473 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.552 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.414 HG22 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.414 ' CZ ' HG22 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.512 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.478 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.494 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.433 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 4.5 m120 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.512 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p . . . . . 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.497 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER . . . . . 0 CA--C 1.502 -0.9 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.554 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.51 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . 0.429 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 8.0 mm100 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.411 HG11 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.58 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.496 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.441 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . 0.405 ' HZ1' ' HB2' ' A' ' 51' ' ' LYS . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.461 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 59' ' ' LEU . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.705 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.441 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.414 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.705 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.424 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.58 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.554 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.535 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.497 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.548 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p . . . . . 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 . . . . . 0 N--CA 1.412 -2.365 0 CA-C-O 120.899 0.381 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.591 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.527 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.563 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.45 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.407 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.569 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.616 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.563 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.407 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.481 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.412 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.553 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.441 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.591 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.591 ' HD3' ' O ' ' A' ' 6' ' ' VAL . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.412 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p . . . . . 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 . . . . . 0 N--CA 1.421 -1.896 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.476 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.427 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.427 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.657 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.515 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.416 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.591 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.423 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.423 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.407 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.443 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.416 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.515 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.416 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.432 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.476 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.488 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p . . . . . 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 CA--C 1.478 -1.82 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.632 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.641 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.445 ' HB2' ' HB2' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.446 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.654 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.41 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.654 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.641 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.632 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.462 ' CE1' HG23 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.41 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.445 ' HB2' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.416 ' HE3' ' HA ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.406 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.401 ' CD ' ' HG ' ' A' ' 31' ' ' SER . 2.3 pm0 . . . . . 0 N--CA 1.438 -1.059 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.418 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.418 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.401 ' HG ' ' CD ' ' A' ' 4' ' ' GLU . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.415 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.431 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.43 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.401 ' C ' ' H ' ' A' ' 66' ' ' TYR . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 64' ' ' ASP . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.576 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.43 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.576 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.416 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.416 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.41 HG23 ' CE2' ' A' ' 100' ' ' TYR . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.41 ' CE2' HG23 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.554 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HZ3' ' HA ' ' A' ' 136' ' ' ALA . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . 0.493 ' HA ' ' HZ3' ' A' ' 134' ' ' LYS . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.493 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.48 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p . . . . . 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.424 -1.748 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.521 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.402 ' HG3' ' O ' ' A' ' 59' ' ' LEU . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.498 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.433 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.51 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.407 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.518 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.533 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.46 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.407 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 1.6 m120 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p . . . . . 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.513 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.568 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.546 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 56.3 m-80 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.546 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.568 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.413 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.413 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.504 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.531 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.513 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.457 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p . . . . . 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 CA--C 1.484 -1.586 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.431 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.518 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.43 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.406 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.43 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 40.8 m-80 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.58 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.443 HD21 ' N ' ' A' ' 89' ' ' ASN . 0.7 OUTLIER -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.431 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.429 HG22 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.429 ' CZ ' HG22 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.557 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.488 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.509 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 . . . . . 0 N--CA 1.44 -0.96 0 CA-C-O 121.724 0.773 . . . . 0.0 112.317 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.406 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HZ3' ' HB2' ' A' ' 47' ' ' LYS . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.554 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.435 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.406 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.624 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.554 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.415 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.509 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.449 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 . . . . . 0 N--CA 1.427 -1.605 0 CA-C-O 121.343 0.592 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.499 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.481 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.439 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.552 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.499 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.439 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.461 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.534 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.495 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p . . . . . 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.427 -1.599 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.491 ' HA ' ' O ' ' A' ' 133' ' ' ILE . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.401 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.409 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 81' ' ' THR . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.427 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.432 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.432 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.454 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.427 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p . . . . . 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.403 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER . . . . . 0 N--CA 1.446 -0.635 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.476 HG13 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.403 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.447 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.413 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.585 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.404 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.425 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.427 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.438 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.438 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.447 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.506 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.517 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.517 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.426 ' CG ' ' HZ1' ' A' ' 134' ' ' LYS . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.506 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p . . . . . 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.456 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 . . . . . 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.573 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.406 ' HZ3' ' HB2' ' A' ' 47' ' ' LYS . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.458 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.573 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.441 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.46 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.477 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.448 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.458 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p . . . . . 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.423 -1.793 0 CA-C-O 120.996 0.427 . . . . 0.0 112.057 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.421 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.528 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.437 HG11 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . 0.417 ' HB2' ' HZ3' ' A' ' 51' ' ' LYS . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.573 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.437 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.573 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.421 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.421 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.427 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.553 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.553 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.427 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p . . . . . 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.46 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.445 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.453 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.453 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.562 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.422 ' HB2' ' HG ' ' A' ' 67' ' ' SER . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.427 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . 0.556 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.556 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.426 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.427 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p . . . . . 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.564 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.431 -1.393 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.534 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.412 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . 0.564 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 32.1 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.568 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.442 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.418 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.568 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.596 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.447 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.447 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p . . . . . 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . 0.41 ' HZ2' ' HB3' ' A' ' 22' ' ' LYS . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.568 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.43 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.446 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.462 ' O ' ' HD2' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.416 ' HB2' ' HZ1' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . 0.43 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.442 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.568 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.414 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.551 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.442 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p . . . . . 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.443 -0.815 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.496 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.451 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.574 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.496 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.446 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' LEU . . . . . 0.515 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.54 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.418 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.418 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.435 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.515 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' LYS . . . . . 0.446 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p . . . . . 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.327 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 11.8 m -88.36 79.11 7.82 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-O 120.951 0.405 . . . . 0.0 110.301 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -167.67 144.6 4.31 Favored 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 177.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.8 m 75.18 -59.49 0.54 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 124.472 1.109 . . . . 0.0 111.334 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.2 p -79.09 -22.59 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 CA-C-O 122.273 1.035 . . . . 0.0 108.681 176.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp -126.12 130.85 51.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.481 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -93.02 139.69 30.26 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 124.466 1.104 . . . . 0.0 109.765 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -116.9 -179.73 3.78 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.481 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.42 ' HZ1' ' CG ' ' A' ' 102' ' ' ASP . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.537 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HG3' ' HB3' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.453 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.418 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.418 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 36.4 m-80 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.665 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.665 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.453 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.42 ' CG ' ' HZ1' ' A' ' 22' ' ' LYS . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.418 ' HB3' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.516 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.534 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.513 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.534 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.527 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p -71.66 -44.82 63.62 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 75.28 35.15 49.23 Favored Glycine 0 N--CA 1.418 -2.529 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.979 -177.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.0 m -75.71 86.32 2.74 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-O 121.599 0.714 . . . . 0.0 110.21 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -171.38 169.63 3.04 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -48.9 -40.09 39.9 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.205 1.937 . . . . 0.0 111.237 171.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 55.7 m -155.13 -66.19 0.13 Allowed 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 173.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 35.2 p . . . . . 0 C--O 1.239 0.507 0 C-N-CA 124.552 1.141 . . . . 0.0 108.057 176.137 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.916 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 41.0 m -74.37 123.22 24.23 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-O 121.239 0.543 . . . . 0.0 111.728 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.39 -12.59 58.92 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.446 176.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 55.1 m -129.58 139.23 51.54 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 59.7 t -82.22 -38.77 15.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.2 mttp -100.8 143.61 30.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.108 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -147.08 98.13 2.99 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 169.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 -97.37 -174.15 2.85 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.649 -173.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.552 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.451 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.439 ' HB2' ' HZ1' ' A' ' 47' ' ' LYS . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.473 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.552 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.414 HG22 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.414 ' CZ ' HG22 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.436 ' O ' ' HA ' ' A' ' 150' ' ' THR . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.512 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.478 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.494 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.433 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 4.5 m120 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.512 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p -88.23 130.8 34.98 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.17 146.28 14.32 Favored Glycine 0 N--CA 1.419 -2.488 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.957 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.6 t -82.98 -30.73 28.0 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 174.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -155.13 147.4 17.52 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 178.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -67.88 140.05 49.39 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 121.907 1.738 . . . . 0.0 109.807 176.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 107' ' ' SER . 94.2 m 71.13 121.37 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.21 0 CA-C-O 122.201 1.001 . . . . 0.0 112.587 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.428 -1.566 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.844 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.883 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 17.0 m -85.06 80.91 9.1 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.359 0.599 . . . . 0.0 109.536 178.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -103.3 -10.66 18.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.766 -178.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 4.6 m -91.85 117.87 30.18 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.337 -177.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.3 t -81.03 102.02 6.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -78.98 138.59 38.12 Favored 'General case' 0 N--CA 1.417 -2.121 0 CA-C-O 122.088 0.947 . . . . 0.0 110.8 -176.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -148.56 100.26 3.1 Favored 'General case' 0 C--N 1.269 -2.897 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 177.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.497 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER -92.42 171.61 8.93 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -172.063 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.554 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.51 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . 0.429 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 8.0 mm100 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.411 HG11 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.58 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.496 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.441 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . 0.405 ' HZ1' ' HB2' ' A' ' 51' ' ' LYS . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.461 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 59' ' ' LEU . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.705 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.441 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.414 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.705 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.424 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.58 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.554 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.422 ' HB1' ' HA2' ' A' ' 146' ' ' GLY . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.548 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.535 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.497 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.499 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.548 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p -74.1 -41.86 60.98 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.422 ' HA2' ' HB1' ' A' ' 111' ' ' ALA . . . 174.19 -92.73 0.09 OUTLIER Glycine 0 CA--C 1.475 -2.406 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.117 178.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.42 ' O ' ' HD3' ' A' ' 149' ' ' PRO . 5.8 p -150.13 158.78 44.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 178.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -88.48 107.72 18.41 Favored Pre-proline 0 C--N 1.31 -1.116 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -177.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.42 ' HD3' ' O ' ' A' ' 147' ' ' SER . 96.3 Cg_endo -89.24 146.31 5.24 Favored 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 122.225 1.95 . . . . 0.0 113.171 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.1 t -76.04 107.8 8.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 174.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.6 m . . . . . 0 C--N 1.298 -1.661 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.024 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.871 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 50.2 m -132.64 13.44 4.46 Favored 'General case' 0 C--N 1.317 -0.823 0 O-C-N 122.234 -0.568 . . . . 0.0 110.859 178.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -72.92 -24.4 60.82 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.037 0.446 . . . . 0.0 112.052 -175.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 19.5 m -131.58 119.67 21.79 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.34 -42.72 17.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mmpt? -147.13 105.79 3.82 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 174.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -160.44 156.33 25.87 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -129.14 163.44 25.51 Favored 'General case' 0 N--CA 1.412 -2.365 0 C-N-CA 122.657 0.383 . . . . 0.0 110.28 -173.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.591 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 147' ' ' SER . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.527 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.563 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.45 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.407 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.569 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.616 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.616 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.563 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.407 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.481 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.412 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.553 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.441 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.591 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.591 ' HD3' ' O ' ' A' ' 6' ' ' VAL . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.412 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.411 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p -93.66 110.77 22.37 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 50.93 -124.41 20.58 Favored Glycine 0 CA--C 1.522 0.493 0 O-C-N 124.487 1.117 . . . . 0.0 114.497 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.432 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 66.9 m -149.64 144.3 26.06 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 124.073 0.949 . . . . 0.0 108.726 177.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -97.52 112.38 61.09 Favored Pre-proline 0 C--N 1.321 -0.648 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -69.16 -24.63 32.19 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.246 1.964 . . . . 0.0 113.821 -177.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.8 m -142.61 102.43 4.06 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.534 -0.729 . . . . 0.0 111.199 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 16.4 t . . . . . 0 N--CA 1.425 -1.71 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.12 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 20.9 m -96.41 2.57 52.74 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 122.48 0.312 . . . . 0.0 110.811 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.31 96.26 0.07 Allowed 'General case' 0 C--N 1.346 0.441 0 C-N-CA 124.884 1.274 . . . . 0.0 110.431 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 33.1 t -105.13 168.0 9.34 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.052 -0.977 . . . . 0.0 108.803 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 p -84.5 -23.32 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.087 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.8 tttm -142.92 145.7 33.3 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.419 -0.512 . . . . 0.0 110.907 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.5 m120 61.67 73.25 0.48 Allowed 'General case' 0 C--N 1.312 -1.042 0 C-N-CA 126.779 2.032 . . . . 0.0 112.352 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -118.94 164.68 15.1 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 113.861 -1.518 . . . . 0.0 110.473 -177.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.476 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.427 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.427 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.657 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.416 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.591 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.423 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.423 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.589 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.488 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.407 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.443 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.416 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.515 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.416 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.432 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.476 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.488 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p -97.87 112.34 24.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -126.62 92.75 0.39 Allowed Glycine 0 N--CA 1.427 -1.964 0 C-N-CA 119.916 -1.135 . . . . 0.0 113.49 -172.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 38.0 m -86.89 -25.62 24.35 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 54.39 81.9 0.25 Allowed Pre-proline 0 C--O 1.24 0.575 0 C-N-CA 126.047 1.739 . . . . 0.0 113.65 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -71.83 97.28 0.81 Allowed 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 121.942 1.761 . . . . 0.0 109.935 176.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 p 64.28 146.33 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.683 1.993 . . . . 0.0 112.013 -174.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 41.8 m . . . . . 0 C--N 1.293 -1.861 0 O-C-N 121.144 -0.973 . . . . 0.0 108.55 179.465 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.732 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 9.2 p -74.44 -42.24 59.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.895 0.379 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -83.8 138.22 33.34 Favored 'General case' 0 N--CA 1.434 -1.237 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.556 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 11.4 p -148.13 75.93 1.35 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 121.889 0.852 . . . . 0.0 109.5 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 47.9 t -91.42 101.85 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 CA-C-N 114.41 -1.268 . . . . 0.0 107.957 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -81.36 168.43 18.39 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-O 121.146 0.498 . . . . 0.0 110.531 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.68 130.78 35.18 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.464 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -100.89 145.73 28.23 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 124.089 0.956 . . . . 0.0 108.449 -177.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.632 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.641 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.445 ' HB2' ' HB2' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.446 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.654 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.41 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.654 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.641 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.632 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.462 HG23 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.462 ' CE1' HG23 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.41 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.446 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.445 ' HB2' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.416 ' HE3' ' HA ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.426 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.406 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p -96.91 101.51 13.11 Favored 'General case' 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.33 104.96 0.72 Allowed Glycine 0 C--N 1.274 -2.914 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -175.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.9 m -60.2 -46.84 88.34 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -154.89 141.25 13.08 Favored Pre-proline 0 N--CA 1.436 -1.162 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.28 49.08 3.09 Favored 'Trans proline' 0 CA--C 1.551 1.328 0 C-N-CA 122.964 2.443 . . . . 0.0 111.946 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 23.3 m -133.55 96.03 3.62 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.49 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 47.0 m . . . . . 0 C--N 1.313 -0.994 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.282 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.254 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.7 m -94.0 126.55 39.28 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -102.44 71.06 1.19 Allowed 'General case' 0 N--CA 1.429 -1.504 0 CA-C-O 121.717 0.77 . . . . 0.0 109.797 178.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 24.7 t -108.69 172.09 7.05 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 176.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 68.0 t 59.94 78.66 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-O 122.579 1.18 . . . . 0.0 107.831 -173.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.452 ' O ' ' HB2' ' A' ' 3' ' ' ASN . 29.8 mtpp -83.14 -162.57 0.62 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.134 -174.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.452 ' HB2' ' O ' ' A' ' 2' ' ' LYS . 21.5 m120 82.73 107.82 0.06 Allowed 'General case' 0 CA--C 1.503 -0.829 0 C-N-CA 125.322 1.449 . . . . 0.0 110.015 -178.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.401 ' CD ' ' HG ' ' A' ' 31' ' ' SER . 2.3 pm0 -144.38 178.96 7.55 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.063 -176.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.418 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.418 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.401 ' HG ' ' CD ' ' A' ' 4' ' ' GLU . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.415 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.431 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.43 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.409 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.401 ' C ' ' H ' ' A' ' 66' ' ' TYR . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 64' ' ' ASP . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.576 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.43 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.576 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.416 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.416 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.588 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.41 HG23 ' CE2' ' A' ' 100' ' ' TYR . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.41 ' CE2' HG23 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.554 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.514 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HZ3' ' HA ' ' A' ' 136' ' ' ALA . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . 0.493 ' HA ' ' HZ3' ' A' ' 134' ' ' LYS . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.493 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.48 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p -90.13 129.87 36.36 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -77.88 64.76 3.31 Favored Glycine 0 C--O 1.219 -0.791 0 O-C-N 123.341 0.401 . . . . 0.0 112.193 -176.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -88.78 25.29 1.8 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 123.77 0.828 . . . . 0.0 111.049 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -77.74 144.72 69.45 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -64.42 103.02 0.42 Allowed 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.914 1.742 . . . . 0.0 111.043 177.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.6 p -108.54 -48.03 3.4 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.676 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 22.8 m . . . . . 0 C--O 1.259 1.587 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 179.619 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.952 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 47.1 m -95.49 94.65 7.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.75 -80.96 0.04 OUTLIER 'General case' 0 C--O 1.238 0.462 0 C-N-CA 125.776 1.63 . . . . 0.0 111.041 -176.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 65.7 m 58.61 23.99 11.56 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.329 1.052 . . . . 0.0 112.271 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.9 p -95.73 -21.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.267 -176.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.0 mttp 65.44 -176.61 0.18 Allowed 'General case' 0 C--N 1.352 0.693 0 C-N-CA 124.497 1.119 . . . . 0.0 111.53 -176.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.493 ' HB3' HG22 ' A' ' 133' ' ' ILE . 3.7 m-20 -101.0 121.37 41.65 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 105.643 -1.984 . . . . 0.0 105.643 171.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -97.77 152.74 18.83 Favored 'General case' 0 C--N 1.282 -2.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.947 -173.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.521 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.407 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.402 ' HG3' ' O ' ' A' ' 59' ' ' LEU . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.498 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.422 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.433 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.51 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.407 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.415 ' HB1' ' O ' ' A' ' 146' ' ' GLY . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.407 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.518 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.533 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.493 HG22 ' HB3' ' A' ' 3' ' ' ASN . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.46 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.407 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 1.6 m120 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p -104.41 116.55 32.33 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.427 ' C ' ' HG ' ' A' ' 147' ' ' SER . . . 95.49 162.04 33.86 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 120.802 -0.713 . . . . 0.0 113.745 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.427 ' HG ' ' C ' ' A' ' 146' ' ' GLY . 47.3 m -158.68 178.88 9.64 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 123.676 0.79 . . . . 0.0 109.362 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -94.3 104.11 12.81 Favored Pre-proline 0 N--CA 1.429 -1.522 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.47 -3.84 13.3 Favored 'Trans proline' 0 N--CA 1.48 0.685 0 C-N-CA 123.194 2.596 . . . . 0.0 114.424 -171.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.7 m 62.42 48.0 4.86 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-O 122.493 1.139 . . . . 0.0 108.32 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.427 -1.583 0 CA-C-N 114.263 -1.335 . . . . 0.0 110.357 -178.092 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.829 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 23.5 m 63.6 17.73 10.6 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.528 1.131 . . . . 0.0 112.131 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -123.86 90.9 3.35 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.592 0.71 . . . . 0.0 111.001 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 50.8 m -99.17 112.84 24.89 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.9 -32.62 23.95 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? 54.83 114.86 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.63 0 C-N-CA 126.937 2.095 . . . . 0.0 112.918 -173.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -103.75 133.62 48.44 Favored 'General case' 0 C--N 1.263 -3.157 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.146 -178.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.513 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 -105.2 -169.21 1.57 Allowed 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 123.317 0.647 . . . . 0.0 109.947 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.568 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.534 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.546 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 56.3 m-80 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.546 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.568 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.413 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.413 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.504 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.531 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.442 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.513 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.457 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p -77.79 134.13 38.09 Favored 'General case' 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -87.75 65.02 3.6 Favored Glycine 0 N--CA 1.441 -0.977 0 CA-C-N 115.388 -0.823 . . . . 0.0 113.688 -177.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -130.25 -48.44 1.09 Allowed 'General case' 0 C--N 1.297 -1.686 0 O-C-N 122.552 -0.381 . . . . 0.0 109.986 175.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 69.19 155.14 0.15 Allowed Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.78 1.632 . . . . 0.0 111.313 -178.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -67.26 -22.01 47.06 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.53 1.487 . . . . 0.0 110.475 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.2 m 61.3 72.5 0.51 Allowed 'General case' 0 N--CA 1.431 -1.398 0 CA-C-O 123.096 1.427 . . . . 0.0 108.955 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.413 -2.275 0 CA-C-N 112.919 -1.946 . . . . 0.0 106.252 -179.122 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.164 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 40.1 m -81.65 126.39 31.71 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -141.55 131.2 24.06 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 21.2 t 68.36 21.94 8.14 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.549 1.14 . . . . 0.0 109.941 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 90.8 t -87.23 139.01 18.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.829 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.678 -177.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -92.49 129.08 38.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . 0.252 18.4 m120 73.64 80.92 0.13 Allowed 'General case' 0 CA--C 1.5 -0.948 0 C-N-CA 125.484 1.513 . . . . 0.0 110.407 -174.113 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -109.08 153.7 23.3 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 112.352 -2.204 . . . . 0.0 110.337 -175.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.431 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.518 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.635 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.635 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.431 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.43 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.406 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.43 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 40.8 m-80 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.58 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.443 HD21 ' N ' ' A' ' 89' ' ' ASN . 0.7 OUTLIER -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.431 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.429 HG22 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.429 ' CZ ' HG22 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.557 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.488 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p -99.99 120.31 39.61 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -166.43 119.18 0.84 Allowed Glycine 0 N--CA 1.417 -2.613 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -177.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.6 m -71.28 -28.32 64.05 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 123.318 0.647 . . . . 0.0 109.663 179.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -158.66 119.13 1.83 Allowed Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 176.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -62.18 -33.22 82.17 Favored 'Trans proline' 0 C--N 1.359 1.107 0 C-N-CA 122.159 1.906 . . . . 0.0 110.586 177.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 t -150.17 136.35 18.74 Favored 'General case' 0 N--CA 1.406 -2.671 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 175.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.426 -1.667 0 O-C-N 123.058 0.224 . . . . 0.0 110.929 -178.324 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.009 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.5 m -97.17 171.72 8.27 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 71.0 -84.59 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.429 1.492 . . . . 0.0 112.631 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.9 m 58.3 24.15 11.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.521 1.128 . . . . 0.0 112.15 179.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.78 -42.33 18.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.6 mtpt -140.07 -175.79 4.36 Favored 'General case' 0 C--O 1.251 1.134 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.353 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 12.2 m120 71.24 95.34 0.07 Allowed 'General case' 0 C--O 1.246 0.887 0 C-N-CA 124.931 1.292 . . . . 0.0 111.254 177.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.509 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 -91.4 -177.38 4.82 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.486 -1.234 . . . . 0.0 112.317 -175.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.406 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HZ3' ' HB2' ' A' ' 47' ' ' LYS . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.542 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.554 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.435 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.624 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.406 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.624 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.554 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.435 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.415 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.509 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.449 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p -77.23 -46.13 24.2 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 85.61 26.38 35.71 Favored Glycine 0 N--CA 1.427 -1.918 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.768 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.0 m -76.56 -41.64 45.71 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -117.36 109.69 41.89 Favored Pre-proline 0 C--N 1.317 -0.805 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -92.3 37.46 0.25 Allowed 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.361 2.708 . . . . 0.0 113.176 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.3 m 70.69 109.94 0.06 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 124.513 1.125 . . . . 0.0 110.671 -178.238 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.215 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.635 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.0 m -104.85 174.68 5.77 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 122.684 -0.303 . . . . 0.0 110.755 -177.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 69.52 77.55 0.21 Allowed 'General case' 0 C--O 1.241 0.657 0 C-N-CA 125.508 1.523 . . . . 0.0 113.995 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -135.16 31.09 3.25 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 171.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.8 m -92.01 175.74 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.054 0 CA-C-N 114.244 -1.344 . . . . 0.0 111.748 -174.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -104.92 -164.53 1.05 Allowed 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.6 m120 76.1 113.8 0.07 Allowed 'General case' 0 C--O 1.245 0.834 0 C-N-CA 124.597 1.159 . . . . 0.0 112.872 174.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -88.59 -167.24 1.82 Allowed 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.789 -1.096 . . . . 0.0 109.624 176.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.404 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.499 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.481 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.439 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.552 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.481 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.499 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.439 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.461 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.534 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.495 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p -81.55 -58.54 2.97 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 95.33 65.86 0.98 Allowed Glycine 0 N--CA 1.417 -2.587 0 C-N-CA 120.348 -0.929 . . . . 0.0 111.366 178.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.4 m -70.32 -22.41 62.82 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.199 0.523 . . . . 0.0 109.725 177.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.55 124.83 90.75 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 172.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.28 -28.83 72.59 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.304 2.003 . . . . 0.0 113.531 -175.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.1 m -146.31 140.08 26.18 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 177.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.295 -1.794 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.135 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.118 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.7 t -158.98 105.8 1.78 Allowed 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 176.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -76.83 146.18 37.94 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 175.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -75.95 54.44 0.83 Allowed 'General case' 0 CA--C 1.554 1.119 0 CA-C-O 122.208 1.004 . . . . 0.0 113.322 -175.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 55.1 t -105.09 -42.78 7.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 170.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.0 mtmp? -93.86 174.43 7.17 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 171.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.7 m120 59.17 73.87 0.46 Allowed 'General case' 0 CA--C 1.501 -0.936 0 O-C-N 124.264 0.977 . . . . 0.0 110.352 176.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.11 168.12 9.43 Favored 'General case' 0 C--N 1.284 -2.279 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.76 -174.093 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.491 ' HA ' ' O ' ' A' ' 133' ' ' ILE . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.401 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.401 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.409 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 81' ' ' THR . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.427 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.492 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.409 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.432 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.432 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.454 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.419 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.427 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p -77.74 -50.53 12.21 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.51 123.29 3.35 Favored Glycine 0 N--CA 1.424 -2.115 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.4 m -70.43 -43.67 69.46 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 122.926 0.49 . . . . 0.0 111.184 -175.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -144.38 130.97 10.09 Favored Pre-proline 0 N--CA 1.428 -1.525 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.21 93.37 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.757 2.305 . . . . 0.0 111.336 176.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 88.7 m -150.49 102.73 3.07 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 30.4 t . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 -179.348 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.2 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 37.9 m 67.68 -69.68 0.13 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.161 1.384 . . . . 0.0 111.14 -178.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -97.13 -175.89 3.37 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 172.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 53.2 p 53.97 34.04 18.77 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 124.025 0.93 . . . . 0.0 112.197 -179.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.1 p -80.71 -31.56 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.076 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -99.73 147.52 25.36 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 174.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.493 ' HB3' HG22 ' A' ' 133' ' ' ILE . 16.0 m120 68.7 93.51 0.08 Allowed 'General case' 0 C--O 1.24 0.605 0 O-C-N 124.476 1.11 . . . . 0.0 110.71 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.403 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER -94.35 169.24 10.37 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.389 -173.965 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.412 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.476 HG13 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.403 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.421 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.447 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.413 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.585 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.404 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.451 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.425 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.427 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.438 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.438 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.413 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.447 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.506 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.517 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.517 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.426 ' CG ' ' HZ1' ' A' ' 134' ' ' LYS . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.493 HG22 ' HB3' ' A' ' 3' ' ' ASN . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.506 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p -77.47 -50.4 12.74 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 88.52 13.82 62.62 Favored Glycine 0 N--CA 1.429 -1.805 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -177.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 7.3 p -81.16 -6.82 59.27 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -177.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -101.57 110.85 62.9 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.09 100.75 1.33 Allowed 'Trans proline' 0 N--CA 1.451 -0.997 0 C-N-CA 122.328 2.019 . . . . 0.0 113.332 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 8.9 t -171.15 138.67 1.27 Allowed 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 176.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 46.0 m . . . . . 0 C--N 1.301 -1.504 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.31 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.079 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 55.8 m -133.78 138.18 45.57 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.433 0.616 . . . . 0.0 112.005 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -131.43 115.16 15.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 174.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.6 p -90.24 -87.67 0.18 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 113.801 1.038 . . . . 0.0 113.801 -172.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p -87.22 -27.56 5.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.34 0.59 . . . . 0.0 110.772 -176.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.16 124.35 48.94 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 17.4 m120 70.61 169.31 0.31 Allowed 'General case' 0 N--CA 1.47 0.567 0 O-C-N 124.612 1.195 . . . . 0.0 112.537 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.456 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 -108.08 -174.93 2.64 Favored 'General case' 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.517 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.462 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.573 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.406 ' HZ3' ' HB2' ' A' ' 47' ' ' LYS . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.458 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.573 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.441 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.46 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.477 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.448 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.458 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p -68.14 -64.96 0.76 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 138.13 34.38 0.18 Allowed Glycine 0 CA--C 1.479 -2.215 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.548 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.6 p -82.89 -17.19 44.62 Favored 'General case' 0 N--CA 1.424 -1.768 0 C-N-CA 123.786 0.835 . . . . 0.0 109.983 177.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 70.3 160.31 0.15 Allowed Pre-proline 0 C--N 1.359 1.009 0 C-N-CA 125.643 1.577 . . . . 0.0 111.785 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -72.8 48.16 1.32 Allowed 'Trans proline' 0 CA--C 1.556 1.62 0 C-N-CA 123.162 2.575 . . . . 0.0 112.126 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 39.4 m 71.97 -66.16 0.32 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.061 1.744 . . . . 0.0 111.67 -178.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 63.1 m . . . . . 0 C--N 1.31 -1.13 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -179.571 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.797 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.8 t -65.29 -38.25 89.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 117.193 0.496 . . . . 0.0 111.018 -177.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.99 84.9 6.82 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.232 0.539 . . . . 0.0 110.323 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 48.4 m -133.69 72.99 1.49 Allowed 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.626 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.7 m -96.97 168.7 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 35.6 mmtp -123.8 157.86 33.12 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.118 0.485 . . . . 0.0 110.327 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -110.14 110.71 21.68 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 172.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -101.92 154.86 18.55 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.057 -174.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.421 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.528 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.437 HG11 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . 0.417 ' HB2' ' HZ3' ' A' ' 51' ' ' LYS . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.573 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.437 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.573 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.421 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.421 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.427 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.553 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.553 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.427 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p -80.23 -47.11 15.13 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 113.71 134.48 5.94 Favored Glycine 0 N--CA 1.411 -2.988 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.638 176.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.8 p -66.94 -32.85 74.37 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 122.393 1.092 . . . . 0.0 108.747 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -132.14 91.83 30.92 Favored Pre-proline 0 N--CA 1.42 -1.94 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 171.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.39 100.6 1.38 Allowed 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 122.362 2.041 . . . . 0.0 112.233 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 m -98.27 101.27 12.68 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.159 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 175.384 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.297 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.2 m -73.07 101.47 3.28 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -124.63 -164.91 1.31 Allowed 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 33.2 m -68.05 90.27 0.32 Allowed 'General case' 0 C--O 1.242 0.68 0 CA-C-O 122.269 1.033 . . . . 0.0 110.275 176.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.9 p -174.49 -34.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 C-N-CA 126.474 1.909 . . . . 0.0 105.925 -177.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.543 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 14.1 ttmm 62.76 -165.27 0.24 Allowed 'General case' 0 C--N 1.369 1.428 0 C-N-CA 125.717 1.607 . . . . 0.0 108.158 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.543 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 46.3 m-20 71.36 -164.39 0.14 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.523 1.129 . . . . 0.0 112.181 170.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.26 -173.44 2.72 Favored 'General case' 0 C--N 1.288 -2.094 0 C-N-CA 123.924 0.89 . . . . 0.0 108.778 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.46 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.445 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.453 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.453 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.562 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.422 ' HB2' ' HG ' ' A' ' 67' ' ' SER . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.427 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . 0.556 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.556 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.426 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.427 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p -79.62 -48.62 13.45 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 176.1 164.47 30.37 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.396 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -87.1 133.84 33.57 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.68 155.83 88.85 Favored Pre-proline 0 C--N 1.31 -1.118 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 174.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.06 113.89 1.54 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.517 2.145 . . . . 0.0 110.987 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 31.8 m 71.41 90.27 0.09 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.284 1.033 . . . . 0.0 111.171 -176.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 49.1 m . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.098 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.232 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 19.8 m -93.69 106.97 18.91 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -110.71 136.64 49.48 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.821 -179.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 30.0 t -90.16 79.87 6.37 Favored 'General case' 0 N--CA 1.427 -1.616 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t -84.35 119.23 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 179.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -108.41 -172.67 2.1 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-O 121.367 0.603 . . . . 0.0 110.863 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.5 m120 79.14 165.56 0.2 Allowed 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 125.956 1.702 . . . . 0.0 115.314 169.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.564 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER -116.89 -169.11 1.58 Allowed 'General case' 0 C--N 1.288 -2.098 0 CA-C-N 113.659 -1.609 . . . . 0.0 109.892 -174.659 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.46 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.534 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.412 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . 0.564 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 32.1 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.596 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.444 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.568 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.442 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.418 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.568 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.596 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.447 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.442 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.444 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.447 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p -76.91 -43.3 36.15 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 86.7 168.69 45.13 Favored Glycine 0 N--CA 1.422 -2.289 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.812 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.1 m -74.65 -54.89 6.57 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 176.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 39.21 85.46 0.16 Allowed Pre-proline 0 C--N 1.357 0.907 0 C-N-CA 125.376 1.47 . . . . 0.0 113.701 177.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.3 39.78 0.77 Allowed 'Trans proline' 0 CA--C 1.549 1.246 0 C-N-CA 122.983 2.455 . . . . 0.0 112.273 -177.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 m -91.61 -30.98 16.06 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 123.763 0.825 . . . . 0.0 110.513 -176.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.438 -1.068 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.152 -176.414 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.947 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 5.8 p -79.52 -31.71 42.21 Favored 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 122.907 0.483 . . . . 0.0 111.288 -178.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -126.46 94.18 4.0 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 27.0 m -137.74 -0.69 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.342 178.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.75 118.75 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt 56.95 97.46 0.02 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 125.504 1.522 . . . . 0.0 112.556 -176.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 13.6 m120 73.01 89.25 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 126.297 1.839 . . . . 0.0 112.308 -176.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -115.76 -163.06 0.87 Allowed 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.586 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.41 ' HZ2' ' HB3' ' A' ' 22' ' ' LYS . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.568 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.43 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.446 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.462 ' O ' ' HD2' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.416 ' HB2' ' HZ1' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . 0.43 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.442 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.568 ' HA ' ' O ' ' A' ' 36' ' ' LEU . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.414 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.551 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.442 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p -108.56 146.99 32.42 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -179.16 154.52 14.12 Favored Glycine 0 N--CA 1.429 -1.805 0 C-N-CA 119.576 -1.297 . . . . 0.0 112.827 178.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.9 t -126.75 13.35 7.43 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 176.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 61.95 104.69 0.03 OUTLIER Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.217 1.407 . . . . 0.0 111.879 -178.289 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_endo -59.24 -25.88 79.79 Favored 'Trans proline' 0 C--N 1.372 1.804 0 C-N-CA 122.929 2.42 . . . . 0.0 112.723 -178.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.4 m -129.63 -80.99 0.56 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 174.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 73.1 m . . . . . 0 C--N 1.312 -1.045 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 176.293 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.859 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.5 t -127.72 65.97 1.34 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.113 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 56.82 45.02 22.35 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -176.024 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.1 m -42.72 -58.36 2.36 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 125.986 1.714 . . . . 0.0 111.645 -174.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.4 m -112.53 -46.76 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.443 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.95 172.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.521 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 38.6 tttt 53.71 -165.45 0.09 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.684 1.594 . . . . 0.0 108.049 -177.5 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.559 ' ND2' ' HB2' ' A' ' 131' ' ' LYS . 17.7 m120 50.4 91.29 0.02 OUTLIER 'General case' 0 C--O 1.243 0.738 0 N-CA-C 116.185 1.92 . . . . 0.0 116.185 164.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.42 147.73 22.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.402 ' HB3' ' OG ' ' A' ' 147' ' ' SER . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.496 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.451 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.574 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.496 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.446 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' LEU . . . . . 0.515 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.54 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.418 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.559 ' HB2' ' ND2' ' A' ' 3' ' ' ASN . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ILE . . . . . 0.418 HG22 ' HB3' ' A' ' 3' ' ' ASN . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.435 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.515 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' LYS . . . . . 0.446 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p -82.63 -55.68 4.31 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 114.44 127.43 4.42 Favored Glycine 0 N--CA 1.429 -1.822 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.39 176.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 16' ' ' ASN . 19.2 m -90.98 13.57 16.28 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.208 0.527 . . . . 0.0 110.462 179.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -104.79 122.14 44.42 Favored Pre-proline 0 N--CA 1.433 -1.306 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.08 140.09 27.74 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.836 2.357 . . . . 0.0 113.591 -177.042 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.1 p -80.89 -46.51 15.14 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 175.118 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.449 -0.489 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.432 ' CG2' ' HB2' ' A' ' 135' ' ' ASP . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.614 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.409 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.672 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.672 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.459 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.532 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.545 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.497 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.487 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.534 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p . . . . . 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.486 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 . . . . . 0 N--CA 1.45 -0.443 0 CA-C-O 120.713 0.292 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.455 HG13 ' HB ' ' A' ' 30' ' ' VAL . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.45 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.571 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.455 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.454 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.571 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.419 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.419 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.505 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.412 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.529 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 131' ' ' LYS . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.505 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.45 ' H ' HG21 ' A' ' 10' ' ' VAL . 63.3 m-20 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.505 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p . . . . . 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.506 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER . . . . . 0 CA--C 1.502 -0.9 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.642 HG21 ' H ' ' A' ' 139' ' ' ASN . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.413 HG23 ' HB3' ' A' ' 141' ' ' LYS . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.589 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLN . . . . . 0.419 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 58.1 mm-40 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.453 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 HG21 ' A' ' 70' ' ' VAL . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 57' ' ' THR . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 90' ' ' TYR . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.425 HG21 HG22 ' A' ' 53' ' ' VAL . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.453 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.451 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.712 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 88' ' ' ALA . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.403 ' N ' HD12 ' A' ' 87' ' ' LEU . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.51 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.589 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.552 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.44 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.515 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.642 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HB3' HG23 ' A' ' 12' ' ' THR . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p . . . . . 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 . . . . . 0 N--CA 1.412 -2.365 0 CA-C-O 120.899 0.381 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.601 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.488 HG21 ' H ' ' A' ' 139' ' ' ASN . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.545 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HB ' HG13 ' A' ' 6' ' ' VAL . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.517 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.63 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.59 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.432 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.508 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.437 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.592 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.612 ' HD2' ' HB2' ' A' ' 8' ' ' LEU . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.405 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.488 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 47' ' ' LYS . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p . . . . . 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 . . . . . 0 N--CA 1.421 -1.896 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.491 HG13 ' HB ' ' A' ' 30' ' ' VAL . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.474 HG21 ' H ' ' A' ' 139' ' ' ASN . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.433 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.491 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.465 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.422 HG12 ' HA ' ' A' ' 101' ' ' LEU . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.598 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.425 ' HB3' HG23 ' A' ' 92' ' ' ILE . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.409 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.409 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.612 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.473 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.612 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.422 ' HA ' HG12 ' A' ' 53' ' ' VAL . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.495 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.465 HG22 HG13 ' A' ' 41' ' ' ILE . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.415 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p . . . . . 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 CA--C 1.478 -1.82 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.449 ' HA ' HG22 ' A' ' 133' ' ' ILE . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.471 HD21 HG21 ' A' ' 125' ' ' VAL . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.4 ' CB ' ' HA ' ' A' ' 107' ' ' SER . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.638 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.672 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.435 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.431 HG22 HG23 ' A' ' 83' ' ' THR . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.423 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.664 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.672 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.638 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.472 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.472 ' CE1' HG21 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.4 ' HA ' ' CB ' ' A' ' 17' ' ' PRO . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.471 HG21 HD21 ' A' ' 8' ' ' LEU . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 5' ' ' THR . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.437 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 . . . . . 0 N--CA 1.438 -1.059 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.446 HG13 ' HB ' ' A' ' 30' ' ' VAL . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.519 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HB2' HD12 ' A' ' 97' ' ' ILE . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.446 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.576 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.411 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.437 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.401 ' CD2' HG23 ' A' ' 94' ' ' VAL . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.41 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.437 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.406 HG22 HG23 ' A' ' 83' ' ' THR . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.469 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.612 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.401 HG23 ' CD2' ' A' ' 59' ' ' LEU . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.477 HD12 ' HB2' ' A' ' 24' ' ' PRO . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 37' ' ' ILE . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.418 ' CE2' HG21 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.416 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.411 HG22 HG13 ' A' ' 41' ' ' ILE . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.524 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.526 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.524 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HG2' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.519 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.489 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p . . . . . 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.424 -1.748 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.423 HG23 HG22 ' A' ' 125' ' ' VAL . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.42 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 90' ' ' TYR . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.497 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.615 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.434 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.402 ' HB2' HG22 ' A' ' 86' ' ' THR . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.538 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.42 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.418 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.541 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.544 ' H ' HG21 ' A' ' 10' ' ' VAL . 28.4 m-20 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p . . . . . 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.522 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.63 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.575 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.586 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.41 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.532 ' HD3' ' H ' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.56 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 26.4 m120 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.56 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.427 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.427 ' HB2' HG22 ' A' ' 86' ' ' THR . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.575 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.417 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.417 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.442 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.471 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.522 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.471 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.63 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p . . . . . 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HG3' ' HB3' ' A' ' 31' ' ' SER . 3.0 mm-40 . . . . . 0 CA--C 1.484 -1.586 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.543 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.646 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.424 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.629 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.445 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.629 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.433 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.433 ' HB2' HG22 ' A' ' 86' ' ' THR . 2.9 m-20 -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.438 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.438 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.534 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HB2' ' HB3' ' A' ' 106' ' ' ASN . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.426 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.541 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.532 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.438 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.52 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 . . . . . 0 N--CA 1.44 -0.96 0 CA-C-O 121.724 0.773 . . . . 0.0 112.317 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.409 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.46 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.56 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.4 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.4 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.644 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.419 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.56 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.411 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.506 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.426 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.45 ' HB ' ' HG2' ' A' ' 134' ' ' LYS . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.52 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.451 ' N ' ' HG1' ' A' ' 32' ' ' THR . 39.3 mm-40 . . . . . 0 N--CA 1.427 -1.605 0 CA-C-O 121.343 0.592 . . . . 0.0 109.624 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.404 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.508 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.451 ' HG1' ' N ' ' A' ' 4' ' ' GLU . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.512 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.664 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 98' ' ' LEU . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.614 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.512 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.508 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.401 ' HA ' HD12 ' A' ' 59' ' ' LEU . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.664 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.422 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 138' ' ' SER . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.535 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.508 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.422 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p . . . . . 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.427 -1.599 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 135' ' ' ASP . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.536 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.433 HG21 HD21 ' A' ' 98' ' ' LEU . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.521 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.439 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.433 HD21 HG21 ' A' ' 37' ' ' ILE . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.439 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PHE . . . . . 0.403 ' CE1' ' HB ' ' A' ' 50' ' ' VAL . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.521 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.4 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.522 ' HB2' HG22 ' A' ' 5' ' ' THR . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.536 ' H ' HG21 ' A' ' 10' ' ' VAL . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p . . . . . 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.413 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER . . . . . 0 N--CA 1.446 -0.635 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASN . . . . . 0.413 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.558 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.532 HG12 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.413 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.44 ' HB ' ' HB2' ' A' ' 68' ' ' PHE . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 63' ' ' THR . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.566 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.409 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.558 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.41 HG21 ' CE1' ' A' ' 100' ' ' TYR . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.412 HD21 HG21 ' A' ' 37' ' ' ILE . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.447 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.524 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ASN . . . . . 0.524 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p . . . . . 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.472 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 . . . . . 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.408 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.407 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.469 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 51' ' ' LYS . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 70' ' ' VAL . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 83' ' ' THR . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 53' ' ' VAL . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.458 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.486 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.469 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p . . . . . 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.423 -1.793 0 CA-C-O 120.996 0.427 . . . . 0.0 112.057 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.505 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.484 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.482 HG12 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LYS . . . . . 0.459 ' HD3' HD11 ' A' ' 104' ' ' ILE . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.595 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.435 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.595 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.513 HG23 ' HB3' ' A' ' 59' ' ' LEU . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.434 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.459 HD11 ' HD3' ' A' ' 51' ' ' LYS . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.411 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.56 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HD3' ' HB2' ' A' ' 136' ' ' ALA . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 134' ' ' LYS . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.484 ' H ' HG21 ' A' ' 10' ' ' VAL . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p . . . . . 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 30' ' ' VAL . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.592 HG21 ' H ' ' A' ' 139' ' ' ASN . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.412 HD23 HG22 ' A' ' 83' ' ' THR . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.422 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.543 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LYS . . . . . 0.45 ' HB2' ' HZ2' ' A' ' 51' ' ' LYS . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.4 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.506 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.506 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.566 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.444 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.57 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.57 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.451 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.592 ' H ' HG21 ' A' ' 10' ' ' VAL . 64.9 t30 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p . . . . . 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.572 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.431 -1.393 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.491 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.438 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLN . . . . . 0.572 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 34.7 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.424 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.623 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.459 ' HB2' HD22 ' A' ' 116' ' ' LEU . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.415 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.415 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.623 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.546 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 37' ' ' ILE . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.456 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.459 HD22 ' HB2' ' A' ' 43' ' ' TYR . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.416 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.511 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.491 ' H ' HG21 ' A' ' 10' ' ' VAL . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p . . . . . 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG2' ' OD1' ' A' ' 135' ' ' ASP . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.463 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.539 ' HZ1' HG13 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.452 ' HB2' ' HZ2' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.539 HG13 ' HZ1' ' A' ' 61' ' ' LYS . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' TYR . . . . . 0.453 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.402 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.578 ' CG1' ' HB3' ' A' ' 134' ' ' LYS . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.425 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.578 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.419 ' OD1' ' HG2' ' A' ' 7' ' ' LYS . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.463 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.44 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p . . . . . 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.443 -0.815 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.414 HG23 ' HB3' ' A' ' 141' ' ' LYS . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.448 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.454 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.585 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.511 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.457 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ASP . . . . . 0.436 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.432 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ALA . . . . . 0.403 ' HB3' ' HD3' ' A' ' 134' ' ' LYS . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.455 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.521 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' LYS . . . . . 0.457 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p . . . . . 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.327 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 11.8 m -88.36 79.11 7.82 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-O 120.951 0.405 . . . . 0.0 110.301 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -167.67 144.6 4.31 Favored 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 177.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.8 m 75.18 -59.49 0.54 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 124.472 1.109 . . . . 0.0 111.334 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.2 p -79.09 -22.59 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 CA-C-O 122.273 1.035 . . . . 0.0 108.681 176.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp -126.12 130.85 51.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.481 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -93.02 139.69 30.26 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 124.466 1.104 . . . . 0.0 109.765 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -116.9 -179.73 3.78 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.432 ' CG2' ' HB2' ' A' ' 135' ' ' ASP . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.614 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.409 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.672 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.672 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.459 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.532 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.533 ' HB2' ' HA3' ' A' ' 146' ' ' GLY . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.545 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.497 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.487 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.534 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p -71.66 -44.82 63.62 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.533 ' HA3' ' HB2' ' A' ' 111' ' ' ALA . . . 75.28 35.15 49.23 Favored Glycine 0 N--CA 1.418 -2.529 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.979 -177.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.0 m -75.71 86.32 2.74 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-O 121.599 0.714 . . . . 0.0 110.21 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -171.38 169.63 3.04 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -48.9 -40.09 39.9 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.205 1.937 . . . . 0.0 111.237 171.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 55.7 m -155.13 -66.19 0.13 Allowed 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 173.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 35.2 p . . . . . 0 C--O 1.239 0.507 0 C-N-CA 124.552 1.141 . . . . 0.0 108.057 176.137 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.916 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 41.0 m -74.37 123.22 24.23 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-O 121.239 0.543 . . . . 0.0 111.728 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.39 -12.59 58.92 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.446 176.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 55.1 m -129.58 139.23 51.54 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 59.7 t -82.22 -38.77 15.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.2 mttp -100.8 143.61 30.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.108 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -147.08 98.13 2.99 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 169.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.486 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 -97.37 -174.15 2.85 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.649 -173.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.455 HG13 ' HB ' ' A' ' 30' ' ' VAL . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.45 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.571 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.455 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.454 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 26.5 t-20 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.571 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.419 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.419 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 150' ' ' THR . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.505 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.412 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.529 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 131' ' ' LYS . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.505 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.45 ' H ' HG21 ' A' ' 10' ' ' VAL . 63.3 m-20 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.505 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p -88.23 130.8 34.98 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.17 146.28 14.32 Favored Glycine 0 N--CA 1.419 -2.488 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.957 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.6 t -82.98 -30.73 28.0 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 174.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -155.13 147.4 17.52 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 178.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -67.88 140.05 49.39 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 121.907 1.738 . . . . 0.0 109.807 176.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 107' ' ' SER . 94.2 m 71.13 121.37 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.21 0 CA-C-O 122.201 1.001 . . . . 0.0 112.587 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.428 -1.566 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.844 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.883 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 17.0 m -85.06 80.91 9.1 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.359 0.599 . . . . 0.0 109.536 178.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -103.3 -10.66 18.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.766 -178.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 4.6 m -91.85 117.87 30.18 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.337 -177.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.3 t -81.03 102.02 6.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -78.98 138.59 38.12 Favored 'General case' 0 N--CA 1.417 -2.121 0 CA-C-O 122.088 0.947 . . . . 0.0 110.8 -176.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 -148.56 100.26 3.1 Favored 'General case' 0 C--N 1.269 -2.897 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 177.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.506 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER -92.42 171.61 8.93 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -172.063 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.642 HG21 ' H ' ' A' ' 139' ' ' ASN . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.413 HG23 ' HB3' ' A' ' 141' ' ' LYS . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.589 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLN . . . . . 0.419 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 58.1 mm-40 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.453 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 HG21 ' A' ' 70' ' ' VAL . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 57' ' ' THR . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 90' ' ' TYR . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.425 HG21 HG22 ' A' ' 53' ' ' VAL . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.453 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.451 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.712 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 88' ' ' ALA . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.403 ' N ' HD12 ' A' ' 87' ' ' LEU . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.51 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.589 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.604 ' HB2' ' HA2' ' A' ' 146' ' ' GLY . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.552 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.44 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.515 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.642 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HB3' HG23 ' A' ' 12' ' ' THR . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p -74.1 -41.86 60.98 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.604 ' HA2' ' HB2' ' A' ' 111' ' ' ALA . . . 174.19 -92.73 0.09 OUTLIER Glycine 0 CA--C 1.475 -2.406 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.117 178.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.427 ' O ' ' HD3' ' A' ' 149' ' ' PRO . 5.8 p -150.13 158.78 44.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 178.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -88.48 107.72 18.41 Favored Pre-proline 0 C--N 1.31 -1.116 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -177.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 147' ' ' SER . 96.3 Cg_endo -89.24 146.31 5.24 Favored 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 122.225 1.95 . . . . 0.0 113.171 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.1 t -76.04 107.8 8.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 174.176 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.6 m . . . . . 0 C--N 1.298 -1.661 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.024 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.871 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 50.2 m -132.64 13.44 4.46 Favored 'General case' 0 C--N 1.317 -0.823 0 O-C-N 122.234 -0.568 . . . . 0.0 110.859 178.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -72.92 -24.4 60.82 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.037 0.446 . . . . 0.0 112.052 -175.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 19.5 m -131.58 119.67 21.79 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.34 -42.72 17.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HA ' ' HE2' ' A' ' 2' ' ' LYS . 7.0 mmpt? -147.13 105.79 3.82 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 174.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -160.44 156.33 25.87 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -129.14 163.44 25.51 Favored 'General case' 0 N--CA 1.412 -2.365 0 C-N-CA 122.657 0.383 . . . . 0.0 110.28 -173.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.601 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.488 HG21 ' H ' ' A' ' 139' ' ' ASN . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 147' ' ' SER . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.545 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HB ' HG13 ' A' ' 6' ' ' VAL . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.517 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.63 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.59 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.432 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.508 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.437 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.592 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.612 ' HD2' ' HB2' ' A' ' 8' ' ' LEU . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.405 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.488 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 47' ' ' LYS . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p -93.66 110.77 22.37 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 50.93 -124.41 20.58 Favored Glycine 0 CA--C 1.522 0.493 0 O-C-N 124.487 1.117 . . . . 0.0 114.497 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.458 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 66.9 m -149.64 144.3 26.06 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 124.073 0.949 . . . . 0.0 108.726 177.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -97.52 112.38 61.09 Favored Pre-proline 0 C--N 1.321 -0.648 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -69.16 -24.63 32.19 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.246 1.964 . . . . 0.0 113.821 -177.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.8 m -142.61 102.43 4.06 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.534 -0.729 . . . . 0.0 111.199 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 16.4 t . . . . . 0 N--CA 1.425 -1.71 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.12 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 20.9 m -96.41 2.57 52.74 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 122.48 0.312 . . . . 0.0 110.811 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.31 96.26 0.07 Allowed 'General case' 0 C--N 1.346 0.441 0 C-N-CA 124.884 1.274 . . . . 0.0 110.431 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 0' ' ' SER . . . . . 0.42 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 33.1 t -105.13 168.0 9.34 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.052 -0.977 . . . . 0.0 108.803 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 p -84.5 -23.32 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.087 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.8 tttm -142.92 145.7 33.3 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.419 -0.512 . . . . 0.0 110.907 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.5 m120 61.67 73.25 0.48 Allowed 'General case' 0 C--N 1.312 -1.042 0 C-N-CA 126.779 2.032 . . . . 0.0 112.352 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.42 ' CD ' ' H ' ' A' ' 0' ' ' SER . 9.5 mm-40 -118.94 164.68 15.1 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 113.861 -1.518 . . . . 0.0 110.473 -177.116 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.491 HG13 ' HB ' ' A' ' 30' ' ' VAL . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.474 HG21 ' H ' ' A' ' 139' ' ' ASN . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.433 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.491 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.465 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.422 HG12 ' HA ' ' A' ' 101' ' ' LEU . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.598 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.425 ' HB3' HG23 ' A' ' 92' ' ' ILE . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.409 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.409 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.612 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.473 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.612 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.422 ' HA ' HG12 ' A' ' 53' ' ' VAL . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.495 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.465 HG22 HG13 ' A' ' 41' ' ' ILE . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.415 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p -97.87 112.34 24.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -126.62 92.75 0.39 Allowed Glycine 0 N--CA 1.427 -1.964 0 C-N-CA 119.916 -1.135 . . . . 0.0 113.49 -172.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 38.0 m -86.89 -25.62 24.35 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 54.39 81.9 0.25 Allowed Pre-proline 0 C--O 1.24 0.575 0 C-N-CA 126.047 1.739 . . . . 0.0 113.65 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -71.83 97.28 0.81 Allowed 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 121.942 1.761 . . . . 0.0 109.935 176.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 p 64.28 146.33 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.683 1.993 . . . . 0.0 112.013 -174.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 41.8 m . . . . . 0 C--N 1.293 -1.861 0 O-C-N 121.144 -0.973 . . . . 0.0 108.55 179.465 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.732 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 9.2 p -74.44 -42.24 59.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.895 0.379 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -83.8 138.22 33.34 Favored 'General case' 0 N--CA 1.434 -1.237 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.556 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 11.4 p -148.13 75.93 1.35 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 121.889 0.852 . . . . 0.0 109.5 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 47.9 t -91.42 101.85 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 CA-C-N 114.41 -1.268 . . . . 0.0 107.957 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -81.36 168.43 18.39 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-O 121.146 0.498 . . . . 0.0 110.531 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.68 130.78 35.18 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.464 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -100.89 145.73 28.23 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 124.089 0.956 . . . . 0.0 108.449 -177.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.449 ' HA ' HG22 ' A' ' 133' ' ' ILE . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.471 HD21 HG21 ' A' ' 125' ' ' VAL . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.4 ' CB ' ' HA ' ' A' ' 107' ' ' SER . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.638 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.672 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.435 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.431 HG22 HG23 ' A' ' 83' ' ' THR . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.423 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.664 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.672 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.638 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.472 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.472 ' CE1' HG21 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.4 ' HA ' ' CB ' ' A' ' 17' ' ' PRO . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.471 HG21 HD21 ' A' ' 8' ' ' LEU . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 5' ' ' THR . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.437 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p -96.91 101.51 13.11 Favored 'General case' 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.33 104.96 0.72 Allowed Glycine 0 C--N 1.274 -2.914 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -175.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.9 m -60.2 -46.84 88.34 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -154.89 141.25 13.08 Favored Pre-proline 0 N--CA 1.436 -1.162 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.28 49.08 3.09 Favored 'Trans proline' 0 CA--C 1.551 1.328 0 C-N-CA 122.964 2.443 . . . . 0.0 111.946 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 23.3 m -133.55 96.03 3.62 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.49 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 47.0 m . . . . . 0 C--N 1.313 -0.994 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.282 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.254 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.7 m -94.0 126.55 39.28 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -102.44 71.06 1.19 Allowed 'General case' 0 N--CA 1.429 -1.504 0 CA-C-O 121.717 0.77 . . . . 0.0 109.797 178.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 24.7 t -108.69 172.09 7.05 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 176.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 68.0 t 59.94 78.66 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-O 122.579 1.18 . . . . 0.0 107.831 -173.143 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -83.14 -162.57 0.62 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.134 -174.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.513 ' HB3' HG21 ' A' ' 133' ' ' ILE . 21.5 m120 82.73 107.82 0.06 Allowed 'General case' 0 CA--C 1.503 -0.829 0 C-N-CA 125.322 1.449 . . . . 0.0 110.015 -178.537 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -144.38 178.96 7.55 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.063 -176.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.446 HG13 ' HB ' ' A' ' 30' ' ' VAL . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HB2' HD12 ' A' ' 97' ' ' ILE . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.446 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.576 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.411 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.437 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.401 ' CD2' HG23 ' A' ' 94' ' ' VAL . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.41 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.437 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.406 HG22 HG23 ' A' ' 83' ' ' THR . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.469 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.612 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.401 HG23 ' CD2' ' A' ' 59' ' ' LEU . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.477 HD12 ' HB2' ' A' ' 24' ' ' PRO . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 37' ' ' ILE . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.418 ' CE2' HG21 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.416 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.411 HG22 HG13 ' A' ' 41' ' ' ILE . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.524 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.526 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.524 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.513 HG21 ' HB3' ' A' ' 3' ' ' ASN . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HG2' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.519 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.489 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p -90.13 129.87 36.36 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -77.88 64.76 3.31 Favored Glycine 0 C--O 1.219 -0.791 0 O-C-N 123.341 0.401 . . . . 0.0 112.193 -176.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -88.78 25.29 1.8 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 123.77 0.828 . . . . 0.0 111.049 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -77.74 144.72 69.45 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -64.42 103.02 0.42 Allowed 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.914 1.742 . . . . 0.0 111.043 177.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.6 p -108.54 -48.03 3.4 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.676 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 22.8 m . . . . . 0 C--O 1.259 1.587 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 179.619 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.952 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 47.1 m -95.49 94.65 7.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.75 -80.96 0.04 OUTLIER 'General case' 0 C--O 1.238 0.462 0 C-N-CA 125.776 1.63 . . . . 0.0 111.041 -176.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 65.7 m 58.61 23.99 11.56 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.329 1.052 . . . . 0.0 112.271 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.9 p -95.73 -21.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.267 -176.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.0 mttp 65.44 -176.61 0.18 Allowed 'General case' 0 C--N 1.352 0.693 0 C-N-CA 124.497 1.119 . . . . 0.0 111.53 -176.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.574 ' HB3' HG21 ' A' ' 133' ' ' ILE . 3.7 m-20 -101.0 121.37 41.65 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 105.643 -1.984 . . . . 0.0 105.643 171.284 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -97.77 152.74 18.83 Favored 'General case' 0 C--N 1.282 -2.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.947 -173.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.423 HG23 HG22 ' A' ' 125' ' ' VAL . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.42 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 90' ' ' TYR . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.497 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.615 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.434 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.402 ' HB2' HG22 ' A' ' 86' ' ' THR . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.538 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.42 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 146' ' ' GLY . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.418 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.541 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.574 HG21 ' HB3' ' A' ' 3' ' ' ASN . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.544 ' H ' HG21 ' A' ' 10' ' ' VAL . 28.4 m-20 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p -104.41 116.55 32.33 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 111' ' ' ALA . . . 95.49 162.04 33.86 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 120.802 -0.713 . . . . 0.0 113.745 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.3 m -158.68 178.88 9.64 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 123.676 0.79 . . . . 0.0 109.362 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -94.3 104.11 12.81 Favored Pre-proline 0 N--CA 1.429 -1.522 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.47 -3.84 13.3 Favored 'Trans proline' 0 N--CA 1.48 0.685 0 C-N-CA 123.194 2.596 . . . . 0.0 114.424 -171.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.7 m 62.42 48.0 4.86 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-O 122.493 1.139 . . . . 0.0 108.32 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.427 -1.583 0 CA-C-N 114.263 -1.335 . . . . 0.0 110.357 -178.092 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.829 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 23.5 m 63.6 17.73 10.6 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.528 1.131 . . . . 0.0 112.131 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -123.86 90.9 3.35 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.592 0.71 . . . . 0.0 111.001 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 50.8 m -99.17 112.84 24.89 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.9 -32.62 23.95 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? 54.83 114.86 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.63 0 C-N-CA 126.937 2.095 . . . . 0.0 112.918 -173.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.49 ' HB3' HG21 ' A' ' 133' ' ' ILE . 48.4 m-80 -103.75 133.62 48.44 Favored 'General case' 0 C--N 1.263 -3.157 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.146 -178.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.522 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 -105.2 -169.21 1.57 Allowed 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 123.317 0.647 . . . . 0.0 109.947 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.63 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.575 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.586 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.41 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.532 ' HD3' ' H ' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.56 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 26.4 m120 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.56 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.427 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.427 ' HB2' HG22 ' A' ' 86' ' ' THR . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.575 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.417 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.417 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.442 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.471 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.522 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.471 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.63 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p -77.79 134.13 38.09 Favored 'General case' 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -87.75 65.02 3.6 Favored Glycine 0 N--CA 1.441 -0.977 0 CA-C-N 115.388 -0.823 . . . . 0.0 113.688 -177.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -130.25 -48.44 1.09 Allowed 'General case' 0 C--N 1.297 -1.686 0 O-C-N 122.552 -0.381 . . . . 0.0 109.986 175.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 69.19 155.14 0.15 Allowed Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.78 1.632 . . . . 0.0 111.313 -178.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -67.26 -22.01 47.06 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.53 1.487 . . . . 0.0 110.475 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.2 m 61.3 72.5 0.51 Allowed 'General case' 0 N--CA 1.431 -1.398 0 CA-C-O 123.096 1.427 . . . . 0.0 108.955 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.413 -2.275 0 CA-C-N 112.919 -1.946 . . . . 0.0 106.252 -179.122 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.164 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 40.1 m -81.65 126.39 31.71 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -141.55 131.2 24.06 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 21.2 t 68.36 21.94 8.14 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.549 1.14 . . . . 0.0 109.941 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 90.8 t -87.23 139.01 18.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.829 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.678 -177.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -92.49 129.08 38.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.023 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . 0.252 47.2 m-80 73.64 80.92 0.13 Allowed 'General case' 0 CA--C 1.5 -0.948 0 C-N-CA 125.484 1.513 . . . . 0.0 110.407 -174.113 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HG3' ' HB3' ' A' ' 31' ' ' SER . 3.0 mm-40 -109.08 153.7 23.3 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 112.352 -2.204 . . . . 0.0 110.337 -175.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.543 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.646 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.424 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 18.0 m120 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.629 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.445 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.629 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.433 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.433 ' HB2' HG22 ' A' ' 86' ' ' THR . 2.9 m-20 -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.438 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.438 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.534 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HB2' ' HB3' ' A' ' 106' ' ' ASN . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.426 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.541 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.532 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.438 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p -99.99 120.31 39.61 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -166.43 119.18 0.84 Allowed Glycine 0 N--CA 1.417 -2.613 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -177.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.6 m -71.28 -28.32 64.05 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 123.318 0.647 . . . . 0.0 109.663 179.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -158.66 119.13 1.83 Allowed Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 176.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -62.18 -33.22 82.17 Favored 'Trans proline' 0 C--N 1.359 1.107 0 C-N-CA 122.159 1.906 . . . . 0.0 110.586 177.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 t -150.17 136.35 18.74 Favored 'General case' 0 N--CA 1.406 -2.671 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 175.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.426 -1.667 0 O-C-N 123.058 0.224 . . . . 0.0 110.929 -178.324 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.009 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.5 m -97.17 171.72 8.27 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 71.0 -84.59 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.429 1.492 . . . . 0.0 112.631 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.9 m 58.3 24.15 11.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.521 1.128 . . . . 0.0 112.15 179.104 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.78 -42.33 18.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.6 mtpt -140.07 -175.79 4.36 Favored 'General case' 0 C--O 1.251 1.134 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.353 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 71.24 95.34 0.07 Allowed 'General case' 0 C--O 1.246 0.887 0 C-N-CA 124.931 1.292 . . . . 0.0 111.254 177.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.52 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 -91.4 -177.38 4.82 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.486 -1.234 . . . . 0.0 112.317 -175.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.409 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.46 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.56 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.4 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.4 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.644 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.419 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.56 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.411 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.506 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.426 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.45 ' HB ' ' HG2' ' A' ' 134' ' ' LYS . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.52 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p -77.23 -46.13 24.2 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 85.61 26.38 35.71 Favored Glycine 0 N--CA 1.427 -1.918 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.768 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.0 m -76.56 -41.64 45.71 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -117.36 109.69 41.89 Favored Pre-proline 0 C--N 1.317 -0.805 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -92.3 37.46 0.25 Allowed 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.361 2.708 . . . . 0.0 113.176 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.3 m 70.69 109.94 0.06 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 124.513 1.125 . . . . 0.0 110.671 -178.238 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.215 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.635 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.0 m -104.85 174.68 5.77 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 122.684 -0.303 . . . . 0.0 110.755 -177.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 69.52 77.55 0.21 Allowed 'General case' 0 C--O 1.241 0.657 0 C-N-CA 125.508 1.523 . . . . 0.0 113.995 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -135.16 31.09 3.25 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 171.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.8 m -92.01 175.74 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.054 0 CA-C-N 114.244 -1.344 . . . . 0.0 111.748 -174.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -104.92 -164.53 1.05 Allowed 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 133' ' ' ILE . 42.2 m-80 76.1 113.8 0.07 Allowed 'General case' 0 C--O 1.245 0.834 0 C-N-CA 124.597 1.159 . . . . 0.0 112.872 174.076 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -88.59 -167.24 1.82 Allowed 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.789 -1.096 . . . . 0.0 109.624 176.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.404 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.508 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.512 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.664 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 98' ' ' LEU . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.614 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.512 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.508 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.401 ' HA ' HD12 ' A' ' 59' ' ' LEU . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.664 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.422 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 138' ' ' SER . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.535 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.508 HG21 ' HB3' ' A' ' 3' ' ' ASN . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.508 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.422 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p -81.55 -58.54 2.97 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 95.33 65.86 0.98 Allowed Glycine 0 N--CA 1.417 -2.587 0 C-N-CA 120.348 -0.929 . . . . 0.0 111.366 178.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.4 m -70.32 -22.41 62.82 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.199 0.523 . . . . 0.0 109.725 177.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.55 124.83 90.75 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 172.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.28 -28.83 72.59 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.304 2.003 . . . . 0.0 113.531 -175.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.1 m -146.31 140.08 26.18 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 177.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.295 -1.794 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.135 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.118 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.7 t -158.98 105.8 1.78 Allowed 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 176.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -76.83 146.18 37.94 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 175.027 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -75.95 54.44 0.83 Allowed 'General case' 0 CA--C 1.554 1.119 0 CA-C-O 122.208 1.004 . . . . 0.0 113.322 -175.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 55.1 t -105.09 -42.78 7.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 170.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.0 mtmp? -93.86 174.43 7.17 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 171.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.7 m120 59.17 73.87 0.46 Allowed 'General case' 0 CA--C 1.501 -0.936 0 O-C-N 124.264 0.977 . . . . 0.0 110.352 176.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.11 168.12 9.43 Favored 'General case' 0 C--N 1.284 -2.279 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.76 -174.093 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 135' ' ' ASP . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.536 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.433 HG21 HD21 ' A' ' 98' ' ' LEU . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.521 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.439 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.433 HD21 HG21 ' A' ' 37' ' ' ILE . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.439 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PHE . . . . . 0.403 ' CE1' ' HB ' ' A' ' 50' ' ' VAL . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.521 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.4 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.522 ' HB2' HG22 ' A' ' 5' ' ' THR . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.536 ' H ' HG21 ' A' ' 10' ' ' VAL . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p -77.74 -50.53 12.21 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.51 123.29 3.35 Favored Glycine 0 N--CA 1.424 -2.115 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.4 m -70.43 -43.67 69.46 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 122.926 0.49 . . . . 0.0 111.184 -175.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -144.38 130.97 10.09 Favored Pre-proline 0 N--CA 1.428 -1.525 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.21 93.37 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.757 2.305 . . . . 0.0 111.336 176.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 88.7 m -150.49 102.73 3.07 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 30.4 t . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 -179.348 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.2 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 37.9 m 67.68 -69.68 0.13 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.161 1.384 . . . . 0.0 111.14 -178.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -97.13 -175.89 3.37 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 172.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 53.2 p 53.97 34.04 18.77 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 124.025 0.93 . . . . 0.0 112.197 -179.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.1 p -80.71 -31.56 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.076 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -99.73 147.52 25.36 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 174.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.607 ' HB3' HG21 ' A' ' 133' ' ' ILE . 16.0 m120 68.7 93.51 0.08 Allowed 'General case' 0 C--O 1.24 0.605 0 O-C-N 124.476 1.11 . . . . 0.0 110.71 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.413 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER -94.35 169.24 10.37 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.389 -173.965 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.413 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.558 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.532 HG12 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.413 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.44 ' HB ' ' HB2' ' A' ' 68' ' ' PHE . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 63' ' ' THR . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.566 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.409 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.558 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.41 HG21 ' CE1' ' A' ' 100' ' ' TYR . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.412 HD21 HG21 ' A' ' 37' ' ' ILE . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.447 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.524 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ASN . . . . . 0.524 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.607 HG21 ' HB3' ' A' ' 3' ' ' ASN . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p -77.47 -50.4 12.74 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 88.52 13.82 62.62 Favored Glycine 0 N--CA 1.429 -1.805 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -177.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 7.3 p -81.16 -6.82 59.27 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -177.382 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -101.57 110.85 62.9 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.416 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.09 100.75 1.33 Allowed 'Trans proline' 0 N--CA 1.451 -0.997 0 C-N-CA 122.328 2.019 . . . . 0.0 113.332 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 8.9 t -171.15 138.67 1.27 Allowed 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 176.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 46.0 m . . . . . 0 C--N 1.301 -1.504 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.31 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.079 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 55.8 m -133.78 138.18 45.57 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.433 0.616 . . . . 0.0 112.005 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -131.43 115.16 15.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 174.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.6 p -90.24 -87.67 0.18 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 113.801 1.038 . . . . 0.0 113.801 -172.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p -87.22 -27.56 5.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.34 0.59 . . . . 0.0 110.772 -176.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.16 124.35 48.94 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.418 ' HB3' HG21 ' A' ' 133' ' ' ILE . 34.8 m-80 70.61 169.31 0.31 Allowed 'General case' 0 N--CA 1.47 0.567 0 O-C-N 124.612 1.195 . . . . 0.0 112.537 178.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.472 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 -108.08 -174.93 2.64 Favored 'General case' 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.408 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.407 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.469 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 51' ' ' LYS . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 70' ' ' VAL . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 83' ' ' THR . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 53' ' ' VAL . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.458 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.424 ' HB2' ' HA2' ' A' ' 146' ' ' GLY . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.486 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.469 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p -68.14 -64.96 0.76 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.424 ' HA2' ' HB2' ' A' ' 111' ' ' ALA . . . 138.13 34.38 0.18 Allowed Glycine 0 CA--C 1.479 -2.215 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.548 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.6 p -82.89 -17.19 44.62 Favored 'General case' 0 N--CA 1.424 -1.768 0 C-N-CA 123.786 0.835 . . . . 0.0 109.983 177.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 70.3 160.31 0.15 Allowed Pre-proline 0 C--N 1.359 1.009 0 C-N-CA 125.643 1.577 . . . . 0.0 111.785 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -72.8 48.16 1.32 Allowed 'Trans proline' 0 CA--C 1.556 1.62 0 C-N-CA 123.162 2.575 . . . . 0.0 112.126 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 39.4 m 71.97 -66.16 0.32 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.061 1.744 . . . . 0.0 111.67 -178.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 63.1 m . . . . . 0 C--N 1.31 -1.13 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -179.571 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.797 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.8 t -65.29 -38.25 89.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 117.193 0.496 . . . . 0.0 111.018 -177.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.99 84.9 6.82 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.232 0.539 . . . . 0.0 110.323 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 48.4 m -133.69 72.99 1.49 Allowed 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.626 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.7 m -96.97 168.7 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 35.6 mmtp -123.8 157.86 33.12 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.118 0.485 . . . . 0.0 110.327 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -110.14 110.71 21.68 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 172.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -101.92 154.86 18.55 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.057 -174.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.505 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.484 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.482 HG12 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.459 ' HD3' HD11 ' A' ' 104' ' ' ILE . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.595 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.435 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.595 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.513 HG23 ' HB3' ' A' ' 59' ' ' LEU . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.434 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.459 HD11 ' HD3' ' A' ' 51' ' ' LYS . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.411 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.56 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HD3' ' HB2' ' A' ' 136' ' ' ALA . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 134' ' ' LYS . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.484 ' H ' HG21 ' A' ' 10' ' ' VAL . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p -80.23 -47.11 15.13 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 113.71 134.48 5.94 Favored Glycine 0 N--CA 1.411 -2.988 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.638 176.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.8 p -66.94 -32.85 74.37 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 122.393 1.092 . . . . 0.0 108.747 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -132.14 91.83 30.92 Favored Pre-proline 0 N--CA 1.42 -1.94 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 171.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.39 100.6 1.38 Allowed 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 122.362 2.041 . . . . 0.0 112.233 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 m -98.27 101.27 12.68 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.159 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 175.384 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.297 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.2 m -73.07 101.47 3.28 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -124.63 -164.91 1.31 Allowed 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 33.2 m -68.05 90.27 0.32 Allowed 'General case' 0 C--O 1.242 0.68 0 CA-C-O 122.269 1.033 . . . . 0.0 110.275 176.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.9 p -174.49 -34.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 C-N-CA 126.474 1.909 . . . . 0.0 105.925 -177.292 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.562 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 14.1 ttmm 62.76 -165.27 0.24 Allowed 'General case' 0 C--N 1.369 1.428 0 C-N-CA 125.717 1.607 . . . . 0.0 108.158 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.562 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 46.3 m-20 71.36 -164.39 0.14 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.523 1.129 . . . . 0.0 112.181 170.226 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.26 -173.44 2.72 Favored 'General case' 0 C--N 1.288 -2.094 0 C-N-CA 123.924 0.89 . . . . 0.0 108.778 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 30' ' ' VAL . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.592 HG21 ' H ' ' A' ' 139' ' ' ASN . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.412 HD23 HG22 ' A' ' 83' ' ' THR . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.422 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.543 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.45 ' HB2' ' HZ2' ' A' ' 51' ' ' LYS . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.4 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.506 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.506 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.566 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.444 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.57 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.57 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.451 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.592 ' H ' HG21 ' A' ' 10' ' ' VAL . 64.9 t30 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p -79.62 -48.62 13.45 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 176.1 164.47 30.37 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.396 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -87.1 133.84 33.57 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.68 155.83 88.85 Favored Pre-proline 0 C--N 1.31 -1.118 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 174.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.06 113.89 1.54 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.517 2.145 . . . . 0.0 110.987 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 31.8 m 71.41 90.27 0.09 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.284 1.033 . . . . 0.0 111.171 -176.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 49.1 m . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.098 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.232 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 19.8 m -93.69 106.97 18.91 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -110.71 136.64 49.48 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.821 -179.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 30.0 t -90.16 79.87 6.37 Favored 'General case' 0 N--CA 1.427 -1.616 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t -84.35 119.23 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 179.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -108.41 -172.67 2.1 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-O 121.367 0.603 . . . . 0.0 110.863 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 79.14 165.56 0.2 Allowed 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 125.956 1.702 . . . . 0.0 115.314 169.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.572 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER -116.89 -169.11 1.58 Allowed 'General case' 0 C--N 1.288 -2.098 0 CA-C-N 113.659 -1.609 . . . . 0.0 109.892 -174.659 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.491 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.438 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLN . . . . . 0.572 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 34.7 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.424 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.623 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.459 ' HB2' HD22 ' A' ' 116' ' ' LEU . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.415 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.415 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.623 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.546 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 37' ' ' ILE . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.456 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.459 HD22 ' HB2' ' A' ' 43' ' ' TYR . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.416 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.511 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.491 ' H ' HG21 ' A' ' 10' ' ' VAL . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p -76.91 -43.3 36.15 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 86.7 168.69 45.13 Favored Glycine 0 N--CA 1.422 -2.289 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.812 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.1 m -74.65 -54.89 6.57 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 176.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 39.21 85.46 0.16 Allowed Pre-proline 0 C--N 1.357 0.907 0 C-N-CA 125.376 1.47 . . . . 0.0 113.701 177.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.3 39.78 0.77 Allowed 'Trans proline' 0 CA--C 1.549 1.246 0 C-N-CA 122.983 2.455 . . . . 0.0 112.273 -177.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 m -91.61 -30.98 16.06 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 123.763 0.825 . . . . 0.0 110.513 -176.538 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.438 -1.068 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.152 -176.414 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.947 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 5.8 p -79.52 -31.71 42.21 Favored 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 122.907 0.483 . . . . 0.0 111.288 -178.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -126.46 94.18 4.0 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 27.0 m -137.74 -0.69 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.342 178.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.75 118.75 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt 56.95 97.46 0.02 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 125.504 1.522 . . . . 0.0 112.556 -176.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 73.01 89.25 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 126.297 1.839 . . . . 0.0 112.308 -176.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -115.76 -163.06 0.87 Allowed 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.586 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG2' ' OD1' ' A' ' 135' ' ' ASP . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.463 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.539 ' HZ1' HG13 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.452 ' HB2' ' HZ2' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.539 HG13 ' HZ1' ' A' ' 61' ' ' LYS . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' TYR . . . . . 0.453 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.402 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.578 ' CG1' ' HB3' ' A' ' 134' ' ' LYS . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.425 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.578 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.419 ' OD1' ' HG2' ' A' ' 7' ' ' LYS . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.463 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.44 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p -108.56 146.99 32.42 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -179.16 154.52 14.12 Favored Glycine 0 N--CA 1.429 -1.805 0 C-N-CA 119.576 -1.297 . . . . 0.0 112.827 178.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.9 t -126.75 13.35 7.43 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 176.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 61.95 104.69 0.03 OUTLIER Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.217 1.407 . . . . 0.0 111.879 -178.289 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_endo -59.24 -25.88 79.79 Favored 'Trans proline' 0 C--N 1.372 1.804 0 C-N-CA 122.929 2.42 . . . . 0.0 112.723 -178.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.4 m -129.63 -80.99 0.56 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 174.185 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 73.1 m . . . . . 0 C--N 1.312 -1.045 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 176.293 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.859 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.5 t -127.72 65.97 1.34 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.113 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 56.82 45.02 22.35 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -176.024 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.1 m -42.72 -58.36 2.36 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 125.986 1.714 . . . . 0.0 111.645 -174.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.4 m -112.53 -46.76 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.443 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.95 172.572 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.545 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 38.6 tttt 53.71 -165.45 0.09 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.684 1.594 . . . . 0.0 108.049 -177.5 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.576 ' ND2' ' HB2' ' A' ' 131' ' ' LYS . 17.7 m120 50.4 91.29 0.02 OUTLIER 'General case' 0 C--O 1.243 0.738 0 N-CA-C 116.185 1.92 . . . . 0.0 116.185 164.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.42 147.73 22.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.414 HG23 ' HB3' ' A' ' 141' ' ' LYS . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.41 ' HB3' ' OG ' ' A' ' 147' ' ' SER . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.448 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.517 HG23 ' HE2' ' A' ' 2' ' ' LYS . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.585 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.511 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.457 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ASP . . . . . 0.436 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.576 ' HB2' ' ND2' ' A' ' 3' ' ' ASN . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ILE . . . . . 0.498 HG21 ' HB3' ' A' ' 3' ' ' ASN . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ALA . . . . . 0.403 ' HB3' ' HD3' ' A' ' 134' ' ' LYS . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.455 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.521 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' LYS . . . . . 0.457 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p -82.63 -55.68 4.31 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 114.44 127.43 4.42 Favored Glycine 0 N--CA 1.429 -1.822 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.39 176.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 16' ' ' ASN . 19.2 m -90.98 13.57 16.28 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.208 0.527 . . . . 0.0 110.462 179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -104.79 122.14 44.42 Favored Pre-proline 0 N--CA 1.433 -1.306 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.371 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.08 140.09 27.74 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.836 2.357 . . . . 0.0 113.591 -177.042 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.1 p -80.89 -46.51 15.14 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 175.118 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.449 -0.489 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.432 ' CG2' ' HB2' ' A' ' 135' ' ' ASP . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.614 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.433 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.409 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 36.4 m-80 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.672 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.672 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.459 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.532 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.545 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.497 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.487 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.534 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p . . . . . 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.486 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 . . . . . 0 N--CA 1.45 -0.443 0 CA-C-O 120.713 0.292 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.455 HG13 ' HB ' ' A' ' 30' ' ' VAL . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.45 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.571 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.455 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.454 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.571 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.419 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.419 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.505 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.412 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.529 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 131' ' ' LYS . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.505 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.45 ' H ' HG21 ' A' ' 10' ' ' VAL . 4.5 m120 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.505 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p . . . . . 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.506 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER . . . . . 0 CA--C 1.502 -0.9 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.642 HG21 ' H ' ' A' ' 139' ' ' ASN . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.413 HG23 ' HB3' ' A' ' 141' ' ' LYS . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.589 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . 0.419 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 8.0 mm100 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.453 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 HG21 ' A' ' 70' ' ' VAL . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 57' ' ' THR . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 90' ' ' TYR . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.425 HG21 HG22 ' A' ' 53' ' ' VAL . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.453 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.451 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.712 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 88' ' ' ALA . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.403 ' N ' HD12 ' A' ' 87' ' ' LEU . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.51 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.589 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.552 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.44 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.515 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.642 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HB3' HG23 ' A' ' 12' ' ' THR . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p . . . . . 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 . . . . . 0 N--CA 1.412 -2.365 0 CA-C-O 120.899 0.381 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.601 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.488 HG21 ' H ' ' A' ' 139' ' ' ASN . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.545 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HB ' HG13 ' A' ' 6' ' ' VAL . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.517 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.63 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.59 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.432 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.508 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.437 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.592 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.612 ' HD2' ' HB2' ' A' ' 8' ' ' LEU . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.405 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.488 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 47' ' ' LYS . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p . . . . . 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 . . . . . 0 N--CA 1.421 -1.896 0 N-CA-C 110.473 -0.195 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.491 HG13 ' HB ' ' A' ' 30' ' ' VAL . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.474 HG21 ' H ' ' A' ' 139' ' ' ASN . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.433 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.491 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.465 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.422 HG12 ' HA ' ' A' ' 101' ' ' LEU . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.598 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.425 ' HB3' HG23 ' A' ' 92' ' ' ILE . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.409 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.409 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.612 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.473 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.612 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.422 ' HA ' HG12 ' A' ' 53' ' ' VAL . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.495 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.465 HG22 HG13 ' A' ' 41' ' ' ILE . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.415 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p . . . . . 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 . . . . . 0 CA--C 1.478 -1.82 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.449 ' HA ' HG22 ' A' ' 133' ' ' ILE . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.471 HD21 HG21 ' A' ' 125' ' ' VAL . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.4 ' CB ' ' HA ' ' A' ' 107' ' ' SER . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.638 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.672 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.435 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.431 HG22 HG23 ' A' ' 83' ' ' THR . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.423 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.664 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.672 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.638 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.472 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.472 ' CE1' HG21 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.4 ' HA ' ' CB ' ' A' ' 17' ' ' PRO . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.471 HG21 HD21 ' A' ' 8' ' ' LEU . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 5' ' ' THR . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.437 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p . . . . . 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 . . . . . 0 N--CA 1.438 -1.059 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.446 HG13 ' HB ' ' A' ' 30' ' ' VAL . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.519 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HB2' HD12 ' A' ' 97' ' ' ILE . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.446 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.576 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.411 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.437 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.401 ' CD2' HG23 ' A' ' 94' ' ' VAL . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.41 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.437 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.406 HG22 HG23 ' A' ' 83' ' ' THR . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.469 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.612 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.401 HG23 ' CD2' ' A' ' 59' ' ' LEU . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.477 HD12 ' HB2' ' A' ' 24' ' ' PRO . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 37' ' ' ILE . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.418 ' CE2' HG21 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.416 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.411 HG22 HG13 ' A' ' 41' ' ' ILE . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.524 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.526 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.524 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HG2' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.519 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.489 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p . . . . . 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 . . . . . 0 N--CA 1.424 -1.748 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.423 HG23 HG22 ' A' ' 125' ' ' VAL . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.42 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 90' ' ' TYR . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.497 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.615 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.434 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.402 ' HB2' HG22 ' A' ' 86' ' ' THR . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.538 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.42 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.418 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.541 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.544 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.6 m120 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p . . . . . 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.522 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 . . . . . 0 N--CA 1.447 -0.623 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.63 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.575 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.586 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.41 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.532 ' HD3' ' H ' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.56 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 56.3 m-80 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.56 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.427 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.427 ' HB2' HG22 ' A' ' 86' ' ' THR . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.575 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.417 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.417 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.442 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.471 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.522 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.471 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.63 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p . . . . . 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HG3' ' HB3' ' A' ' 31' ' ' SER . 3.0 mm-40 . . . . . 0 CA--C 1.484 -1.586 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.543 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.646 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.448 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.424 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.448 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 40.8 m-80 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.629 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.445 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.629 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.433 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.453 HD22 ' N ' ' A' ' 89' ' ' ASN . 0.7 OUTLIER -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.438 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.438 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.534 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HB2' ' HB3' ' A' ' 106' ' ' ASN . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.426 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.541 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.532 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.438 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p . . . . . 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.52 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 . . . . . 0 N--CA 1.44 -0.96 0 CA-C-O 121.724 0.773 . . . . 0.0 112.317 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.409 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.46 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.56 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.4 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.4 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.644 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.419 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.56 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.411 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.506 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.426 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.45 ' HB ' ' HG2' ' A' ' 134' ' ' LYS . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.52 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p . . . . . 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.451 ' N ' ' HG1' ' A' ' 32' ' ' THR . 39.3 mm-40 . . . . . 0 N--CA 1.427 -1.605 0 CA-C-O 121.343 0.592 . . . . 0.0 109.624 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.404 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.508 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.451 ' HG1' ' N ' ' A' ' 4' ' ' GLU . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.512 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.664 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 98' ' ' LEU . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.614 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.512 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.508 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.401 ' HA ' HD12 ' A' ' 59' ' ' LEU . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.664 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.422 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 138' ' ' SER . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.535 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.508 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.422 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p . . . . . 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.427 -1.599 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 135' ' ' ASP . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.536 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.433 HG21 HD21 ' A' ' 98' ' ' LEU . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.521 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.439 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.433 HD21 HG21 ' A' ' 37' ' ' ILE . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.439 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . 0.403 ' CE1' ' HB ' ' A' ' 50' ' ' VAL . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.521 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.4 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.522 ' HB2' HG22 ' A' ' 5' ' ' THR . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.536 ' H ' HG21 ' A' ' 10' ' ' VAL . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p . . . . . 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.413 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER . . . . . 0 N--CA 1.446 -0.635 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . 0.413 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.558 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.532 HG12 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.413 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.44 ' HB ' ' HB2' ' A' ' 68' ' ' PHE . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 63' ' ' THR . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.566 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.409 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.558 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.41 HG21 ' CE1' ' A' ' 100' ' ' TYR . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.412 HD21 HG21 ' A' ' 37' ' ' ILE . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.447 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.524 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . 0.524 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p . . . . . 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.472 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 . . . . . 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.408 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.472 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.407 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.469 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 51' ' ' LYS . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 70' ' ' VAL . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 83' ' ' THR . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 53' ' ' VAL . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.458 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.486 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.469 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p . . . . . 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 . . . . . 0 N--CA 1.423 -1.793 0 CA-C-O 120.996 0.427 . . . . 0.0 112.057 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.505 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.484 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.482 HG12 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . 0.459 ' HD3' HD11 ' A' ' 104' ' ' ILE . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.595 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.435 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.595 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.513 HG23 ' HB3' ' A' ' 59' ' ' LEU . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.434 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.459 HD11 ' HD3' ' A' ' 51' ' ' LYS . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.411 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.56 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HD3' ' HB2' ' A' ' 136' ' ' ALA . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 134' ' ' LYS . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.484 ' H ' HG21 ' A' ' 10' ' ' VAL . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p . . . . . 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 30' ' ' VAL . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.592 HG21 ' H ' ' A' ' 139' ' ' ASN . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.412 HD23 HG22 ' A' ' 83' ' ' THR . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.422 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.543 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . 0.45 ' HB2' ' HZ2' ' A' ' 51' ' ' LYS . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.4 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.506 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.506 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.566 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.425 ' HB1' HD21 ' A' ' 139' ' ' ASN . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.444 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.57 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.57 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.451 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.592 ' H ' HG21 ' A' ' 10' ' ' VAL . 3.0 t-20 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p . . . . . 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.572 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER . . . . . 0 N--CA 1.431 -1.393 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.491 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.438 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . 0.572 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 32.1 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.424 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.623 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.459 ' HB2' HD22 ' A' ' 116' ' ' LEU . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.415 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.415 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.623 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.546 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 37' ' ' ILE . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.456 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.459 HD22 ' HB2' ' A' ' 43' ' ' TYR . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.416 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.511 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.491 ' H ' HG21 ' A' ' 10' ' ' VAL . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p . . . . . 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 N--CA 1.444 -0.737 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG2' ' OD1' ' A' ' 135' ' ' ASP . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.463 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.539 ' HZ1' HG13 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.452 ' HB2' ' HZ2' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.539 HG13 ' HZ1' ' A' ' 61' ' ' LYS . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . 0.453 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.402 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.578 ' CG1' ' HB3' ' A' ' 134' ' ' LYS . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.425 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.578 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.419 ' OD1' ' HG2' ' A' ' 7' ' ' LYS . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.463 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.44 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p . . . . . 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.443 -0.815 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.414 HG23 ' HB3' ' A' ' 141' ' ' LYS . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.448 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.511 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.454 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.585 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.511 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.457 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ASP . . . . . 0.436 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.432 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ALA . . . . . 0.403 ' HB3' ' HD3' ' A' ' 134' ' ' LYS . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.455 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.521 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' LYS . . . . . 0.457 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p . . . . . 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.327 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 11.8 m -88.36 79.11 7.82 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-O 120.951 0.405 . . . . 0.0 110.301 -179.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -167.67 144.6 4.31 Favored 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 177.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.8 m 75.18 -59.49 0.54 Allowed 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 124.472 1.109 . . . . 0.0 111.334 177.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.2 p -79.09 -22.59 12.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 CA-C-O 122.273 1.035 . . . . 0.0 108.681 176.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp -126.12 130.85 51.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.481 176.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -93.02 139.69 30.26 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 124.466 1.104 . . . . 0.0 109.765 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -116.9 -179.73 3.78 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 120.706 0.289 . . . . 0.0 111.002 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.432 ' CG2' ' HB2' ' A' ' 135' ' ' ASP . 26.7 m -95.3 108.31 20.47 Favored 'General case' 0 N--CA 1.424 -1.758 0 CA-C-O 121.255 0.55 . . . . 0.0 109.785 -179.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.1 t -90.51 120.02 38.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.577 -178.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.487 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 63.0 mttm -88.46 128.08 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-O 120.986 0.422 . . . . 0.0 111.822 178.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -103.66 113.42 26.93 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.9 t -120.8 149.65 42.24 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.32 -0.854 . . . . 0.0 111.074 -172.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 27.8 m -139.96 163.46 24.34 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.49 -164.08 10.45 Favored Glycine 0 C--N 1.289 -2.046 0 C-N-CA 118.574 -1.774 . . . . 0.0 111.75 -178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 52.9 m -110.58 126.5 54.51 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.41 165.26 13.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-N 115.067 -0.97 . . . . 0.0 108.845 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.3 m -133.44 148.37 51.75 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 122.22 -0.3 . . . . 0.0 110.526 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.59 171.62 34.8 Favored Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 110.934 -0.866 . . . . 0.0 110.934 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -111.06 166.03 11.56 Favored Pre-proline 0 C--N 1.306 -1.294 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 -176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -65.83 116.49 3.99 Favored 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 121.656 1.571 . . . . 0.0 110.668 175.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.21 -6.32 57.98 Favored Glycine 0 C--N 1.321 -0.258 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.965 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -90.02 139.57 30.48 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.8 m -92.98 124.28 36.84 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -110.46 142.87 21.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -177.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.3 ttmm -118.12 119.61 35.25 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.9 t -102.24 112.82 65.86 Favored Pre-proline 0 C--N 1.304 -1.397 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.799 -177.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.1 Cg_endo -87.06 124.86 2.17 Favored 'Trans proline' 0 CA--C 1.546 1.124 0 C-N-CA 122.406 2.07 . . . . 0.0 112.9 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.39 113.92 27.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 177.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.9 m -98.47 132.74 43.67 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -173.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.8 tt -107.08 121.93 60.56 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 176.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.2 m -129.13 148.87 51.11 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -174.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 66.0 29.95 9.89 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 125.99 1.716 . . . . 0.0 112.725 174.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.7 137.69 21.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.693 179.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.5 m -136.96 -25.85 1.06 Allowed 'General case' 0 N--CA 1.422 -1.862 0 CA-C-O 121.22 0.533 . . . . 0.0 111.574 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 79.8 m -91.14 136.11 27.65 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 26.3 Cg_exo -63.68 122.73 10.92 Favored 'Trans proline' 0 C--N 1.364 1.394 0 C-N-CA 121.366 1.377 . . . . 0.0 112.467 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.417 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.2 p -88.9 149.62 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.391 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.134 177.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -135.94 -26.76 0.44 Allowed Glycine 0 N--CA 1.442 -0.962 0 C-N-CA 120.047 -1.073 . . . . 0.0 112.749 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 75.8 mt -116.78 112.44 21.15 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-O 120.826 0.346 . . . . 0.0 111.242 -177.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 31.8 mt -129.97 128.62 65.11 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.418 177.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 23.3 t -138.55 143.21 39.35 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 106.989 -1.485 . . . . 0.0 106.989 176.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.3 ptm -157.38 138.17 13.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.903 0.382 . . . . 0.0 110.56 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 7.4 t0 -111.58 121.05 44.12 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -103.54 108.67 25.02 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 24.8 m -102.0 110.86 22.93 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -126.57 174.84 8.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.57 -176.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -77.8 107.72 10.52 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.18 -16.32 63.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 113.353 0.872 . . . . 0.0 113.353 -176.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.5 m -91.88 -37.54 12.84 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 120.837 0.351 . . . . 0.0 110.536 -178.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.614 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 37.6 ttmt -83.06 -32.4 26.84 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.467 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -127.4 156.73 41.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.026 0.441 . . . . 0.0 110.011 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.6 m -141.62 115.91 9.45 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 13.1 p -69.19 137.71 23.73 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-O 120.827 0.346 . . . . 0.0 111.5 -179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.5 mttt -89.42 -62.37 1.49 Allowed 'General case' 0 CA--C 1.504 -0.815 0 CA-C-O 121.476 0.655 . . . . 0.0 109.266 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -167.67 177.28 5.92 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -175.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.0 m -130.03 141.41 46.45 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 99.3 mt -103.07 115.92 63.26 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -78.49 142.89 18.86 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.578 1.518 . . . . 0.0 109.914 175.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.3 t30 -79.68 111.14 15.68 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.702 -0.799 . . . . 0.0 108.974 175.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 17.9 p -75.32 -5.55 45.3 Favored 'General case' 0 N--CA 1.434 -1.272 0 CA-C-N 115.205 -0.907 . . . . 0.0 113.009 -175.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -70.65 -41.57 71.95 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 171.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.2 mt -89.95 -64.41 1.14 Allowed 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.176 -178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.7 t -82.6 107.4 14.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -177.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HG2' ' CE2' ' A' ' 90' ' ' TYR . 7.3 tppt? -112.5 154.5 25.8 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -175.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.433 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 5.8 m-20 49.79 57.09 6.91 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 124.384 1.053 . . . . 0.0 112.535 175.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.409 ' HA ' ' HB2' ' A' ' 67' ' ' SER . 11.4 p -59.06 -18.88 38.99 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.718 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -69.67 -8.93 51.96 Favored 'General case' 0 C--O 1.219 -0.544 0 C-N-CA 125.169 1.388 . . . . 0.0 111.949 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 36.4 m-80 -90.61 18.24 6.58 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.071 0.462 . . . . 0.0 110.417 177.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 24.5 t80 67.43 39.08 3.0 Favored 'General case' 0 C--N 1.347 0.475 0 C-N-CA 125.353 1.461 . . . . 0.0 108.241 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.672 ' HA ' ' O ' ' A' ' 83' ' ' THR . 4.6 m -87.92 -17.05 32.21 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.683 -1.599 . . . . 0.0 108.768 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -115.28 113.78 24.31 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 114.757 -1.111 . . . . 0.0 108.332 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -129.67 115.56 34.82 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 90.1 t -125.64 116.4 46.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 174.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -110.55 113.93 26.94 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 m -82.0 92.71 6.83 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-O 121.993 0.901 . . . . 0.0 108.758 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 16.5 m -65.87 177.05 1.4 Allowed 'General case' 0 C--N 1.307 -1.263 0 C-N-CA 126.427 1.891 . . . . 0.0 111.545 179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 9.8 m -47.4 136.3 9.38 Favored Pre-proline 0 CA--C 1.564 1.491 0 C-N-CA 124.172 0.989 . . . . 0.0 109.195 176.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -34.83 120.98 0.15 Allowed 'Trans proline' 0 C--N 1.385 2.5 1 C-N-CA 125.439 4.093 . . . . 0.0 115.273 -173.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.86 -18.75 36.71 Favored Glycine 0 C--O 1.201 -1.914 0 CA-C-N 114.638 -1.165 . . . . 0.0 112.238 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -114.95 131.67 56.82 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 117.585 0.693 . . . . 0.0 112.646 178.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -123.32 117.08 50.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 44.2 m -96.38 110.26 22.64 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 176.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.1 mt -111.72 136.06 49.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 93.8 m -143.59 130.75 20.74 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -121.85 107.96 12.9 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 175.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.672 ' O ' ' HA ' ' A' ' 67' ' ' SER . 31.5 p -127.81 118.53 23.89 Favored 'General case' 0 C--N 1.279 -2.479 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -116.02 120.69 35.03 Favored Pre-proline 0 C--N 1.29 -2.019 0 C-N-CA 119.385 -0.926 . . . . 0.0 112.408 -174.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -81.24 -5.02 12.71 Favored 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.871 2.38 . . . . 0.0 112.116 176.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.88 17.05 19.05 Favored 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 122.889 0.475 . . . . 0.0 110.067 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.49 -16.39 15.07 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 116.051 1.871 . . . . 0.0 116.051 -175.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.66 -30.89 24.5 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.541 177.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -80.99 -41.28 22.99 Favored 'General case' 0 CA--C 1.497 -1.076 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.458 178.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.459 ' CE2' ' HG2' ' A' ' 61' ' ' LYS . 46.2 m-85 -123.0 101.98 38.21 Favored Pre-proline 0 N--CA 1.432 -1.338 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -89.51 105.2 0.38 Allowed 'Trans proline' 0 N--CA 1.423 -2.674 0 C-N-CA 121.476 1.45 . . . . 0.0 111.056 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.581 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 44.7 mt -74.35 90.11 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -132.58 12.43 4.48 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-O 122.273 1.035 . . . . 0.0 109.038 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -117.98 149.85 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 109.037 -177.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -85.22 168.17 15.0 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.608 -171.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.09 -154.01 25.54 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 109.999 -1.24 . . . . 0.0 109.999 178.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.88 140.43 17.96 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 174.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.0 tp -85.14 -51.83 6.36 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.98 0.419 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.76 154.21 33.61 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.221 -178.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -110.94 123.76 50.8 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 28.5 mt -98.95 121.11 40.48 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 -178.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -101.7 115.84 31.42 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -120.68 133.29 55.36 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.535 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 60.4 mt -91.36 126.17 44.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 173.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 58.2 mt -77.98 129.24 37.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.776 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 174.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.532 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 8.4 t-20 -62.82 156.56 23.7 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 123.725 0.64 . . . . 0.0 111.979 -172.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.7 m -69.19 -29.64 67.66 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.347 0.594 . . . . 0.0 110.262 176.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.9 t30 -101.96 15.77 28.03 Favored 'General case' 0 CA--C 1.548 0.871 0 CA-C-O 122.032 0.92 . . . . 0.0 109.015 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -77.32 137.27 38.67 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.719 -177.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 9.7 p -89.58 139.85 30.13 Favored 'General case' 0 N--CA 1.431 -1.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.011 -178.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.533 ' HB2' ' HA3' ' A' ' 146' ' ' GLY . . . -64.64 153.75 38.51 Favored 'General case' 0 C--O 1.245 0.848 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.422 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.72 -177.66 17.68 Favored Glycine 0 N--CA 1.425 -2.068 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.27 123.27 34.58 Favored 'General case' 0 CA--C 1.488 -1.42 0 CA-C-O 121.123 0.487 . . . . 0.0 111.016 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 38.9 m -133.33 114.97 14.34 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.519 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.71 149.01 21.59 Favored 'General case' 0 N--CA 1.434 -1.242 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.028 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.545 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 18.6 mt -92.33 118.76 31.24 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 18.6 m -80.8 103.82 10.9 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.9 t -86.96 113.71 25.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.463 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 18.7 t70 -62.13 115.21 14.55 Favored Pre-proline 0 C--N 1.315 -0.934 0 O-C-N 124.129 0.893 . . . . 0.0 110.875 -173.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -68.11 -19.75 44.76 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.989 2.459 . . . . 0.0 113.825 -175.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.57 -37.94 22.3 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.911 0.386 . . . . 0.0 110.329 -178.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.7 m -84.76 -12.46 53.65 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.543 0.687 . . . . 0.0 109.964 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.6 tt -80.67 111.6 17.25 Favored 'General case' 0 N--CA 1.433 -1.302 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 77.0 mt -127.98 127.77 68.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.0 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 -177.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 77.9 t -131.75 96.51 2.55 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.2 146.5 45.13 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.178 -177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.417 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -93.29 -163.5 1.06 Allowed 'General case' 0 C--N 1.288 -2.07 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.895 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -72.37 -20.87 61.38 Favored 'General case' 0 CA--C 1.55 0.954 0 CA-C-O 120.873 0.368 . . . . 0.0 111.767 178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -88.55 8.96 25.63 Favored 'General case' 0 CA--C 1.547 0.845 0 CA-C-O 122.034 0.921 . . . . 0.0 108.612 175.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.99 22.74 7.56 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.341 2.257 . . . . 0.0 114.456 174.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.4 mmtt -93.57 128.5 39.74 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.497 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 23.7 t70 -73.45 106.26 5.17 Favored 'General case' 0 CA--C 1.508 -0.668 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 175.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 pt -109.46 32.69 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.257 -170.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.465 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 23.3 pttm -105.04 131.28 52.75 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -174.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.487 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 21.6 t70 -97.31 103.71 15.66 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 103.199 -2.889 . . . . 0.0 103.199 160.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -128.5 134.32 48.67 Favored 'General case' 0 C--N 1.282 -2.34 0 C-N-CA 118.567 -1.253 . . . . 0.0 113.412 -172.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.62 113.29 8.14 Favored 'General case' 0 N--CA 1.425 -1.713 0 N-CA-C 104.89 -2.263 . . . . 0.0 104.89 171.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.3 m -141.44 105.73 4.82 Favored 'General case' 0 N--CA 1.418 -2.074 0 CA-C-O 122.114 0.959 . . . . 0.0 112.199 -176.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 16.8 m120 -139.47 92.29 2.56 Favored 'General case' 0 N--CA 1.404 -2.74 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 172.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.534 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -66.82 111.49 4.17 Favored Glycine 0 CA--C 1.489 -1.543 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 -177.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.9 ttpp -98.81 128.32 45.0 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.685 -173.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.2 mt -115.71 117.69 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-N 114.874 -1.057 . . . . 0.0 108.258 -178.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.1 m -88.48 106.06 18.02 Favored 'General case' 0 N--CA 1.412 -2.343 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 176.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.8 t -80.44 121.02 33.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 176.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 35.3 p -71.66 -44.82 63.62 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 123.395 0.435 . . . . 0.0 111.602 -176.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.533 ' HA3' ' HB2' ' A' ' 111' ' ' ALA . . . 75.28 35.15 49.23 Favored Glycine 0 N--CA 1.418 -2.529 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.979 -177.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.0 m -75.71 86.32 2.74 Favored 'General case' 0 N--CA 1.435 -1.2 0 CA-C-O 121.599 0.714 . . . . 0.0 110.21 178.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -171.38 169.63 3.04 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -48.9 -40.09 39.9 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.205 1.937 . . . . 0.0 111.237 171.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 55.7 m -155.13 -66.19 0.13 Allowed 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 173.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 35.2 p . . . . . 0 C--O 1.239 0.507 0 C-N-CA 124.552 1.141 . . . . 0.0 108.057 176.137 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.916 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 41.0 m -74.37 123.22 24.23 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-O 121.239 0.543 . . . . 0.0 111.728 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.39 -12.59 58.92 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.446 176.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 55.1 m -129.58 139.23 51.54 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 59.7 t -82.22 -38.77 15.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.2 mttp -100.8 143.61 30.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.108 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.422 HD22 HG21 ' A' ' 133' ' ' ILE . 12.2 m120 -147.08 98.13 2.99 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 169.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.486 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 1.2 pm0 -97.37 -174.15 2.85 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.649 -173.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -95.49 109.51 21.71 Favored 'General case' 0 N--CA 1.418 -2.044 0 CA-C-O 122.24 1.019 . . . . 0.0 108.875 175.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.455 HG13 ' HB ' ' A' ' 30' ' ' VAL . 86.3 t -85.76 115.84 27.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 CA-C-N 115.022 -0.99 . . . . 0.0 108.808 -178.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt -88.39 119.58 28.96 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.825 -174.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -100.51 123.63 44.98 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 34.1 t -121.29 147.27 45.88 Favored 'General case' 0 N--CA 1.417 -2.077 0 CA-C-O 121.806 0.812 . . . . 0.0 111.358 -172.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.45 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.4 m -137.45 162.04 33.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.752 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.38 -173.95 13.15 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.5 m -112.3 128.65 56.33 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.4 m -119.44 164.38 15.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -131.54 152.39 50.8 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.788 0.328 . . . . 0.0 110.857 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.02 174.14 35.29 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -118.4 159.37 43.95 Favored Pre-proline 0 C--N 1.307 -1.264 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -63.27 113.6 2.13 Favored 'Trans proline' 0 C--N 1.365 1.446 0 C-N-CA 122.302 2.001 . . . . 0.0 111.478 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.83 -15.59 37.31 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -90.26 156.23 18.44 Favored 'General case' 0 C--N 1.313 -1.008 0 C-N-CA 123.149 0.58 . . . . 0.0 110.37 -178.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -92.49 143.77 26.02 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.9 p -134.67 143.21 38.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 -177.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 39.4 ttpt -129.97 129.14 43.4 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -109.28 116.25 55.29 Favored Pre-proline 0 C--N 1.309 -1.156 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -84.57 125.22 3.29 Favored 'Trans proline' 0 N--CA 1.445 -1.344 0 C-N-CA 121.86 1.707 . . . . 0.0 112.481 176.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.3 119.67 37.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 177.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.0 m -105.59 143.74 33.33 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -174.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.571 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 15.1 tt -125.97 136.58 60.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.6 m -138.05 155.42 48.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 112.296 0.48 . . . . 0.0 112.296 -175.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 63.35 18.75 11.25 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 125.786 1.634 . . . . 0.0 115.104 174.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.455 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.6 p -90.99 120.41 39.87 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 122.311 -0.243 . . . . 0.0 110.748 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.1 m -117.28 -36.97 3.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 122.161 -0.337 . . . . 0.0 110.625 175.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.4 m -71.42 132.35 85.84 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.51 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 16.9 Cg_exo -64.94 122.63 10.49 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 121.079 1.186 . . . . 0.0 112.85 -177.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.2 p -89.3 133.56 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.802 0 CA-C-N 114.986 -1.006 . . . . 0.0 109.372 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -121.83 -13.44 5.05 Favored Glycine 0 N--CA 1.428 -1.838 0 C-N-CA 119.917 -1.135 . . . . 0.0 113.287 -177.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tt -137.89 112.15 8.59 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 117.823 0.811 . . . . 0.0 109.779 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.1 mt -120.29 123.05 69.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 176.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 50.9 t -125.05 139.54 53.71 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.4 147.93 21.11 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 122.751 0.42 . . . . 0.0 111.111 179.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 7.6 t70 -115.92 116.84 28.67 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 178.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -100.66 108.24 22.73 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 56.7 m -98.66 122.23 41.61 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 176.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -127.87 172.7 10.63 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.862 -175.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -84.33 111.56 19.53 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 175.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.92 -14.63 59.85 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.5 m -92.52 -15.08 27.47 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.578 0.704 . . . . 0.0 109.373 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.454 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -106.39 -40.05 5.71 Favored 'General case' 0 N--CA 1.436 -1.164 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.566 -176.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -118.54 138.38 52.57 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 120.904 0.383 . . . . 0.0 110.316 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 7.0 m -119.48 112.63 19.62 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.4 p -76.73 135.82 25.89 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 C-N-CA 120.307 -0.557 . . . . 0.0 110.218 -178.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -92.3 -62.27 1.44 Allowed 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -171.56 172.46 5.03 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -174.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.5 m -126.9 142.71 42.61 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 90.6 mt -111.54 121.19 40.74 Favored Pre-proline 0 C--N 1.293 -1.854 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_endo -79.95 152.25 21.77 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 121.916 1.744 . . . . 0.0 110.702 177.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.8 t30 -80.04 114.45 18.96 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.7 p -65.92 -16.46 63.88 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 124.666 1.186 . . . . 0.0 112.761 -175.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -68.52 -27.7 66.34 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.502 0.667 . . . . 0.0 109.929 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 74.0 mt -108.74 -57.28 2.16 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.083 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' THR . 32.3 t -90.4 104.11 14.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.5 tmtt? -109.53 142.39 40.66 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -174.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 51.06 77.48 0.13 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 125.331 1.452 . . . . 0.0 112.715 -177.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 26.3 p -65.19 -15.0 61.98 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -175.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -66.45 -16.49 64.15 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.741 1.216 . . . . 0.0 111.175 -179.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OG ' ' A' ' 67' ' ' SER . 81.9 m-20 -74.66 6.06 4.25 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.806 0.443 . . . . 0.0 111.365 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 78.6 t80 71.48 30.77 2.42 Favored 'General case' 0 C--O 1.207 -1.18 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 -174.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.2 m -76.75 -29.31 56.09 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.907 176.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.4 t80 -105.79 106.36 16.83 Favored 'General case' 0 N--CA 1.429 -1.509 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.289 -176.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -119.98 108.14 22.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 87.2 t -126.03 110.07 22.99 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.994 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 176.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -97.8 110.02 22.67 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 21.4 m -81.15 91.12 6.1 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 178.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 m -68.3 175.81 3.11 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 113.489 -1.687 . . . . 0.0 110.936 -179.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 13.6 m -52.28 132.19 42.64 Favored Pre-proline 0 C--O 1.248 0.989 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 176.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -35.65 129.32 0.32 Allowed 'Trans proline' 0 C--N 1.383 2.346 0 C-N-CA 124.671 3.581 . . . . 0.0 113.875 -175.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.71 -13.19 38.74 Favored Glycine 0 N--CA 1.434 -1.486 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.796 -175.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.7 mttm -136.37 141.23 43.69 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 27.0 mt -131.87 127.18 58.19 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 174.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.8 m -107.3 112.21 24.95 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.39 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.52 134.89 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 120.982 0.42 . . . . 0.0 110.131 -176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 35.3 m -138.46 125.31 21.08 Favored 'General case' 0 N--CA 1.414 -2.262 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 176.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -112.17 109.27 18.87 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 175.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.613 ' O ' ' HA ' ' A' ' 67' ' ' SER . 11.5 t -147.0 119.64 8.55 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 177.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -107.54 133.23 20.48 Favored Pre-proline 0 C--N 1.3 -1.573 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.996 -175.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.08 -8.04 13.07 Favored 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.14 2.56 . . . . 0.0 114.133 -177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.3 t -116.0 34.43 4.98 Favored 'General case' 0 N--CA 1.432 -1.345 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -55.02 -15.58 2.18 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 115.658 1.725 . . . . 0.0 115.658 -176.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.45 -24.41 31.85 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.376 0.608 . . . . 0.0 109.88 178.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -93.37 -41.35 9.89 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.336 179.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 53.2 m-85 -119.29 100.35 50.01 Favored Pre-proline 0 N--CA 1.444 -0.755 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 172.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -102.86 142.02 0.16 Allowed 'Trans proline' 0 N--CA 1.437 -1.848 0 C-N-CA 122.313 2.008 . . . . 0.0 113.29 179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.8 mt -94.48 90.44 2.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 171.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.1 p -123.48 11.16 9.23 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-O 121.6 0.714 . . . . 0.0 110.815 -175.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.72 156.71 41.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.571 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.2 p30 -95.72 178.82 5.33 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -176.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.8 -140.03 9.81 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.419 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 47.3 mm -92.88 138.22 20.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 177.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 62.3 tp -93.26 -51.52 4.97 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.97 165.62 35.67 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.501 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.419 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 93.9 m-85 -120.65 119.29 32.4 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 177.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.3 mt -88.85 116.95 27.5 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 178.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -108.15 114.66 28.72 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.22 0.533 . . . . 0.0 110.62 -173.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.67 153.62 42.03 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.797 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 74.5 mt -107.09 127.67 62.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 105.595 -2.002 . . . . 0.0 105.595 169.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.9 mt -79.31 127.23 39.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 174.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -58.67 143.66 45.89 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 123.803 0.69 . . . . 0.0 110.085 -175.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 150' ' ' THR . 11.0 m -66.69 -23.16 66.09 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-O 121.055 0.455 . . . . 0.0 110.118 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -103.0 23.64 11.97 Favored 'General case' 0 CA--C 1.553 1.091 0 CA-C-O 122.323 1.058 . . . . 0.0 109.029 178.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.454 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.33 153.43 27.03 Favored 'General case' 0 C--O 1.249 1.034 0 CA-C-O 121.738 0.78 . . . . 0.0 111.205 179.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.2 m -91.57 148.18 22.47 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.18 156.57 24.37 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.694 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.19 161.24 8.76 Favored Glycine 0 C--N 1.294 -1.804 0 N-CA-C 111.366 -0.694 . . . . 0.0 111.366 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 39.0 t70 -78.6 116.64 19.12 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.0 m -126.83 119.7 27.47 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.604 -173.209 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -93.4 147.36 23.02 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.505 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 33.8 mt -92.76 143.61 26.11 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 104.197 -2.52 . . . . 0.0 104.197 172.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 12.6 m -114.92 104.58 12.07 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 119.226 -0.99 . . . . 0.0 110.251 -176.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 48.6 t -83.6 119.35 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 177.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.412 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 23.2 t70 -69.38 117.06 48.93 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 123.771 0.669 . . . . 0.0 111.378 -174.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 23.4 Cg_exo -65.77 -23.9 55.12 Favored 'Trans proline' 0 C--N 1.362 1.249 0 C-N-CA 123.361 2.707 . . . . 0.0 114.147 -177.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.36 -34.91 54.97 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.003 0.43 . . . . 0.0 110.323 -178.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 4.6 m -86.78 -7.05 58.61 Favored 'General case' 0 N--CA 1.427 -1.595 0 CA-C-O 121.697 0.761 . . . . 0.0 109.827 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.529 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.6 tt -89.62 113.6 25.08 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 59.6 mt -131.34 128.02 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 94.5 t -129.33 97.38 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -110.18 138.37 46.66 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.692 -175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.3 p-10 -83.75 -169.59 2.64 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -67.78 -20.34 65.2 Favored 'General case' 0 CA--C 1.549 0.915 0 CA-C-N 118.632 0.651 . . . . 0.0 110.97 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -83.74 -2.44 56.28 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 123.449 0.699 . . . . 0.0 109.808 177.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 36.2 t70 70.34 23.56 4.98 Favored 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 125.123 1.369 . . . . 0.0 111.024 175.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.458 ' HE2' ' HA ' ' A' ' 131' ' ' LYS . 10.9 mmpt? -95.51 125.17 39.93 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.9 t70 -73.3 123.09 23.06 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 172.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.486 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 9.6 pt -132.97 33.7 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 CA-C-N 116.197 -0.456 . . . . 0.0 112.168 -173.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.505 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.9 pptp? -105.36 131.27 53.0 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 116.597 2.073 . . . . 0.0 116.597 -172.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -97.27 103.68 15.63 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 104.758 -2.312 . . . . 0.0 104.758 165.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.6 121.11 31.26 Favored 'General case' 0 C--N 1.291 -1.958 0 C-N-CA 118.381 -1.327 . . . . 0.0 113.975 -171.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -114.23 113.97 25.35 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 103.586 -2.746 . . . . 0.0 103.586 168.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 m -136.66 110.01 7.89 Favored 'General case' 0 C--N 1.291 -1.943 0 CA-C-O 122.096 0.95 . . . . 0.0 112.698 -172.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.45 ' H ' HG21 ' A' ' 10' ' ' VAL . 4.5 m120 -126.64 -80.07 0.6 Allowed 'General case' 0 N--CA 1.413 -2.315 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.072 177.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.505 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 94.0 63.6 1.04 Allowed Glycine 0 CA--C 1.486 -1.774 0 N-CA-C 107.136 -2.386 . . . . 0.0 107.136 -174.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 27.0 ttpp -80.13 129.54 34.57 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-N 114.787 -0.707 . . . . 0.0 111.488 -171.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 63.6 mt -117.72 115.8 49.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.66 -176.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 34.8 m -85.95 108.8 18.36 Favored 'General case' 0 N--CA 1.416 -2.133 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 175.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.95 107.24 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.326 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 24.1 p -88.23 130.8 34.98 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.17 146.28 14.32 Favored Glycine 0 N--CA 1.419 -2.488 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.957 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.6 t -82.98 -30.73 28.0 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 174.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -155.13 147.4 17.52 Favored Pre-proline 0 N--CA 1.436 -1.15 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 178.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -67.88 140.05 49.39 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 121.907 1.738 . . . . 0.0 109.807 176.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 107' ' ' SER . 94.2 m 71.13 121.37 0.04 OUTLIER 'General case' 0 CA--C 1.556 1.21 0 CA-C-O 122.201 1.001 . . . . 0.0 112.587 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.428 -1.566 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.844 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.883 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 17.0 m -85.06 80.91 9.1 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.359 0.599 . . . . 0.0 109.536 178.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -103.3 -10.66 18.51 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.766 -178.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 4.6 m -91.85 117.87 30.18 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.337 -177.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 61.3 t -81.03 102.02 6.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -78.98 138.59 38.12 Favored 'General case' 0 N--CA 1.417 -2.121 0 CA-C-O 122.088 0.947 . . . . 0.0 110.8 -176.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -148.56 100.26 3.1 Favored 'General case' 0 C--N 1.269 -2.897 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 177.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.506 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 0.8 OUTLIER -92.42 171.61 8.93 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 112.298 0.481 . . . . 0.0 112.298 -172.063 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.4 m -86.57 112.55 21.68 Favored 'General case' 0 N--CA 1.422 -1.854 0 CA-C-O 121.841 0.829 . . . . 0.0 109.938 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.37 122.69 45.07 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-N 114.536 -1.211 . . . . 0.0 108.015 -176.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG3' ' HG3' ' A' ' 29' ' ' GLN . 27.4 mmmt -89.5 113.63 25.04 Favored 'General case' 0 C--N 1.272 -2.798 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.812 -176.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -93.74 124.53 37.8 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 173.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.9 m -126.87 153.33 45.85 Favored 'General case' 0 N--CA 1.394 -3.275 0 CA-C-O 122.07 0.938 . . . . 0.0 113.297 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.642 HG21 ' H ' ' A' ' 139' ' ' ASN . 20.7 m -127.34 163.1 31.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 CA-C-N 114.364 -1.289 . . . . 0.0 109.056 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.73 173.03 22.0 Favored Glycine 0 N--CA 1.424 -2.127 0 C-N-CA 120.415 -0.897 . . . . 0.0 110.869 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.413 HG23 ' HB3' ' A' ' 141' ' ' LYS . 50.0 m -110.7 129.53 55.81 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -124.76 164.22 23.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.48 -178.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 p -118.87 160.63 21.58 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -166.84 178.38 41.18 Favored Glycine 0 N--CA 1.436 -1.301 0 C-N-CA 120.875 -0.678 . . . . 0.0 111.856 179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 54.0 m-80 -139.16 157.2 71.57 Favored Pre-proline 0 C--N 1.321 -0.662 0 C-N-CA 123.702 0.801 . . . . 0.0 109.011 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo -58.28 131.7 44.61 Favored 'Trans proline' 0 C--N 1.365 1.438 0 C-N-CA 122.776 2.317 . . . . 0.0 112.189 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.45 35.3 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.847 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -90.41 147.28 23.54 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 120.954 0.407 . . . . 0.0 110.752 -177.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.9 m -88.21 127.58 35.45 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.4 p -110.31 141.77 24.67 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -120.49 126.2 49.78 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.51 112.87 53.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -79.3 122.6 5.22 Favored 'Trans proline' 0 CA--C 1.545 1.046 0 C-N-CA 121.975 1.784 . . . . 0.0 112.722 178.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -89.76 113.65 26.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 176.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 5.4 m -99.36 139.96 34.25 Favored 'General case' 0 N--CA 1.412 -2.367 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.449 -171.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.589 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.4 tt -126.11 132.07 70.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 177.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.527 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 49.7 m -143.16 159.88 41.46 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.869 -0.52 . . . . 0.0 111.439 -178.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . 0.419 ' HG3' ' HG3' ' A' ' 7' ' ' LYS . 8.0 mm100 75.01 19.92 2.26 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 124.259 1.024 . . . . 0.0 112.463 172.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 95' ' ' ASP . 9.2 p -94.23 134.91 30.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.2 m -130.26 -33.0 1.74 Allowed 'General case' 0 N--CA 1.416 -2.126 0 CA-C-O 120.916 0.388 . . . . 0.0 110.76 176.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.5 m -76.64 135.74 68.07 Favored Pre-proline 0 C--N 1.319 -0.747 0 N-CA-C 107.026 -1.472 . . . . 0.0 107.026 175.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.9 Cg_exo -60.47 122.75 11.78 Favored 'Trans proline' 0 C--N 1.357 0.976 0 C-N-CA 121.048 1.165 . . . . 0.0 111.668 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.6 p -88.91 146.2 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.365 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.696 179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.96 -12.52 0.31 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 119.171 -1.49 . . . . 0.0 113.975 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 92.1 mt -128.99 112.19 13.79 Favored 'General case' 0 CA--C 1.498 -1.053 0 CA-C-N 117.196 0.498 . . . . 0.0 110.622 -177.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -130.41 130.73 65.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.8 t -137.31 145.66 43.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -157.65 145.87 19.07 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 122.543 0.337 . . . . 0.0 111.522 178.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 10.0 t70 -116.92 114.12 23.4 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -179.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 3.7 mp -108.53 121.21 61.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -176.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.453 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 12.9 m -107.54 126.35 52.43 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.2 p90 -141.39 173.47 11.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -78.72 109.07 12.62 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.16 -26.17 65.62 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -82.36 -32.51 29.23 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.969 0.414 . . . . 0.0 110.546 -179.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 76.6 tttt -82.79 -36.85 25.27 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.326 -174.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -127.46 156.78 41.58 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 -178.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 56.6 m -137.51 113.77 10.06 Favored 'General case' 0 C--N 1.289 -2.064 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.6 p -73.39 133.44 31.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.769 179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -96.03 -47.47 6.08 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -173.48 177.37 2.59 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.425 HG22 HG21 ' A' ' 70' ' ' VAL . 15.8 m -130.89 139.0 52.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 N-CA-C 105.813 -1.921 . . . . 0.0 105.813 174.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 97.9 mt -100.92 109.75 59.0 Favored Pre-proline 0 C--N 1.284 -2.261 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -178.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_endo -78.83 145.85 20.35 Favored 'Trans proline' 0 N--CA 1.439 -1.69 0 C-N-CA 122.14 1.893 . . . . 0.0 111.235 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.0 t30 -81.89 112.22 18.81 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 5.5 p -73.66 -1.01 17.18 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 113.545 0.943 . . . . 0.0 113.545 -176.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -80.71 -18.13 48.85 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.357 0.599 . . . . 0.0 109.484 172.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.474 ' O ' ' HG2' ' A' ' 61' ' ' LYS . 75.0 mt -110.59 -69.07 0.89 Allowed 'General case' 0 C--O 1.195 -1.781 0 CA-C-N 115.193 -0.912 . . . . 0.0 108.983 175.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 57' ' ' THR . 48.2 t -68.9 113.4 4.56 Favored 'Isoleucine or valine' 0 C--O 1.244 0.792 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.51 ' HG3' ' HB3' ' A' ' 90' ' ' TYR . 75.0 mmtt -98.49 130.85 45.08 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -170.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.5 t70 36.77 86.94 0.01 OUTLIER 'General case' 0 C--O 1.244 0.777 0 C-N-CA 127.36 2.264 . . . . 0.0 111.853 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.0 p -53.09 -28.63 26.12 Favored 'General case' 0 C--O 1.241 0.657 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 -170.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -61.76 -20.67 63.82 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 124.561 1.144 . . . . 0.0 111.819 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -78.46 9.65 3.79 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 178.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 32.3 t80 74.75 33.36 0.79 Allowed 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 124.935 1.294 . . . . 0.0 108.782 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.3 m -80.64 -24.14 39.23 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.175 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.9 t80 -104.95 115.38 30.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.812 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.1 mp -131.71 109.84 16.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.425 HG21 HG22 ' A' ' 53' ' ' VAL . 91.2 t -127.72 116.18 42.26 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 176.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -104.0 119.65 39.38 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.111 -0.95 . . . . 0.0 109.752 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.4 p -77.81 94.48 4.51 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 122.168 0.985 . . . . 0.0 109.023 173.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 17.0 m -77.19 174.65 10.48 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.066 -1.425 . . . . 0.0 111.147 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.8 m -49.54 133.22 18.98 Favored Pre-proline 0 C--O 1.249 1.065 0 C-N-CA 124.007 0.923 . . . . 0.0 109.23 176.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -36.55 124.93 0.39 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.782 3.654 . . . . 0.0 113.924 -176.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.34 -16.43 38.16 Favored Glycine 0 N--CA 1.427 -1.923 0 CA-C-N 114.848 -1.069 . . . . 0.0 111.601 -177.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.453 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 76.1 mttt -128.54 156.63 43.0 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 113.95 1.092 . . . . 0.0 113.95 177.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.1 mt -136.28 134.76 49.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 174.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.2 m -115.29 113.56 24.01 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 68.0 mt -112.66 139.26 38.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.451 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 66.0 m -141.87 139.9 32.75 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -127.87 114.52 17.31 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 174.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.712 ' O ' ' HA ' ' A' ' 67' ' ' SER . 50.7 p -123.07 118.08 26.9 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 177.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -110.35 112.77 56.82 Favored Pre-proline 0 C--N 1.292 -1.9 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.796 -173.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -83.72 -8.13 10.35 Favored 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 122.433 2.088 . . . . 0.0 112.507 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 8.76 44.58 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 123.682 0.793 . . . . 0.0 112.266 -176.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.403 HD12 ' N ' ' A' ' 88' ' ' ALA . 2.8 pp -50.87 -25.67 4.84 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 116.196 1.925 . . . . 0.0 116.196 -177.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.403 ' N ' HD12 ' A' ' 87' ' ' LEU . . . -89.3 -27.39 20.58 Favored 'General case' 0 C--N 1.323 -0.575 0 O-C-N 121.838 -0.539 . . . . 0.0 111.188 -178.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -89.38 -41.59 12.03 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.299 -178.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.51 ' HB3' ' HG3' ' A' ' 61' ' ' LYS . 81.2 m-85 -119.76 103.52 45.87 Favored Pre-proline 0 N--CA 1.427 -1.593 0 N-CA-C 105.719 -1.956 . . . . 0.0 105.719 174.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -83.0 124.37 3.82 Favored 'Trans proline' 0 N--CA 1.445 -1.342 0 C-N-CA 121.232 1.288 . . . . 0.0 113.601 -175.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 12.3 mt -90.83 89.23 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 105.608 -1.997 . . . . 0.0 105.608 171.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.6 p -132.19 13.01 4.68 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.433 0.635 . . . . 0.0 110.974 -175.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 19.3 m -121.37 157.44 24.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.589 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.2 p30 -107.21 176.23 5.23 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -178.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.16 -130.57 3.4 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -106.09 131.75 54.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 178.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 53.7 tp -81.76 -53.23 6.37 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-O 121.156 0.503 . . . . 0.0 109.94 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.37 155.21 37.16 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.662 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.5 124.09 50.49 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 48.6 mt -85.35 122.19 29.15 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -113.17 105.11 13.04 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 121.619 0.723 . . . . 0.0 109.946 -173.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -114.04 146.13 40.62 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.891 -175.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 61.4 mt -94.62 132.48 38.54 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 105.628 -1.99 . . . . 0.0 105.628 169.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 46.8 mt -85.81 120.68 36.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 173.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -56.82 139.84 49.88 Favored 'General case' 0 C--N 1.316 -0.871 0 O-C-N 124.069 0.855 . . . . 0.0 111.002 -173.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 17.5 m -62.16 -21.64 65.23 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 123.518 0.727 . . . . 0.0 111.077 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.2 t30 -96.45 1.92 52.06 Favored 'General case' 0 CA--C 1.56 1.327 0 CA-C-O 121.528 0.68 . . . . 0.0 110.746 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -74.44 153.19 39.29 Favored 'General case' 0 C--O 1.24 0.602 0 O-C-N 121.698 -0.626 . . . . 0.0 111.145 -179.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 8.0 m -108.22 161.45 14.98 Favored 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -178.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.604 ' HB2' ' HA2' ' A' ' 146' ' ' GLY . . . -71.05 155.94 40.21 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.037 0.446 . . . . 0.0 111.629 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.62 166.91 11.48 Favored Glycine 0 N--CA 1.42 -2.376 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -178.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -84.34 154.71 22.73 Favored 'General case' 0 C--N 1.291 -1.975 0 C-N-CA 123.203 0.601 . . . . 0.0 110.854 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 67.8 m -143.93 117.72 9.31 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.271 175.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -87.6 140.08 29.88 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 177.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.552 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.8 mt -99.99 113.1 25.45 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 87.1 m -86.04 106.65 17.35 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 21.7 t -103.64 114.89 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 176.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.44 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 28.5 t70 -72.1 113.28 19.1 Favored Pre-proline 0 C--N 1.307 -1.261 0 O-C-N 123.874 0.734 . . . . 0.0 111.576 -174.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.4 Cg_exo -67.56 -12.65 36.36 Favored 'Trans proline' 0 C--N 1.368 1.576 0 C-N-CA 123.804 3.003 . . . . 0.0 114.058 -177.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -84.95 -38.77 18.93 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 120.943 0.402 . . . . 0.0 110.155 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 12.8 m -83.03 -13.05 56.62 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-O 121.981 0.896 . . . . 0.0 108.824 176.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.8 tt -82.86 120.48 25.71 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 176.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 69.0 mt -131.75 127.68 59.2 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 86.5 t -129.78 96.89 3.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 176.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -112.17 147.6 35.8 Favored 'General case' 0 N--CA 1.414 -2.225 0 CA-C-N 114.597 -1.183 . . . . 0.0 109.511 -178.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.547 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.6 p-10 -85.87 -168.75 2.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.045 -178.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.05 -26.86 69.04 Favored 'General case' 0 CA--C 1.539 0.521 0 CA-C-O 120.733 0.302 . . . . 0.0 111.334 178.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 56.5 t30 -89.7 8.11 33.3 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 123.42 0.688 . . . . 0.0 109.816 179.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 37.5 t70 62.54 29.38 17.01 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 125.247 1.419 . . . . 0.0 112.402 173.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 48.3 mmtm -97.05 122.13 39.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.076 -1.015 . . . . 0.0 108.351 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -72.05 112.96 8.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 12.1 pt -118.46 27.91 3.28 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.241 -172.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.515 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.09 131.3 52.77 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 114.994 1.479 . . . . 0.0 114.994 -174.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -98.31 103.67 15.63 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 161.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.41 120.57 36.34 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 118.535 -1.266 . . . . 0.0 113.329 -173.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -107.26 112.69 25.67 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.7 m -130.95 105.71 7.93 Favored 'General case' 0 N--CA 1.407 -2.585 0 CA-C-O 122.649 1.214 . . . . 0.0 111.939 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.642 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.1 t-20 -158.89 90.14 0.98 Allowed 'General case' 0 C--N 1.288 -2.088 0 CA-C-N 113.188 -1.824 . . . . 0.0 106.797 176.629 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.37 166.04 54.78 Favored Glycine 0 CA--C 1.495 -1.213 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HB3' HG23 ' A' ' 12' ' ' THR . 45.8 tttp -146.5 128.97 15.96 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 118.655 1.227 . . . . 0.0 109.256 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.7 mt -112.42 123.24 67.94 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 177.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 12.2 m -106.73 105.9 16.16 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-O 120.79 0.329 . . . . 0.0 110.163 -178.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 55.0 t -81.97 113.81 21.88 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 16.5 p -74.1 -41.86 60.98 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -173.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.604 ' HA2' ' HB2' ' A' ' 111' ' ' ALA . . . 174.19 -92.73 0.09 OUTLIER Glycine 0 CA--C 1.475 -2.406 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.117 178.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.427 ' O ' ' HD3' ' A' ' 149' ' ' PRO . 5.8 p -150.13 158.78 44.52 Favored 'General case' 0 C--N 1.283 -2.293 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 178.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -88.48 107.72 18.41 Favored Pre-proline 0 C--N 1.31 -1.116 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -177.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 147' ' ' SER . 96.3 Cg_endo -89.24 146.31 5.24 Favored 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 122.225 1.95 . . . . 0.0 113.171 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.1 t -76.04 107.8 8.5 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 174.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 37.6 m . . . . . 0 C--N 1.298 -1.661 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.024 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.871 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 50.2 m -132.64 13.44 4.46 Favored 'General case' 0 C--N 1.317 -0.823 0 O-C-N 122.234 -0.568 . . . . 0.0 110.859 178.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -72.92 -24.4 60.82 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.037 0.446 . . . . 0.0 112.052 -175.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 19.5 m -131.58 119.67 21.79 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -178.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.7 p -84.34 -42.72 17.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 177.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HA ' ' HE2' ' A' ' 2' ' ' LYS . 7.0 mmpt? -147.13 105.79 3.82 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 174.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -160.44 156.33 25.87 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 -177.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.0 mm-40 -129.14 163.44 25.51 Favored 'General case' 0 N--CA 1.412 -2.365 0 C-N-CA 122.657 0.383 . . . . 0.0 110.28 -173.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.1 m -91.16 107.73 19.4 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 174.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.601 ' O ' ' HD3' ' A' ' 134' ' ' LYS . 25.8 t -90.98 121.98 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.52 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -172.084 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 56.3 mttm -84.97 143.14 29.14 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-O 121.419 0.628 . . . . 0.0 112.543 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 134' ' ' LYS . 20.0 tp -120.24 113.21 20.08 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 172.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.6 t -114.78 147.72 39.4 Favored 'General case' 0 C--N 1.291 -1.953 0 O-C-N 124.043 0.839 . . . . 0.0 110.5 -173.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.488 HG21 ' H ' ' A' ' 139' ' ' ASN . 21.9 m -121.64 162.46 20.83 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.042 179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.64 176.32 20.22 Favored Glycine 0 N--CA 1.421 -2.317 0 C-N-CA 119.612 -1.28 . . . . 0.0 111.68 -179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.4 m -110.67 120.11 41.33 Favored 'General case' 0 N--CA 1.422 -1.827 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.3 m -114.5 163.47 11.73 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-N 114.987 -1.006 . . . . 0.0 108.587 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 p -123.02 149.38 44.41 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.0 172.87 35.81 Favored Glycine 0 N--CA 1.439 -1.165 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 30.0 m-80 -118.67 152.93 51.99 Favored Pre-proline 0 C--N 1.306 -1.318 0 CA-C-N 117.277 0.538 . . . . 0.0 109.728 -177.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 147' ' ' SER . 22.2 Cg_exo -66.56 116.41 4.06 Favored 'Trans proline' 0 C--N 1.351 0.684 0 C-N-CA 122.372 2.048 . . . . 0.0 110.614 175.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.88 -19.5 35.42 Favored Glycine 0 N--CA 1.442 -0.961 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -91.26 163.8 14.1 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 124.229 1.012 . . . . 0.0 109.934 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.4 m -98.58 146.0 26.26 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.0 p -134.47 141.84 42.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -123.32 126.15 46.34 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.21 108.85 61.59 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -81.27 123.49 4.47 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.971 1.78 . . . . 0.0 112.288 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.03 121.12 39.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 177.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.7 m -96.32 135.51 38.06 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.239 0.542 . . . . 0.0 110.646 -172.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.545 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -122.28 134.18 66.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 175.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 55.2 m -147.06 165.86 28.64 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 67.93 27.27 7.26 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.095 0.958 . . . . 0.0 112.962 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HB ' HG13 ' A' ' 6' ' ' VAL . 11.1 p -96.97 140.68 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.373 0 CA-C-O 121.137 0.494 . . . . 0.0 109.879 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.9 t -143.95 -42.46 0.27 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.3 m -76.44 131.72 74.14 Favored Pre-proline 0 N--CA 1.424 -1.763 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 175.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.0 Cg_exo -59.85 124.88 16.29 Favored 'Trans proline' 0 C--O 1.243 0.741 0 C-N-CA 121.764 1.643 . . . . 0.0 110.548 175.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.9 p -84.96 144.42 9.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.762 -179.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -117.77 -29.68 1.98 Allowed Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.781 -176.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.8 tt -139.9 112.84 8.11 Favored 'General case' 0 C--O 1.218 -0.578 0 CA-C-N 117.517 0.658 . . . . 0.0 109.643 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 81' ' ' THR . 58.5 mt -117.42 118.14 57.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 173.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.7 t -123.99 139.86 53.54 Favored 'General case' 0 C--N 1.284 -2.268 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 177.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.24 152.32 25.98 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -126.63 120.64 30.02 Favored 'General case' 0 CA--C 1.487 -1.459 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.9 mm -99.84 108.36 22.57 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -175.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.5 m -101.02 125.95 47.67 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 176.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -143.69 170.2 16.3 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 -175.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -82.46 105.22 13.34 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 121.522 0.677 . . . . 0.0 109.525 175.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.8 5.09 22.73 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.223 -176.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -88.53 -31.56 18.63 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 174.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.517 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 73.5 tttt -98.27 -36.05 10.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.52 -174.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -119.99 151.07 39.52 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 24.7 m -128.77 114.03 16.06 Favored 'General case' 0 C--N 1.281 -2.412 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -72.97 132.83 32.86 Favored 'Isoleucine or valine' 0 C--O 1.25 1.115 0 CA-C-O 121.427 0.632 . . . . 0.0 111.117 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -86.2 -57.83 2.87 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.704 175.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -178.99 177.37 0.82 Allowed 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 -176.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.0 m -124.67 137.45 57.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 177.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 71.5 mt -96.26 118.05 65.77 Favored Pre-proline 0 C--N 1.287 -2.15 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -177.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -77.38 138.61 17.78 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.512 1.474 . . . . 0.0 109.258 176.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -76.85 108.93 10.24 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 176.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.3 p -74.27 -0.88 18.37 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -173.477 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -79.67 -27.04 40.83 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.998 0.904 . . . . 0.0 108.657 171.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 57.9 mt -106.08 -69.17 0.84 Allowed 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.573 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 13.8 t -89.63 101.89 12.58 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 -179.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.445 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.8 tttm -121.07 158.09 28.62 Favored 'General case' 0 N--CA 1.415 -2.193 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 59.31 47.33 11.54 Favored 'General case' 0 CA--C 1.506 -0.739 0 O-C-N 124.499 1.124 . . . . 0.0 109.802 179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 24.1 p -57.42 -19.51 24.08 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-N 113.688 -1.596 . . . . 0.0 113.074 -176.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -58.48 -23.3 57.47 Favored 'General case' 0 C--O 1.214 -0.796 0 C-N-CA 125.095 1.358 . . . . 0.0 111.255 175.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -79.32 15.32 1.25 Allowed 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 31.8 t80 68.75 33.45 3.73 Favored 'General case' 0 C--O 1.216 -0.674 0 C-N-CA 124.945 1.298 . . . . 0.0 108.499 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.6 m -80.73 -20.5 42.64 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.385 -1.28 . . . . 0.0 108.936 176.354 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -112.56 106.63 15.11 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 114.474 -1.239 . . . . 0.0 108.895 -176.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.6 mp -117.79 107.9 23.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.0 t -128.64 110.66 21.64 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.4 t30 -103.15 122.82 45.49 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.158 -0.928 . . . . 0.0 108.589 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.6 p -74.84 102.96 4.89 Favored 'General case' 0 N--CA 1.418 -2.053 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 174.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 8.3 m -81.8 175.18 10.65 Favored 'General case' 0 N--CA 1.418 -2.057 0 CA-C-N 114.622 -1.172 . . . . 0.0 110.586 -177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 24.7 m -48.92 133.45 14.71 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 124.034 0.934 . . . . 0.0 108.991 174.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -35.87 121.47 0.23 Allowed 'Trans proline' 0 C--N 1.38 2.198 0 C-N-CA 124.906 3.737 . . . . 0.0 113.948 -175.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.13 -6.78 37.11 Favored Glycine 0 C--O 1.209 -1.467 0 CA-C-N 115.278 -0.874 . . . . 0.0 112.528 -177.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -132.75 149.53 52.27 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 117.389 0.595 . . . . 0.0 111.919 176.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.2 mt -138.47 115.47 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 N-CA-C 106.662 -1.607 . . . . 0.0 106.662 175.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 47.1 m -91.77 112.19 24.02 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 177.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.9 mt -115.37 131.36 67.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 44.9 m -141.89 128.0 19.68 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-O 121.116 0.484 . . . . 0.0 109.852 177.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -115.34 109.05 17.35 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.63 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.2 t -138.55 119.36 14.19 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 176.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -112.36 124.44 32.02 Favored Pre-proline 0 C--N 1.296 -1.729 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.088 -174.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -80.59 -3.39 12.43 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 122.9 2.4 . . . . 0.0 112.134 178.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.7 16.56 26.12 Favored 'General case' 0 CA--C 1.557 1.239 0 C-N-CA 123.432 0.693 . . . . 0.0 109.722 -176.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -54.38 -18.81 4.52 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 116.328 1.973 . . . . 0.0 116.328 -174.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.86 -26.71 27.19 Favored 'General case' 0 C--N 1.316 -0.888 0 O-C-N 121.855 -0.528 . . . . 0.0 110.565 178.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -95.06 -40.66 9.52 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.862 -179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.445 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 93.9 m-85 -113.7 100.72 52.72 Favored Pre-proline 0 N--CA 1.432 -1.333 0 N-CA-C 106.695 -1.594 . . . . 0.0 106.695 172.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_endo -93.62 105.45 0.15 Allowed 'Trans proline' 0 N--CA 1.42 -2.842 0 C-N-CA 121.389 1.392 . . . . 0.0 111.512 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.59 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.4 mt -71.4 90.95 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 176.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p -133.26 6.67 3.87 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.411 -174.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.49 160.65 18.09 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 7.6 p-10 -111.93 -176.3 2.9 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 121.663 0.744 . . . . 0.0 112.969 -173.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.68 -135.88 5.95 Favored Glycine 0 N--CA 1.428 -1.855 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -178.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.01 138.29 22.41 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 172.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.3 tp -82.79 -51.65 7.47 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 121.477 0.656 . . . . 0.0 109.869 -178.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.29 153.09 31.96 Favored 'General case' 0 N--CA 1.432 -1.375 0 CA-C-N 115.326 -0.852 . . . . 0.0 109.211 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.432 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 70.5 m-85 -108.71 117.01 33.06 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 177.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 42.9 mt -85.69 116.37 23.92 Favored 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -109.08 114.74 28.73 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 120.239 -0.585 . . . . 0.0 110.573 -172.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -124.13 154.31 40.21 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.668 -175.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.5 mt -105.72 132.72 51.99 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.162 0 N-CA-C 105.2 -2.148 . . . . 0.0 105.2 169.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -85.36 127.61 39.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.752 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 175.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -60.05 137.0 58.19 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 123.806 0.691 . . . . 0.0 109.423 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.5 p -72.36 -10.4 59.74 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-O 121.392 0.615 . . . . 0.0 112.046 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -94.76 -5.42 45.34 Favored 'General case' 0 CA--C 1.546 0.802 0 CA-C-O 121.812 0.815 . . . . 0.0 109.237 176.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.517 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -82.03 161.25 23.02 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.768 -178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.1 t -115.44 179.62 3.91 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.421 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.04 158.59 30.46 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.93 0.892 . . . . 0.0 111.727 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.35 159.26 9.01 Favored Glycine 0 N--CA 1.434 -1.487 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.575 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -81.7 127.54 33.03 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.587 0.755 . . . . 0.0 109.749 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 37.1 m -136.14 114.61 11.77 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.508 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -89.82 153.25 20.81 Favored 'General case' 0 N--CA 1.424 -1.725 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.543 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 23.6 mt -92.19 147.61 22.8 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 176.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 m -112.29 104.13 12.29 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.6 t -88.65 121.62 39.08 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.437 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 14.2 t70 -68.84 111.68 9.1 Favored Pre-proline 0 C--N 1.319 -0.733 0 O-C-N 124.182 0.926 . . . . 0.0 109.766 -177.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 5.2 Cg_exo -74.66 -13.98 22.1 Favored 'Trans proline' 0 C--N 1.358 1.072 0 C-N-CA 122.579 2.186 . . . . 0.0 113.654 -176.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.58 -36.85 43.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.457 0.646 . . . . 0.0 109.945 -179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.9 m -82.85 -12.59 57.31 Favored 'General case' 0 N--CA 1.421 -1.897 0 CA-C-N 115.298 -0.865 . . . . 0.0 109.937 177.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 6.2 tt -79.59 110.91 15.36 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.0 mt -125.1 129.35 73.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.3 t -131.47 96.63 2.66 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 176.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.97 139.6 41.11 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.952 -177.189 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.5 p-10 -83.98 -167.09 1.61 Allowed 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.564 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.11 -29.27 70.66 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 123.044 0.537 . . . . 0.0 110.827 176.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -91.38 16.35 10.35 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 178.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.3 p30 56.86 23.64 8.35 Favored 'General case' 0 N--CA 1.484 1.249 0 C-N-CA 127.543 2.337 . . . . 0.0 114.768 174.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.413 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 43.4 mmtm -105.29 143.35 33.59 Favored 'General case' 0 C--N 1.309 -1.164 0 O-C-N 121.476 -0.765 . . . . 0.0 111.175 -179.014 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.592 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.7 t70 -77.84 130.96 37.29 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -177.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.4 pt -139.85 32.03 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.212 -174.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.612 ' HD2' ' HB2' ' A' ' 8' ' ' LEU . 14.6 tppt? -104.86 128.94 53.25 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.432 -1.307 . . . . 0.0 114.263 -174.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.405 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 23.9 t70 -96.94 103.4 15.32 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 166.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.25 136.85 54.91 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 114.079 1.14 . . . . 0.0 114.079 -175.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -126.5 113.08 16.34 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 102.748 -3.056 . . . . 0.0 102.748 166.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.9 m -132.32 106.87 8.18 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 118.343 -1.343 . . . . 0.0 113.925 -170.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.488 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.9 m120 -133.08 -87.36 0.43 Allowed 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.707 -1.588 . . . . 0.0 109.921 176.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . 96.64 94.44 1.84 Allowed Glycine 0 N--CA 1.433 -1.534 0 N-CA-C 107.587 -2.205 . . . . 0.0 107.587 -175.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 28.6 ttpp -102.82 129.13 49.39 Favored 'General case' 0 C--N 1.293 -1.858 0 C-N-CA 119.734 -0.787 . . . . 0.0 111.143 -173.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.2 mt -108.9 113.57 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.817 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.0 m -87.86 105.55 17.5 Favored 'General case' 0 N--CA 1.418 -2.067 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 175.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.455 HG21 ' HE2' ' A' ' 47' ' ' LYS . 44.7 t -80.44 118.11 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.0 p -93.66 110.77 22.37 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 115.684 -0.689 . . . . 0.0 112.047 -176.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 50.93 -124.41 20.58 Favored Glycine 0 CA--C 1.522 0.493 0 O-C-N 124.487 1.117 . . . . 0.0 114.497 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.458 ' HA ' ' HD2' ' A' ' 17' ' ' PRO . 66.9 m -149.64 144.3 26.06 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 124.073 0.949 . . . . 0.0 108.726 177.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -97.52 112.38 61.09 Favored Pre-proline 0 C--N 1.321 -0.648 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -69.16 -24.63 32.19 Favored 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.246 1.964 . . . . 0.0 113.821 -177.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.8 m -142.61 102.43 4.06 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.534 -0.729 . . . . 0.0 111.199 -178.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 16.4 t . . . . . 0 N--CA 1.425 -1.71 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 177.12 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 20.9 m -96.41 2.57 52.74 Favored 'General case' 0 C--N 1.314 -0.94 0 C-N-CA 122.48 0.312 . . . . 0.0 110.811 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.31 96.26 0.07 Allowed 'General case' 0 C--N 1.346 0.441 0 C-N-CA 124.884 1.274 . . . . 0.0 110.431 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . 0.42 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 33.1 t -105.13 168.0 9.34 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.052 -0.977 . . . . 0.0 108.803 -178.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.6 p -84.5 -23.32 7.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.087 179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.8 tttm -142.92 145.7 33.3 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.419 -0.512 . . . . 0.0 110.907 -178.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.5 m120 61.67 73.25 0.48 Allowed 'General case' 0 C--N 1.312 -1.042 0 C-N-CA 126.779 2.032 . . . . 0.0 112.352 -178.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.42 ' CD ' ' H ' ' A' ' 0' ' ' SER . 9.5 mm-40 -118.94 164.68 15.1 Favored 'General case' 0 N--CA 1.421 -1.896 0 CA-C-N 113.861 -1.518 . . . . 0.0 110.473 -177.116 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 27.2 m -67.35 107.27 2.35 Favored 'General case' 0 CA--C 1.555 1.139 0 O-C-N 124.17 0.919 . . . . 0.0 111.372 -179.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.491 HG13 ' HB ' ' A' ' 30' ' ' VAL . 67.1 t -97.07 126.1 49.93 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.921 0 C-N-CA 124.194 0.998 . . . . 0.0 109.862 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 60.4 mttm -88.48 138.51 31.37 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -118.46 128.11 54.29 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 171.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.2 t -130.79 159.09 38.35 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-O 120.975 0.417 . . . . 0.0 110.126 -175.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.474 HG21 ' H ' ' A' ' 139' ' ' ASN . 12.8 m -139.93 161.7 26.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 C-N-CA 124.941 1.296 . . . . 0.0 108.729 -176.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.15 -177.28 14.88 Favored Glycine 0 N--CA 1.435 -1.419 0 C-N-CA 120.23 -0.986 . . . . 0.0 112.414 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 88.8 m -111.34 137.85 48.58 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 m -133.03 164.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 124.151 0.98 . . . . 0.0 108.715 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.7 m -124.13 159.19 30.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 177.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.3 173.28 41.06 Favored Glycine 0 N--CA 1.436 -1.352 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 178.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.433 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 48.7 m-80 -118.52 155.49 52.11 Favored Pre-proline 0 C--N 1.311 -1.102 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_exo -60.7 123.01 12.14 Favored 'Trans proline' 0 CA--C 1.539 0.762 0 C-N-CA 122.279 1.986 . . . . 0.0 110.985 174.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 99.77 -16.5 58.54 Favored Glycine 0 C--N 1.316 -0.556 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.6 t70 -89.78 149.87 22.52 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.555 0.742 . . . . 0.0 110.549 -179.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.7 m -92.71 123.54 36.07 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -178.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 p -115.15 148.49 17.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 -175.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.1 ttmm -129.83 131.5 46.16 Favored 'General case' 0 C--N 1.315 -0.917 0 C-N-CA 123.044 0.538 . . . . 0.0 109.877 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -116.63 117.67 37.71 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -84.84 127.09 3.51 Favored 'Trans proline' 0 CA--C 1.547 1.166 0 C-N-CA 122.135 1.89 . . . . 0.0 113.475 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.6 t -90.95 113.89 27.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.8 m -97.63 143.7 28.03 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.466 -174.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.5 tt -126.68 134.11 67.03 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 108.05 -1.092 . . . . 0.0 108.05 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.2 m -144.17 158.2 43.86 Favored 'General case' 0 C--N 1.309 -1.194 0 O-C-N 122.121 -0.362 . . . . 0.0 110.899 -176.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 62.89 26.17 15.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 124.593 1.157 . . . . 0.0 112.337 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.491 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.2 p -83.41 109.5 17.16 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.82 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.58 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.2 m -111.33 8.71 21.47 Favored 'General case' 0 N--CA 1.429 -1.513 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.001 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 57.6 m -136.72 131.57 18.22 Favored Pre-proline 0 C--N 1.302 -1.461 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 53.3 Cg_exo -57.0 124.27 15.83 Favored 'Trans proline' 0 C--N 1.356 0.972 0 C-N-CA 121.656 1.571 . . . . 0.0 111.527 177.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 9.9 p -87.74 148.74 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.764 -178.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -133.87 -28.91 0.48 Allowed Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 119.46 -1.352 . . . . 0.0 114.576 -176.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -131.16 112.29 12.71 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 -176.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 4.3 mp -125.14 122.59 63.47 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 33.9 t -130.02 139.31 51.04 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 107.229 -1.397 . . . . 0.0 107.229 176.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ptp -157.43 142.92 17.26 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.006 0.431 . . . . 0.0 111.191 179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.6 t0 -111.74 116.78 31.3 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 106.808 -1.553 . . . . 0.0 106.808 177.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.465 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.42 107.85 22.29 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 33.8 m -94.34 132.44 38.94 Favored 'General case' 0 C--N 1.289 -2.029 0 N-CA-C 107.47 -1.307 . . . . 0.0 107.47 176.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.3 p90 -137.05 174.25 10.82 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.658 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -74.14 103.03 4.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.27 -14.84 63.17 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 113.28 0.844 . . . . 0.0 113.28 -175.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.3 t -89.85 -26.6 20.43 Favored 'General case' 0 N--CA 1.428 -1.549 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 61.8 mttp -98.92 -36.01 9.9 Favored 'General case' 0 N--CA 1.441 -0.912 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -120.83 157.28 30.12 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.389 -0.924 . . . . 0.0 111.39 -173.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 32.1 m -139.34 116.81 11.32 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 172.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.1 p -68.89 135.02 29.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.145 0.498 . . . . 0.0 111.154 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.3 mtpm? -89.79 -62.16 1.53 Allowed 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.885 0.85 . . . . 0.0 108.794 175.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -173.4 176.28 2.88 Favored 'General case' 0 N--CA 1.423 -1.804 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 -173.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.422 HG12 ' HA ' ' A' ' 101' ' ' LEU . 19.9 m -128.93 142.4 44.11 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.848 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.071 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 94.0 mt -99.12 122.79 51.2 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -78.27 133.31 11.96 Favored 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 121.648 1.565 . . . . 0.0 109.888 176.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 12.1 t30 -78.93 102.83 8.48 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.598 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 7.6 p -68.45 -6.37 24.48 Favored 'General case' 0 C--O 1.241 0.629 0 N-CA-C 114.984 1.475 . . . . 0.0 114.984 -169.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -65.05 -37.8 88.73 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 171.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.425 ' HB3' HG23 ' A' ' 92' ' ' ILE . 61.4 mt -98.25 -66.06 0.92 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.341 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.8 t -80.63 110.9 16.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -177.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -126.5 155.94 41.53 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -175.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.409 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 0.6 OUTLIER 55.15 57.03 5.86 Favored 'General case' 0 CA--C 1.496 -1.116 0 O-C-N 124.382 1.051 . . . . 0.0 111.893 -177.599 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 10.8 p -64.36 -16.82 62.98 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.387 -1.279 . . . . 0.0 112.448 -177.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -69.93 -10.45 58.6 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 124.494 1.117 . . . . 0.0 110.95 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.409 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 90.1 m-20 -87.07 16.81 4.66 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 121.928 -0.482 . . . . 0.0 110.232 176.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 21.8 t80 65.41 36.91 6.5 Favored 'General case' 0 C--O 1.212 -0.908 0 C-N-CA 125.284 1.433 . . . . 0.0 108.42 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.612 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.2 m -82.47 -21.97 35.37 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.332 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -104.98 106.39 16.86 Favored 'General case' 0 N--CA 1.437 -1.1 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.085 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.14 111.78 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 57.6 t -128.97 126.61 64.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.681 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 175.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 21.5 t30 -115.18 119.73 37.37 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -82.09 95.01 7.33 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 177.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.9 t -77.0 174.98 10.02 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-N 114.947 -1.024 . . . . 0.0 109.78 -175.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.7 m -48.44 132.42 13.33 Favored Pre-proline 0 CA--C 1.548 0.881 0 C-N-CA 124.649 1.18 . . . . 0.0 109.51 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -34.53 118.58 0.12 Allowed 'Trans proline' 0 C--N 1.382 2.326 0 C-N-CA 125.147 3.898 . . . . 0.0 114.868 -173.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.29 6.07 34.09 Favored Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 114.296 -1.32 . . . . 0.0 112.439 -176.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.4 mttm -143.61 133.1 23.46 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.203 0.816 . . . . 0.0 113.203 177.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.2 mt -117.63 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 173.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.473 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.0 m -107.52 111.22 23.39 Favored 'General case' 0 C--N 1.288 -2.098 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.2 mt -116.61 138.49 47.01 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.093 0 CA-C-O 120.988 0.423 . . . . 0.0 109.89 -176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 58.6 m -142.13 124.69 15.8 Favored 'General case' 0 N--CA 1.418 -2.057 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.0 m-85 -114.0 112.79 23.86 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 175.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.612 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.2 t -134.71 119.25 18.02 Favored 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 173.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -117.33 123.93 29.5 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.811 -173.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -83.35 -6.08 11.0 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 122.701 2.268 . . . . 0.0 111.886 176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.62 9.28 39.33 Favored 'General case' 0 N--CA 1.435 -1.187 0 C-N-CA 123.062 0.545 . . . . 0.0 110.898 -173.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.8 pp -61.4 -13.89 23.65 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 124.088 0.955 . . . . 0.0 113.557 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -74.46 -28.85 61.22 Favored 'General case' 0 N--CA 1.438 -1.061 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.673 175.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -99.38 -41.77 7.27 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.866 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 47.5 m-85 -116.26 103.13 53.38 Favored Pre-proline 0 C--N 1.314 -0.972 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -83.15 116.16 2.38 Favored 'Trans proline' 0 N--CA 1.43 -2.247 0 C-N-CA 120.806 1.004 . . . . 0.0 110.402 177.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.681 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 56.4 mt -82.84 89.53 2.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 176.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 9.3 p -137.73 15.77 2.9 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.99 -174.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.8 m -118.97 153.72 21.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 177.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -82.74 165.2 20.13 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.231 -176.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.95 -136.33 6.11 Favored Glycine 0 N--CA 1.425 -2.035 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 -179.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -106.74 141.58 21.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 59.1 tp -91.49 -53.28 4.39 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -154.99 160.6 41.2 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.032 -178.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -115.13 120.84 41.12 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.422 ' HA ' HG12 ' A' ' 53' ' ' VAL . 63.5 mt -85.99 121.83 29.17 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -117.73 118.84 33.16 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.033 -174.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -124.81 160.05 29.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.25 0.548 . . . . 0.0 111.041 -174.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.7 mt -109.9 133.76 54.17 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 105.318 -2.105 . . . . 0.0 105.318 169.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 47.0 mt -84.48 130.18 36.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 175.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 58.0 t30 -68.55 157.73 35.41 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.836 1.254 . . . . 0.0 111.374 -175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 m -80.99 -14.62 57.77 Favored 'General case' 0 CA--C 1.543 0.674 0 CA-C-O 121.79 0.805 . . . . 0.0 110.144 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.4 t-20 -106.73 23.24 14.61 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 107.413 -1.329 . . . . 0.0 107.413 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 136.24 33.1 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.433 176.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.2 m -92.65 152.68 19.42 Favored 'General case' 0 C--N 1.279 -2.458 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -74.6 158.93 32.84 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.231 0.539 . . . . 0.0 111.385 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.34 166.2 12.4 Favored Glycine 0 N--CA 1.431 -1.641 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.49 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 3.6 p30 -85.16 139.41 31.7 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 117.594 0.697 . . . . 0.0 110.536 178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 63.0 m -135.34 130.9 35.72 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -91.64 147.71 22.8 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.612 -178.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.495 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 25.3 mt -93.23 143.25 26.44 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 175.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 32.4 m -117.57 109.57 16.86 Favored 'General case' 0 C--N 1.264 -3.119 0 O-C-N 121.268 -0.895 . . . . 0.0 110.007 -177.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.465 HG22 HG13 ' A' ' 41' ' ' ILE . 43.6 t -86.49 114.96 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.922 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 177.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.479 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 19.2 t70 -60.72 112.04 5.03 Favored Pre-proline 0 C--N 1.315 -0.93 0 O-C-N 124.192 0.933 . . . . 0.0 110.668 -175.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -63.31 -23.6 72.03 Favored 'Trans proline' 0 C--N 1.36 1.168 0 C-N-CA 123.036 2.49 . . . . 0.0 114.299 -176.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -38.13 61.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.743 0.306 . . . . 0.0 110.608 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 6.1 m -85.43 -12.71 51.33 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-O 121.431 0.634 . . . . 0.0 109.809 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.401 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -80.45 107.89 13.62 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.1 mt -128.4 123.93 60.93 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.76 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 59.5 t -125.73 96.88 3.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 175.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.415 ' HB1' ' C ' ' A' ' 130' ' ' ASP . . . -114.89 144.02 44.21 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.452 -1.249 . . . . 0.0 110.429 -173.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.556 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.2 p-10 -77.63 -167.82 1.05 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.447 -177.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -21.46 65.76 Favored 'General case' 0 CA--C 1.554 1.104 0 CA-C-O 121.12 0.486 . . . . 0.0 112.267 177.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -95.95 12.36 30.63 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 122.484 1.135 . . . . 0.0 109.033 174.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.415 ' C ' ' HB1' ' A' ' 126' ' ' ALA 0.288 1.0 OUTLIER 54.92 30.05 13.26 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 128.019 2.527 . . . . 0.0 115.313 174.719 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.57 127.95 39.48 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 175.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.2 t70 -74.63 109.68 8.3 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 177.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.9 pt -124.29 39.01 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 123.941 0.896 . . . . 0.0 110.739 -173.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.63 131.83 52.52 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 115.785 1.772 . . . . 0.0 115.785 -170.47 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 27.2 t70 -96.9 103.36 15.28 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 103.804 -2.665 . . . . 0.0 103.804 165.044 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -119.65 137.57 53.8 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 118.063 -1.455 . . . . 0.0 114.501 -170.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -123.48 112.12 17.13 Favored 'General case' 0 N--CA 1.407 -2.598 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 165.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.4 m -136.01 106.41 6.45 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-O 122.496 1.141 . . . . 0.0 110.226 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 116' ' ' LEU . 28.2 t-20 -149.16 -85.1 0.09 Allowed 'General case' 0 C--N 1.281 -2.401 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.004 -175.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 87.7 129.02 2.89 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -129.9 132.23 46.32 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 119.113 -1.035 . . . . 0.0 111.4 -176.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 57.2 mt -113.34 122.06 66.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.49 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 25.8 m -93.52 108.38 20.09 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 177.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 61.2 t -82.83 117.98 29.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 27.6 p -97.87 112.34 24.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 175.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -126.62 92.75 0.39 Allowed Glycine 0 N--CA 1.427 -1.964 0 C-N-CA 119.916 -1.135 . . . . 0.0 113.49 -172.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 38.0 m -86.89 -25.62 24.35 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 174.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 54.39 81.9 0.25 Allowed Pre-proline 0 C--O 1.24 0.575 0 C-N-CA 126.047 1.739 . . . . 0.0 113.65 177.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -71.83 97.28 0.81 Allowed 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 121.942 1.761 . . . . 0.0 109.935 176.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 p 64.28 146.33 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 126.683 1.993 . . . . 0.0 112.013 -174.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 41.8 m . . . . . 0 C--N 1.293 -1.861 0 O-C-N 121.144 -0.973 . . . . 0.0 108.55 179.465 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.502 -0.732 0 N-CA-C 110.684 -0.967 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 9.2 p -74.44 -42.24 59.48 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.895 0.379 . . . . 0.0 110.856 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -83.8 138.22 33.34 Favored 'General case' 0 N--CA 1.434 -1.237 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.556 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 11.4 p -148.13 75.93 1.35 Allowed 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 121.889 0.852 . . . . 0.0 109.5 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 47.9 t -91.42 101.85 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 CA-C-N 114.41 -1.268 . . . . 0.0 107.957 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -81.36 168.43 18.39 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-O 121.146 0.498 . . . . 0.0 110.531 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -81.68 130.78 35.18 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.464 -177.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -100.89 145.73 28.23 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 124.089 0.956 . . . . 0.0 108.449 -177.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.449 ' HA ' HG22 ' A' ' 133' ' ' ILE . 1.6 m -77.15 105.67 8.39 Favored 'General case' 0 N--CA 1.42 -1.961 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 -177.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 41.8 t -64.8 114.33 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.809 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.657 -175.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 62.7 mttp -88.97 117.95 28.34 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.773 -178.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.471 HD21 HG21 ' A' ' 125' ' ' VAL . 3.4 mm? -101.34 120.69 40.64 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 70.7 m -128.09 142.74 51.12 Favored 'General case' 0 N--CA 1.408 -2.557 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.913 -175.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 17.1 m -130.12 161.63 39.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 175.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.8 -167.58 11.31 Favored Glycine 0 N--CA 1.431 -1.659 0 C-N-CA 118.658 -1.734 . . . . 0.0 113.571 -175.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.536 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 27.7 m -110.47 118.71 37.0 Favored 'General case' 0 N--CA 1.422 -1.833 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -177.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' ILE . 29.2 m -123.5 155.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.2 p -110.24 151.13 27.72 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 111.601 0.223 . . . . 0.0 111.601 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.48 -179.64 31.63 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -124.32 156.99 66.16 Favored Pre-proline 0 C--N 1.312 -1.05 0 CA-C-N 117.086 0.443 . . . . 0.0 110.467 -177.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.4 ' CB ' ' HA ' ' A' ' 107' ' ' SER . 15.6 Cg_exo -69.89 114.19 3.64 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 122.568 2.179 . . . . 0.0 110.681 177.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.98 -17.25 32.46 Favored Glycine 0 C--O 1.243 0.679 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -175.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 23.8 t70 -89.64 146.09 24.78 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 123.799 0.839 . . . . 0.0 110.789 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.9 m -93.19 122.07 35.2 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 178.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -109.77 142.7 21.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-O 121.02 0.438 . . . . 0.0 110.299 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.38 118.73 37.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.899 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -105.57 110.98 64.83 Favored Pre-proline 0 C--N 1.309 -1.158 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 177.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -84.05 125.72 3.66 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 122.178 1.919 . . . . 0.0 113.658 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.3 t -90.95 114.81 28.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 176.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.2 m -96.76 135.23 39.0 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-O 120.998 0.428 . . . . 0.0 109.971 -175.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.638 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 10.0 tt -121.2 128.82 76.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 177.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 15.2 m -131.44 151.25 51.71 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 122.137 -0.352 . . . . 0.0 111.508 -176.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 44.3 mt-30 68.25 15.6 9.33 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 115.943 1.831 . . . . 0.0 115.943 174.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 32' ' ' THR . 10.9 p -75.61 105.04 4.22 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -97.18 -34.36 11.15 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.841 0.829 . . . . 0.0 109.663 -175.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 0.9 OUTLIER -97.12 153.09 38.6 Favored Pre-proline 0 N--CA 1.404 -2.75 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.571 177.684 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.672 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 20.3 Cg_exo -64.01 124.76 14.04 Favored 'Trans proline' 0 N--CA 1.456 -0.719 0 C-N-CA 121.401 1.401 . . . . 0.0 112.166 178.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.36 148.01 4.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 175.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.28 -21.4 1.19 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 119.654 -1.26 . . . . 0.0 113.967 -177.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 95.3 mt -128.57 115.45 18.11 Favored 'General case' 0 CA--C 1.492 -1.26 0 CA-C-N 116.991 0.395 . . . . 0.0 110.752 -178.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 36.6 mt -126.71 129.83 71.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 176.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.9 t -141.02 140.28 34.27 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.2 ptp -157.14 134.11 10.24 Favored 'General case' 0 C--O 1.24 0.571 0 C-N-CA 123.468 0.707 . . . . 0.0 109.706 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -112.52 114.4 27.05 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 52.9 mt -100.48 134.23 40.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.017 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 41.6 m -131.89 118.76 20.26 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -123.85 179.44 4.82 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.844 -0.617 . . . . 0.0 109.749 -176.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -77.25 112.69 14.22 Favored 'General case' 0 C--O 1.244 0.79 0 CA-C-O 121.027 0.441 . . . . 0.0 110.298 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -64.66 -24.65 67.65 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 114.085 1.143 . . . . 0.0 114.085 -175.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.8 m -94.82 -12.44 27.02 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 120.993 0.425 . . . . 0.0 111.783 -177.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -107.16 -31.72 8.13 Favored 'General case' 0 N--CA 1.435 -1.184 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.753 -173.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -127.02 157.67 38.98 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 178.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 27.3 m -136.99 114.43 10.96 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 176.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.3 p -73.9 137.89 22.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.889 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -101.61 -62.21 1.28 Allowed 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.254 174.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -147.12 170.45 17.16 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.651 -171.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.6 m -131.82 132.21 61.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.778 0 N-CA-C 105.029 -2.212 . . . . 0.0 105.029 169.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 82.9 mt -105.05 110.0 63.95 Favored Pre-proline 0 C--N 1.276 -2.597 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.3 134.94 19.79 Favored 'Trans proline' 0 N--CA 1.442 -1.55 0 C-N-CA 121.845 1.697 . . . . 0.0 109.968 178.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -75.48 112.78 12.16 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 18.4 p -75.21 0.86 15.0 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.218 -176.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.06 -21.61 33.72 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 174.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 66.6 mt -112.52 -66.68 1.06 Allowed 'General case' 0 N--CA 1.436 -1.171 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.171 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.8 t -76.69 115.96 19.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 -178.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -128.24 146.58 50.69 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.732 -0.213 . . . . 0.0 111.567 -172.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 35.0 t0 56.44 58.07 4.47 Favored 'General case' 0 N--CA 1.466 0.341 0 O-C-N 125.04 1.463 . . . . 0.0 109.747 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 3.3 p -61.09 -22.75 64.92 Favored 'General case' 0 C--O 1.242 0.682 0 CA-C-N 113.501 -1.681 . . . . 0.0 115.091 -172.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -67.72 -7.92 31.1 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.159 0.584 . . . . 0.0 112.505 -176.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 73.4 m-20 -84.66 21.73 1.46 Allowed 'General case' 0 N--CA 1.481 1.11 0 O-C-N 121.458 -0.776 . . . . 0.0 110.514 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 40.8 t80 66.42 37.44 4.71 Favored 'General case' 0 C--N 1.342 0.273 0 C-N-CA 124.872 1.269 . . . . 0.0 108.07 -178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.664 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.8 m -83.88 -32.63 25.08 Favored 'General case' 0 N--CA 1.435 -1.18 0 CA-C-N 114.156 -1.384 . . . . 0.0 108.177 176.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.6 t80 -96.6 108.48 21.09 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.497 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.55 107.67 18.84 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.066 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.41 109.86 21.24 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 27.1 t-20 -89.28 119.96 30.21 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.312 -177.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -79.16 92.92 5.12 Favored 'General case' 0 N--CA 1.406 -2.648 0 CA-C-O 122.292 1.044 . . . . 0.0 108.208 174.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.9 m -81.44 175.55 10.46 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 113.375 -1.739 . . . . 0.0 111.109 -174.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.4 m -50.01 132.48 22.68 Favored Pre-proline 0 CA--C 1.551 1.016 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 173.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -38.11 123.54 0.64 Allowed 'Trans proline' 0 C--N 1.381 2.271 0 C-N-CA 124.613 3.542 . . . . 0.0 113.609 -176.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.405 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.26 -18.52 35.9 Favored Glycine 0 N--CA 1.429 -1.831 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.573 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -114.63 147.21 39.87 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 117.682 0.741 . . . . 0.0 112.672 177.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.5 mt -139.42 112.11 5.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.0 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 174.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.435 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 19.3 m -98.31 111.05 23.52 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 176.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.9 mt -108.11 130.08 61.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.431 HG22 HG23 ' A' ' 83' ' ' THR . 47.9 m -142.29 131.73 23.71 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.03 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.423 ' HA ' ' O ' ' A' ' 67' ' ' SER . 77.7 m-85 -121.35 108.78 14.11 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 175.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.664 ' O ' ' HA ' ' A' ' 67' ' ' SER . 75.4 p -115.48 117.97 31.87 Favored 'General case' 0 C--N 1.294 -1.815 0 N-CA-C 105.55 -2.018 . . . . 0.0 105.55 176.18 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -119.44 119.06 31.94 Favored Pre-proline 0 C--N 1.288 -2.106 0 C-N-CA 118.183 -1.407 . . . . 0.0 113.831 -172.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -85.59 -2.99 9.21 Favored 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.472 2.781 . . . . 0.0 112.277 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.28 4.11 52.57 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.719 0.408 . . . . 0.0 111.189 -172.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.9 pp -55.76 -20.4 14.66 Favored 'General case' 0 N--CA 1.478 0.941 0 N-CA-C 116.037 1.866 . . . . 0.0 116.037 -175.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.36 -28.76 22.01 Favored 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 120.565 -0.454 . . . . 0.0 109.796 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -89.44 -41.1 12.27 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.239 -179.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -127.87 102.24 22.42 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 175.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -88.3 128.71 2.24 Favored 'Trans proline' 0 N--CA 1.432 -2.1 0 C-N-CA 121.501 1.467 . . . . 0.0 112.991 -179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.672 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -89.69 88.83 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 171.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 p -125.84 18.68 7.9 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 121.994 0.902 . . . . 0.0 109.573 -176.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.9 m -137.05 150.93 26.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.638 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -101.67 -174.3 2.56 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -174.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 149.98 -136.29 5.64 Favored Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 -179.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.472 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.3 mm -99.82 134.7 38.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 N-CA-C 106.405 -1.702 . . . . 0.0 106.405 174.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 56.7 tp -84.08 -51.72 6.86 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.265 0.555 . . . . 0.0 110.022 -178.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.97 154.32 34.76 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.623 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.472 ' CE1' HG21 ' A' ' 97' ' ' ILE . 88.6 m-85 -110.88 119.53 39.39 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 176.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 53.1 mt -86.16 127.64 34.75 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -110.58 105.99 15.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.171 0.51 . . . . 0.0 109.712 -176.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -118.77 144.71 46.12 Favored 'General case' 0 C--O 1.212 -0.889 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.223 -177.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 66.8 mt -95.25 128.32 46.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.884 0 N-CA-C 105.407 -2.071 . . . . 0.0 105.407 168.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -82.91 124.53 39.56 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 172.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -67.14 148.31 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -177.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.4 ' HA ' ' CB ' ' A' ' 17' ' ' PRO . 6.6 p -73.3 -11.17 60.4 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -177.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -84.82 -4.41 59.07 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 124.089 0.956 . . . . 0.0 109.575 176.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.41 130.9 41.79 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-O 121.802 0.811 . . . . 0.0 112.342 -176.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 4.3 p -81.81 152.92 26.7 Favored 'General case' 0 N--CA 1.417 -2.104 0 CA-C-N 114.029 -1.441 . . . . 0.0 110.079 178.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -71.64 154.05 41.66 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 121.049 0.452 . . . . 0.0 110.769 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 124.9 174.52 14.01 Favored Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.976 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.66 123.47 32.54 Favored 'General case' 0 C--N 1.297 -1.686 0 CA-C-O 121.231 0.538 . . . . 0.0 112.086 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 4.9 m -117.87 123.63 46.35 Favored 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.24 -0.891 . . . . 0.0 108.641 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.89 142.32 27.45 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.443 0.639 . . . . 0.0 111.602 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 36.4 mt -99.32 114.48 27.36 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.0 m -79.96 117.77 21.1 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-O 120.629 0.252 . . . . 0.0 111.171 -173.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 25.9 t -112.16 130.79 65.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.457 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 21.7 t70 -82.64 122.31 78.47 Favored Pre-proline 0 C--N 1.299 -1.602 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -175.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.8 Cg_exo -73.77 -14.57 24.28 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 123.294 2.662 . . . . 0.0 114.849 -178.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.13 -38.23 19.3 Favored 'General case' 0 C--N 1.318 -0.764 0 O-C-N 121.798 -0.564 . . . . 0.0 110.148 -179.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -86.11 -2.83 58.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.798 175.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.1 tm? -79.55 108.26 12.95 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 105.155 -2.165 . . . . 0.0 105.155 173.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 61.7 mt -125.73 124.86 67.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.471 HG21 HD21 ' A' ' 8' ' ' LEU . 85.5 t -132.08 96.6 2.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 177.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.612 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -106.65 133.57 51.12 Favored 'General case' 0 N--CA 1.415 -2.197 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.457 -177.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -65.09 -176.8 0.31 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 126.346 1.858 . . . . 0.0 110.03 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.9 -14.96 58.93 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-O 121.761 0.791 . . . . 0.0 108.992 176.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 58.7 t30 -82.25 5.23 20.65 Favored 'General case' 0 CA--C 1.567 1.6 0 CA-C-N 114.359 -1.291 . . . . 0.0 107.832 170.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.266 2.6 p30 56.75 19.28 4.27 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 128.344 2.658 . . . . 0.0 114.946 176.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -97.97 137.14 37.24 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.455 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -74.52 112.06 10.33 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 5' ' ' THR . 82.5 mt -132.0 90.84 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -174.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 2.2 pptp? -155.63 133.62 11.38 Favored 'General case' 0 C--O 1.244 0.812 0 N-CA-C 115.471 1.656 . . . . 0.0 115.471 -173.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.437 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 2.6 m-20 -95.91 104.11 16.03 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 167.171 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -132.4 132.19 42.57 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 118.648 -1.221 . . . . 0.0 113.298 -174.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -135.77 114.31 11.77 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 171.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -133.0 106.31 7.59 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-O 122.52 1.152 . . . . 0.0 112.179 -175.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -152.0 86.57 1.31 Allowed 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.888 -1.893 . . . . 0.0 105.888 175.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -63.28 152.02 47.63 Favored Glycine 0 C--O 1.2 -2.017 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 12' ' ' THR . 59.4 tttm -138.34 128.62 25.93 Favored 'General case' 0 C--N 1.282 -2.369 0 CA-C-N 118.497 1.148 . . . . 0.0 109.489 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 64.7 mt -119.3 122.64 69.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.662 -177.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 7.6 m -87.71 106.22 17.9 Favored 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 176.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 39.8 t -83.35 119.59 33.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.1 p -96.91 101.51 13.11 Favored 'General case' 0 N--CA 1.405 -2.679 0 N-CA-C 107.349 -1.352 . . . . 0.0 107.349 173.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -127.33 104.96 0.72 Allowed Glycine 0 C--N 1.274 -2.914 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -175.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.9 m -60.2 -46.84 88.34 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -154.89 141.25 13.08 Favored Pre-proline 0 N--CA 1.436 -1.162 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.28 49.08 3.09 Favored 'Trans proline' 0 CA--C 1.551 1.328 0 C-N-CA 122.964 2.443 . . . . 0.0 111.946 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 23.3 m -133.55 96.03 3.62 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.49 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 47.0 m . . . . . 0 C--N 1.313 -0.994 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.282 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.254 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.7 m -94.0 126.55 39.28 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -102.44 71.06 1.19 Allowed 'General case' 0 N--CA 1.429 -1.504 0 CA-C-O 121.717 0.77 . . . . 0.0 109.797 178.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 24.7 t -108.69 172.09 7.05 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 105.834 -1.913 . . . . 0.0 105.834 176.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 68.0 t 59.94 78.66 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-O 122.579 1.18 . . . . 0.0 107.831 -173.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -83.14 -162.57 0.62 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.134 -174.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.513 ' HB3' HG21 ' A' ' 133' ' ' ILE . 21.5 m120 82.73 107.82 0.06 Allowed 'General case' 0 CA--C 1.503 -0.829 0 C-N-CA 125.322 1.449 . . . . 0.0 110.015 -178.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -144.38 178.96 7.55 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.063 -176.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.5 m -69.15 105.82 2.61 Favored 'General case' 0 C--N 1.322 -0.604 0 O-C-N 123.446 0.466 . . . . 0.0 111.494 -177.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.446 HG13 ' HB ' ' A' ' 30' ' ' VAL . 98.3 t -98.51 111.8 29.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 178.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 40.7 mttm -83.94 117.12 23.15 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 113.035 0.754 . . . . 0.0 113.035 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -108.27 111.35 23.27 Favored 'General case' 0 C--O 1.26 1.639 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 168.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.8 t -125.14 167.16 15.19 Favored 'General case' 0 N--CA 1.411 -2.38 0 O-C-N 124.627 1.205 . . . . 0.0 110.501 -171.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.8 m -128.95 162.04 37.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 C-N-CA 124.438 1.095 . . . . 0.0 109.373 -178.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 173.79 21.72 Favored Glycine 0 N--CA 1.422 -2.248 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 62.7 m -111.22 120.97 44.06 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.506 0.67 . . . . 0.0 110.42 -177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.8 m -114.51 163.97 11.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.922 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 27.2 p -117.79 157.97 25.61 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 177.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -155.95 168.78 33.5 Favored Glycine 0 N--CA 1.437 -1.29 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.419 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 33.6 m-80 -116.39 156.55 47.19 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 -177.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.489 ' HD3' ' O ' ' A' ' 145' ' ' THR . 19.7 Cg_exo -69.5 118.67 5.82 Favored 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 122.486 2.124 . . . . 0.0 111.123 178.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.69 -12.26 62.81 Favored Glycine 0 C--N 1.318 -0.47 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 -176.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 21.7 t70 -90.45 152.84 20.79 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 123.985 0.914 . . . . 0.0 109.69 178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.0 m -104.63 126.71 51.98 Favored 'General case' 0 C--N 1.293 -1.869 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 -178.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.9 p -114.0 145.01 20.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -175.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -117.02 128.54 55.27 Favored 'General case' 0 N--CA 1.429 -1.503 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 24.7 t -111.56 112.13 54.24 Favored Pre-proline 0 C--N 1.308 -1.22 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.477 ' HB2' HD12 ' A' ' 97' ' ' ILE . 61.3 Cg_endo -86.63 132.04 3.47 Favored 'Trans proline' 0 CA--C 1.548 1.203 0 C-N-CA 122.16 1.907 . . . . 0.0 113.414 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 56.4 t -91.2 119.61 38.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 174.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 31.8 m -96.28 138.07 34.43 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 120.862 0.363 . . . . 0.0 111.184 -173.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 7' ' ' LYS . 12.5 tt -123.39 131.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 176.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 50.8 m -147.14 159.77 43.22 Favored 'General case' 0 C--N 1.312 -1.055 0 O-C-N 121.976 -0.452 . . . . 0.0 111.734 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 65.02 25.71 12.64 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 125.28 1.432 . . . . 0.0 112.953 176.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.446 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.59 137.67 22.57 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.971 -178.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -138.4 8.58 2.66 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-O 122.215 1.007 . . . . 0.0 110.774 173.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.37 132.1 21.32 Favored Pre-proline 0 C--N 1.29 -1.993 0 CA-C-N 114.96 -1.018 . . . . 0.0 108.761 177.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.612 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.5 Cg_exo -65.26 123.35 11.39 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 N-CA-C 109.348 -1.059 . . . . 0.0 109.348 174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 12.6 p -87.87 142.83 12.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.413 -176.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -128.63 -22.46 1.31 Allowed Glycine 0 N--CA 1.438 -1.186 0 C-N-CA 119.822 -1.18 . . . . 0.0 113.407 -178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HB2' ' HB3' ' A' ' 126' ' ' ALA . 93.5 mt -129.04 112.49 14.07 Favored 'General case' 0 CA--C 1.485 -1.529 0 CA-C-N 116.926 0.363 . . . . 0.0 110.763 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.469 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 20.3 mt -129.45 119.88 49.43 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.576 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.9 t -133.51 138.45 46.11 Favored 'General case' 0 C--N 1.273 -2.732 0 N-CA-C 107.799 -1.185 . . . . 0.0 107.799 177.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.0 ptp -157.55 141.25 15.76 Favored 'General case' 0 C--N 1.32 -0.684 0 C-N-CA 123.288 0.635 . . . . 0.0 109.361 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -124.07 117.97 25.9 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 -178.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.411 HG13 HG22 ' A' ' 118' ' ' VAL . 3.3 mp -101.06 128.57 53.15 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.043 -173.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.437 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 7.0 m -116.24 126.9 54.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.5 p90 -139.18 171.32 14.46 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 -176.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -72.28 105.43 4.05 Favored 'General case' 0 C--O 1.24 0.566 0 O-C-N 123.443 0.464 . . . . 0.0 109.768 177.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.11 -28.6 70.18 Favored 'General case' 0 C--O 1.211 -0.951 0 C-N-CA 124.159 0.984 . . . . 0.0 112.614 -177.256 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 p -86.22 -10.3 54.91 Favored 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 121.174 0.512 . . . . 0.0 111.784 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 38.4 ttmt -105.66 -37.3 6.79 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.414 -175.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -127.48 157.31 40.42 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -177.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.3 m -133.62 110.07 9.64 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 175.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.2 p -79.63 137.76 21.13 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.469 -0.493 . . . . 0.0 109.896 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 48.0 mtmt -92.29 -62.07 1.48 Allowed 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 175.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -163.43 177.43 8.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 -177.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.8 m -121.8 141.98 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.611 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 177.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -99.08 118.86 62.0 Favored Pre-proline 0 C--N 1.289 -2.054 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -78.95 136.79 13.4 Favored 'Trans proline' 0 N--CA 1.437 -1.83 0 C-N-CA 121.303 1.335 . . . . 0.0 109.419 175.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 38.7 t30 -75.87 106.85 7.67 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 177.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 12.6 p -70.95 -5.24 29.48 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -176.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -67.35 -33.83 76.05 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 171.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.401 ' CD2' HG23 ' A' ' 94' ' ' VAL . 61.2 mt -102.96 -64.28 1.09 Allowed 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.536 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 48.3 t -70.09 127.99 32.78 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 C-N-CA 123.606 0.762 . . . . 0.0 109.18 -176.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.41 ' HG3' ' CG ' ' A' ' 90' ' ' TYR . 75.3 mmtt -116.03 131.05 57.05 Favored 'General case' 0 C--N 1.313 -0.994 0 C-N-CA 121.113 -0.235 . . . . 0.0 111.041 -175.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 22.3 t70 43.24 96.03 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 126.805 2.042 . . . . 0.0 114.821 -178.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 30.0 p -64.83 -29.97 70.95 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.432 -176.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -62.04 -27.18 68.71 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 124.349 1.06 . . . . 0.0 112.035 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -72.32 12.98 0.37 Allowed 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 t80 68.13 36.72 3.14 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.618 1.567 . . . . 0.0 109.198 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 83' ' ' THR . 36.7 t -89.15 -33.94 16.88 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-N 114.321 -1.308 . . . . 0.0 108.118 175.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 83.9 t80 -99.98 106.28 18.06 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.354 -176.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -121.66 107.4 19.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 N-CA-C 107.68 -1.229 . . . . 0.0 107.68 174.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 76.9 t -126.55 113.12 31.96 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -100.49 112.37 24.72 Favored 'General case' 0 C--N 1.28 -2.432 0 CA-C-N 114.402 -1.272 . . . . 0.0 107.67 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 26.7 m -73.61 98.96 2.96 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 176.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 27.1 t -73.8 175.32 7.36 Favored 'General case' 0 N--CA 1.427 -1.615 0 CA-C-N 114.627 -1.17 . . . . 0.0 111.325 -173.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.2 m -49.6 135.04 18.92 Favored Pre-proline 0 N--CA 1.433 -1.311 0 C-N-CA 125.648 1.579 . . . . 0.0 109.086 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -33.97 117.73 0.11 Allowed 'Trans proline' 0 C--N 1.379 2.154 0 C-N-CA 125.262 3.975 . . . . 0.0 114.423 -173.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.18 -2.11 35.15 Favored Glycine 0 N--CA 1.428 -1.852 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.443 -177.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.437 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 63.6 mttt -134.78 156.6 48.58 Favored 'General case' 0 C--O 1.24 0.583 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 176.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.7 mt -137.94 121.57 21.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 18.8 m -105.73 111.13 23.68 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.1 mt -111.34 128.91 67.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 -176.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.406 HG22 HG23 ' A' ' 83' ' ' THR . 41.4 m -139.98 119.28 12.89 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.45 0.643 . . . . 0.0 109.95 176.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.469 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 95.8 m-85 -109.83 108.94 19.44 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 175.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.588 ' O ' ' HA ' ' A' ' 67' ' ' SER . 37.0 p -111.97 117.62 33.22 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 105.347 -2.094 . . . . 0.0 105.347 173.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -115.22 112.7 43.91 Favored Pre-proline 0 C--N 1.294 -1.819 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.959 -170.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -85.31 -9.66 8.19 Favored 'Trans proline' 0 CA--C 1.551 1.352 0 C-N-CA 122.983 2.456 . . . . 0.0 112.024 174.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -79.77 -13.45 59.42 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 123.909 0.884 . . . . 0.0 112.429 -171.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 2.9 pp -49.3 -21.44 0.84 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 116.642 2.09 . . . . 0.0 116.642 -177.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.67 -24.4 36.3 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.507 0.67 . . . . 0.0 110.209 178.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -96.14 -41.82 8.52 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 71.1 m-85 -131.47 102.79 15.19 Favored Pre-proline 0 C--N 1.314 -0.963 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.24 111.28 3.16 Favored 'Trans proline' 0 N--CA 1.451 -0.988 0 C-N-CA 121.762 1.641 . . . . 0.0 111.65 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.612 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.1 mt -78.74 89.82 1.27 Allowed 'Isoleucine or valine' 0 C--O 1.221 -0.425 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 175.507 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 29.6 p -135.45 21.85 3.4 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.828 0.823 . . . . 0.0 109.444 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.401 HG23 ' CD2' ' A' ' 59' ' ' LEU . 6.8 m -120.46 156.78 23.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.462 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -92.35 -176.11 4.23 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -172.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 131.4 -137.76 9.68 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.477 HD12 ' HB2' ' A' ' 24' ' ' PRO . 47.7 mm -102.42 140.19 21.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 176.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.43 HD21 HG21 ' A' ' 37' ' ' ILE . 57.9 tp -87.15 -55.74 3.68 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 121.215 0.531 . . . . 0.0 110.205 178.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -148.18 156.54 42.7 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.418 ' CE2' HG21 ' A' ' 97' ' ' ILE . 42.7 m-85 -116.35 120.76 39.88 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.3 mt -86.35 130.12 34.62 Favored 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -118.74 113.03 20.52 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.434 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -118.64 133.85 55.55 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.598 -174.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.4 mt -88.9 126.98 41.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 170.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 48.9 mt -85.98 131.94 33.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -61.37 142.51 56.88 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.8 m -69.87 -18.22 63.4 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-O 121.167 0.508 . . . . 0.0 110.885 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -111.91 26.31 10.73 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 122.024 0.916 . . . . 0.0 108.742 178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.416 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -70.75 150.55 45.78 Favored 'General case' 0 C--O 1.246 0.873 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.657 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -74.37 130.3 39.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 177.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.33 155.57 24.7 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 -178.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 117.45 -163.62 12.66 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 121.054 -0.594 . . . . 0.0 112.91 177.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -72.06 116.27 12.27 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 123.0 0.52 . . . . 0.0 109.869 179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.8 m -122.64 107.9 12.48 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.56 137.99 32.28 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 121.402 0.62 . . . . 0.0 112.672 -175.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.49 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 25.2 mt -100.98 114.05 27.6 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 105.341 -2.096 . . . . 0.0 105.341 175.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.7 m -86.22 128.38 34.89 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -174.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.411 HG22 HG13 ' A' ' 41' ' ' ILE . 40.5 t -105.94 118.02 52.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.075 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 175.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -63.86 113.09 8.85 Favored Pre-proline 0 C--N 1.322 -0.607 0 O-C-N 123.923 0.764 . . . . 0.0 110.205 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -70.23 -20.45 32.58 Favored 'Trans proline' 0 C--N 1.359 1.129 0 C-N-CA 122.842 2.361 . . . . 0.0 114.132 -176.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -76.23 -38.34 56.5 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.129 0.49 . . . . 0.0 110.571 -178.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.3 m -84.6 -13.09 52.66 Favored 'General case' 0 N--CA 1.42 -1.932 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.373 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 1.7 tt -81.9 110.93 17.64 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 75.9 mt -130.95 127.48 61.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.524 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 57.7 t -132.5 97.19 2.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 175.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.404 ' HB3' ' HB2' ' A' ' 36' ' ' LEU . . . -115.39 143.96 44.51 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.517 -178.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -84.77 -166.74 1.56 Allowed 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.322 -178.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -61.97 -26.4 68.18 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.089 0.556 . . . . 0.0 111.28 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -88.43 8.74 26.37 Favored 'General case' 0 CA--C 1.552 1.036 0 C-N-CA 123.803 0.841 . . . . 0.0 110.396 179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 20.8 t70 70.33 10.42 7.25 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 123.996 0.918 . . . . 0.0 112.887 171.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.526 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.6 124.32 46.02 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 120.613 -1.305 . . . . 0.0 111.036 -173.921 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.524 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 10.8 t70 -71.81 115.34 10.89 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 175.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.513 HG21 ' HB3' ' A' ' 3' ' ' ASN . 13.6 pt -131.64 30.98 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.255 -172.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HG2' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -104.08 149.62 25.04 Favored 'General case' 0 N--CA 1.416 -2.143 0 C-N-CA 118.992 -1.083 . . . . 0.0 112.503 -170.321 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -91.05 133.5 35.27 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 105.679 -1.971 . . . . 0.0 105.679 173.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -113.49 118.9 35.76 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -173.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.58 111.42 6.65 Favored 'General case' 0 N--CA 1.42 -1.943 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 163.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.1 m -146.52 104.43 3.76 Favored 'General case' 0 N--CA 1.42 -1.931 0 CA-C-O 122.733 1.254 . . . . 0.0 110.676 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.519 ' H ' HG21 ' A' ' 10' ' ' VAL . 27.2 t-20 -175.8 79.64 0.02 OUTLIER 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 112.802 -1.999 . . . . 0.0 105.869 -177.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -68.85 136.47 29.2 Favored Glycine 0 CA--C 1.483 -1.945 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -122.54 131.86 54.04 Favored 'General case' 0 C--N 1.276 -2.622 0 C-N-CA 118.244 -1.383 . . . . 0.0 111.489 -177.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 64.2 mt -110.18 126.52 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.171 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 25.2 m -96.85 105.66 17.83 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 175.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.1 t -83.38 116.08 26.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.489 ' O ' ' HD3' ' A' ' 17' ' ' PRO . 25.9 p -90.13 129.87 36.36 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 176.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -77.88 64.76 3.31 Favored Glycine 0 C--O 1.219 -0.791 0 O-C-N 123.341 0.401 . . . . 0.0 112.193 -176.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -88.78 25.29 1.8 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 123.77 0.828 . . . . 0.0 111.049 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -77.74 144.72 69.45 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -64.42 103.02 0.42 Allowed 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.914 1.742 . . . . 0.0 111.043 177.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.6 p -108.54 -48.03 3.4 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.676 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 22.8 m . . . . . 0 C--O 1.259 1.587 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 179.619 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.952 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 47.1 m -95.49 94.65 7.91 Favored 'General case' 0 N--CA 1.433 -1.282 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 70.75 -80.96 0.04 OUTLIER 'General case' 0 C--O 1.238 0.462 0 C-N-CA 125.776 1.63 . . . . 0.0 111.041 -176.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 65.7 m 58.61 23.99 11.56 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.329 1.052 . . . . 0.0 112.271 -179.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.9 p -95.73 -21.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.267 -176.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 62.0 mttp 65.44 -176.61 0.18 Allowed 'General case' 0 C--N 1.352 0.693 0 C-N-CA 124.497 1.119 . . . . 0.0 111.53 -176.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.574 ' HB3' HG21 ' A' ' 133' ' ' ILE . 3.7 m-20 -101.0 121.37 41.65 Favored 'General case' 0 N--CA 1.423 -1.787 0 N-CA-C 105.643 -1.984 . . . . 0.0 105.643 171.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -97.77 152.74 18.83 Favored 'General case' 0 C--N 1.282 -2.346 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.947 -173.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.2 m -79.89 105.5 11.22 Favored 'General case' 0 N--CA 1.421 -1.908 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.22 110.45 18.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 115.194 -0.912 . . . . 0.0 108.983 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 45.7 mtmt -88.51 129.38 35.47 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.853 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.47 130.11 42.4 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 173.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -129.13 146.22 51.12 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-O 121.863 0.84 . . . . 0.0 109.62 -176.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.9 m -127.69 162.11 34.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.938 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.55 171.53 22.58 Favored Glycine 0 N--CA 1.42 -2.432 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.631 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 43.9 m -110.96 118.91 37.37 Favored 'General case' 0 N--CA 1.417 -2.081 0 CA-C-O 121.415 0.626 . . . . 0.0 110.27 -178.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.01 161.28 9.59 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.048 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.7 m -123.69 152.67 41.81 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.14 169.23 34.74 Favored Glycine 0 N--CA 1.431 -1.647 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -107.29 153.76 40.96 Favored Pre-proline 0 C--N 1.302 -1.498 0 C-N-CA 123.183 0.593 . . . . 0.0 109.568 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.7 117.56 4.62 Favored 'Trans proline' 0 C--N 1.355 0.91 0 C-N-CA 122.307 2.005 . . . . 0.0 110.796 176.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 109.2 -16.32 32.56 Favored Glycine 0 C--N 1.31 -0.869 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -89.54 148.45 23.39 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 12.2 m -95.18 121.82 37.22 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.0 p -111.53 134.1 55.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 CA-C-O 121.69 0.757 . . . . 0.0 110.71 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -104.79 118.86 37.62 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.354 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.0 t -102.83 111.96 65.34 Favored Pre-proline 0 C--N 1.306 -1.325 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -82.69 126.18 4.53 Favored 'Trans proline' 0 N--CA 1.444 -1.413 0 C-N-CA 121.903 1.735 . . . . 0.0 112.682 179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 62.9 t -89.83 113.75 26.57 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 N-CA-C 106.204 -1.776 . . . . 0.0 106.204 176.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.3 m -96.37 134.51 39.43 Favored 'General case' 0 C--N 1.285 -2.224 0 CA-C-O 121.365 0.603 . . . . 0.0 110.248 -172.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.4 tt -119.93 134.32 63.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.743 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 28.0 m -136.05 150.93 49.37 Favored 'General case' 0 C--N 1.309 -1.185 0 O-C-N 121.964 -0.46 . . . . 0.0 111.854 -176.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 68.15 17.72 9.38 Favored 'General case' 0 N--CA 1.484 1.272 0 C-N-CA 124.984 1.314 . . . . 0.0 114.115 175.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 4.2 p -84.79 105.45 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 175.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.9 t -114.4 -33.71 5.51 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.2 m -76.54 133.89 70.26 Favored Pre-proline 0 N--CA 1.428 -1.532 0 N-CA-C 106.785 -1.561 . . . . 0.0 106.785 175.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 52.8 Cg_exo -58.63 124.47 15.86 Favored 'Trans proline' 0 C--N 1.355 0.901 0 C-N-CA 121.442 1.428 . . . . 0.0 110.603 176.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.5 p -87.7 149.09 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.709 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.757 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -107.98 -53.89 0.64 Allowed Glycine 0 N--CA 1.424 -2.108 0 C-N-CA 120.531 -0.843 . . . . 0.0 113.16 -176.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.4 tt -132.05 112.77 12.64 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -174.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.423 HG23 HG22 ' A' ' 125' ' ' VAL . 68.1 mt -108.36 118.18 55.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 173.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 51.5 t -121.35 135.79 55.04 Favored 'General case' 0 C--N 1.273 -2.726 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 178.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.3 ptm -157.06 136.8 12.37 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 11.9 t70 -115.24 123.17 48.14 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.42 108.48 23.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-O 121.575 0.703 . . . . 0.0 109.242 -176.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 23.8 m -97.01 134.31 40.54 Favored 'General case' 0 C--N 1.28 -2.456 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 177.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.2 p90 -150.7 169.35 21.82 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.414 -176.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -74.78 100.75 4.12 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -75.21 -9.5 58.6 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.2 m -93.58 -16.96 23.85 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 tttt -107.23 -32.06 7.96 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.311 -173.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 -128.3 157.76 40.05 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 14.0 m -138.55 111.52 7.82 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.7 p -71.46 138.95 20.67 Favored 'Isoleucine or valine' 0 C--O 1.246 0.88 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.7 mtmm -95.26 -54.52 3.38 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 175.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -163.77 176.18 9.78 Favored 'General case' 0 N--CA 1.429 -1.52 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 -175.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.5 m -127.54 138.39 54.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.42 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 93.7 mt -97.06 116.32 65.99 Favored Pre-proline 0 C--N 1.293 -1.891 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.26 137.57 15.23 Favored 'Trans proline' 0 N--CA 1.441 -1.613 0 C-N-CA 121.432 1.421 . . . . 0.0 109.659 177.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -75.75 108.46 8.61 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.103 -1.039 . . . . 0.0 108.507 175.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.6 p -71.43 -9.37 58.07 Favored 'General case' 0 N--CA 1.433 -1.31 0 C-N-CA 124.649 1.18 . . . . 0.0 112.968 -175.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -71.6 -32.72 68.33 Favored 'General case' 0 CA--C 1.513 -0.469 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 174.123 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 98' ' ' LEU . 43.4 mt -95.26 -67.8 0.83 Allowed 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.209 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 57' ' ' THR . 40.8 t -74.51 115.69 16.05 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 O-C-N 124.323 1.015 . . . . 0.0 108.354 -177.091 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB2' ' HB3' ' A' ' 90' ' ' TYR . 61.1 mttp -112.36 142.14 45.24 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.14 -174.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.0 t70 46.91 80.41 0.05 OUTLIER 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 125.843 1.657 . . . . 0.0 111.965 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.497 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 24.3 p -67.42 -17.86 64.87 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -174.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -66.8 -26.09 66.77 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 123.996 0.918 . . . . 0.0 110.268 176.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -84.66 28.21 0.68 Allowed 'General case' 0 C--O 1.215 -0.745 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.548 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.302 50.3 p90 51.74 43.56 29.89 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 126.02 1.728 . . . . 0.0 114.221 178.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 83' ' ' THR . 5.5 p -86.52 -14.64 42.43 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 122.368 1.08 . . . . 0.0 108.969 172.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -111.06 106.69 15.83 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 113.731 -1.577 . . . . 0.0 108.307 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.53 108.17 21.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 174.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.8 t -125.46 113.97 37.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.932 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -103.13 118.41 36.73 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 177.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.2 p -75.63 94.81 3.26 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-O 121.697 0.761 . . . . 0.0 109.217 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.7 m -79.29 173.65 12.37 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.384 -179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.4 m -57.89 131.77 83.1 Favored Pre-proline 0 C--O 1.247 0.954 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -34.69 130.64 0.2 Allowed 'Trans proline' 0 C--N 1.39 2.718 0 C-N-CA 124.91 3.74 . . . . 0.0 114.063 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.21 -12.38 40.37 Favored Glycine 0 N--CA 1.43 -1.725 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.226 -175.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 51.8 mttm -142.9 145.15 32.8 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 123.351 0.66 . . . . 0.0 111.272 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 31.4 mt -137.25 110.25 7.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.1 m -91.75 111.36 22.85 Favored 'General case' 0 C--N 1.296 -1.72 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.135 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 53.9 mt -115.02 141.59 31.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.251 -177.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 53.1 m -140.32 124.47 17.63 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -112.17 109.38 19.04 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.615 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.3 t -137.67 119.91 15.71 Favored 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 9.2 t0 -96.22 115.93 65.88 Favored Pre-proline 0 C--N 1.309 -1.196 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 -178.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -78.4 -2.98 12.98 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.654 2.236 . . . . 0.0 112.185 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.434 ' HB ' ' CD2' ' A' ' 90' ' ' TYR . 0.5 OUTLIER -119.19 25.4 10.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -176.534 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 90' ' ' TYR . 3.0 pp -50.65 -20.42 1.21 Allowed 'General case' 0 N--CA 1.503 2.186 0 N-CA-C 116.515 2.043 . . . . 0.0 116.515 -174.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.16 -23.67 38.08 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.103 0.478 . . . . 0.0 110.894 178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.402 ' HB2' HG22 ' A' ' 86' ' ' THR . 25.7 m-80 -106.55 -41.4 5.28 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.538 ' O ' ' HA ' ' A' ' 87' ' ' LEU . 21.7 m-85 -105.11 101.94 33.32 Favored Pre-proline 0 N--CA 1.437 -1.102 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 174.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -92.52 119.78 0.46 Allowed 'Trans proline' 0 N--CA 1.422 -2.687 0 C-N-CA 121.064 1.176 . . . . 0.0 113.829 -175.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.508 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 28.5 mt -98.69 89.9 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 104.427 -2.434 . . . . 0.0 104.427 167.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 3.9 p -140.87 23.62 2.24 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.018 -174.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.3 m -136.82 152.22 28.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 114.929 -1.032 . . . . 0.0 108.446 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.542 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.9 p30 -96.19 177.23 5.79 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 146.42 -138.37 7.38 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.304 -1.919 . . . . 0.0 108.304 -177.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.3 mp -100.99 138.15 26.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 174.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.44 ' HA ' HD12 ' A' ' 59' ' ' LEU . 64.6 tp -84.66 -52.72 5.88 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.351 0.596 . . . . 0.0 110.543 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -149.59 151.28 33.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.507 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.42 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 49.4 m-85 -109.2 114.01 27.34 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 51.0 mt -85.95 125.16 33.15 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -178.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -109.04 106.36 16.26 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.312 0.577 . . . . 0.0 110.554 -175.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -114.86 134.57 55.03 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.497 -177.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 72.1 mt -90.04 126.92 42.88 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 171.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.76 124.87 36.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -69.66 155.2 40.88 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 123.697 0.623 . . . . 0.0 110.38 -173.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 49.5 m -72.98 -20.36 61.04 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.302 0.572 . . . . 0.0 109.574 173.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -75.49 -14.92 60.45 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.456 176.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -78.32 135.78 37.58 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.792 -175.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 7.4 m -108.94 157.27 18.8 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' A' ' 146' ' ' GLY . . . -62.06 149.15 41.88 Favored 'General case' 0 C--O 1.246 0.913 0 C-N-CA 124.073 0.949 . . . . 0.0 111.784 -176.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 148.24 154.74 6.38 Favored Glycine 0 N--CA 1.415 -2.726 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 -178.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 37.0 t70 -77.41 116.25 17.85 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 6.8 m -116.76 120.69 39.35 Favored 'General case' 0 C--N 1.295 -1.782 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.884 -172.216 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.17 144.12 25.59 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-O 121.148 0.499 . . . . 0.0 110.598 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.418 ' HB2' ' O ' ' A' ' 139' ' ' ASN . 40.4 mt -99.72 156.45 17.09 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 173.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 55.4 m -122.49 109.2 14.06 Favored 'General case' 0 C--N 1.279 -2.479 0 CA-C-N 118.37 0.532 . . . . 0.0 111.103 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 61.0 t -86.77 115.1 27.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 107.091 -1.448 . . . . 0.0 107.091 174.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.443 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 12.8 t70 -58.72 110.49 2.67 Favored Pre-proline 0 C--N 1.318 -0.768 0 C-N-CA 124.705 1.202 . . . . 0.0 110.92 -173.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.51 -28.85 53.35 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 123.212 2.608 . . . . 0.0 112.921 -176.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -73.0 -31.72 64.67 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.121 0.486 . . . . 0.0 110.687 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.5 m -93.4 -9.69 37.82 Favored 'General case' 0 N--CA 1.421 -1.88 0 CA-C-O 121.042 0.449 . . . . 0.0 110.645 179.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 4.2 tt -83.77 108.9 17.1 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 74.0 mt -133.4 129.69 56.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 98.6 t -132.71 97.83 2.74 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.69 140.74 38.28 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.586 -177.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.8 p-10 -81.94 -166.56 1.26 Allowed 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 122.465 0.306 . . . . 0.0 111.372 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -62.21 -28.06 69.42 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.239 0.616 . . . . 0.0 111.287 176.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -94.81 16.04 16.9 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 123.61 0.764 . . . . 0.0 109.2 178.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.8 p30 58.58 19.42 6.65 Favored 'General case' 0 N--CA 1.501 2.103 0 C-N-CA 126.471 1.909 . . . . 0.0 115.123 176.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -95.44 126.9 41.05 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.837 -0.539 . . . . 0.0 109.664 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.541 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -69.12 119.1 12.87 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.945 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.574 HG21 ' HB3' ' A' ' 3' ' ' ASN . 8.0 pt -126.68 34.28 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.877 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.938 -173.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.509 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 2.2 pptp? -105.19 130.06 53.44 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 115.692 1.738 . . . . 0.0 115.692 -173.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -97.26 105.39 17.52 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 167.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -109.21 133.08 53.49 Favored 'General case' 0 C--N 1.286 -2.164 0 N-CA-C 114.532 1.308 . . . . 0.0 114.532 -169.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.38 112.02 10.64 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 103.099 -2.926 . . . . 0.0 103.099 165.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 61.7 m -146.44 107.12 4.09 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.337 1.065 . . . . 0.0 112.601 -173.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.544 ' H ' HG21 ' A' ' 10' ' ' VAL . 1.6 m120 -129.15 -76.94 0.55 Allowed 'General case' 0 C--N 1.28 -2.45 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.122 173.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.71 122.39 3.97 Favored Glycine 0 CA--C 1.478 -2.248 0 N-CA-C 106.114 -2.794 . . . . 0.0 106.114 -174.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -134.38 131.38 38.18 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 117.476 -1.689 . . . . 0.0 110.762 -172.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 53.3 mt -117.75 112.22 37.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 CA-C-N 115.171 -0.922 . . . . 0.0 108.567 -177.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 29.0 m -85.47 106.94 17.18 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 176.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.0 t -80.37 117.51 26.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.9 p -104.41 116.55 32.33 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.756 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 111' ' ' ALA . . . 95.49 162.04 33.86 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 120.802 -0.713 . . . . 0.0 113.745 178.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.3 m -158.68 178.88 9.64 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 123.676 0.79 . . . . 0.0 109.362 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -94.3 104.11 12.81 Favored Pre-proline 0 N--CA 1.429 -1.522 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 168.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -70.47 -3.84 13.3 Favored 'Trans proline' 0 N--CA 1.48 0.685 0 C-N-CA 123.194 2.596 . . . . 0.0 114.424 -171.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.7 m 62.42 48.0 4.86 Favored 'General case' 0 CA--C 1.542 0.671 0 CA-C-O 122.493 1.139 . . . . 0.0 108.32 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 12.7 p . . . . . 0 N--CA 1.427 -1.583 0 CA-C-N 114.263 -1.335 . . . . 0.0 110.357 -178.092 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.829 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 23.5 m 63.6 17.73 10.6 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.528 1.131 . . . . 0.0 112.131 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -123.86 90.9 3.35 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.592 0.71 . . . . 0.0 111.001 -177.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 50.8 m -99.17 112.84 24.89 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.9 -32.62 23.95 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.4 tmtt? 54.83 114.86 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.63 0 C-N-CA 126.937 2.095 . . . . 0.0 112.918 -173.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.49 ' HB3' HG21 ' A' ' 133' ' ' ILE . 19.0 m120 -103.75 133.62 48.44 Favored 'General case' 0 C--N 1.263 -3.157 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.146 -178.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.522 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 43.8 mm-40 -105.2 -169.21 1.57 Allowed 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 123.317 0.647 . . . . 0.0 109.947 179.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.0 m -116.37 104.85 11.88 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 173.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 54.8 t -83.66 112.93 21.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.12 117.45 27.01 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.729 -177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -93.59 126.34 38.7 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 173.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 t -126.76 139.41 53.15 Favored 'General case' 0 N--CA 1.417 -2.119 0 CA-C-O 122.153 0.978 . . . . 0.0 110.876 -174.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.63 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.5 m -125.54 161.75 29.68 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 CA-C-N 114.087 -1.415 . . . . 0.0 107.674 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.39 179.72 17.44 Favored Glycine 0 N--CA 1.425 -2.07 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.818 -179.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.6 m -111.14 118.91 37.26 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 36.0 m -112.67 165.3 7.63 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.8 m -123.98 148.22 47.13 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -147.94 165.03 28.9 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 33.6 m-80 -117.36 149.75 45.2 Favored Pre-proline 0 C--N 1.303 -1.44 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -59.12 121.24 9.61 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.292 1.995 . . . . 0.0 111.081 176.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.85 -13.16 57.78 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 -179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -90.62 151.46 21.28 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 123.309 0.643 . . . . 0.0 109.834 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.4 m -99.84 123.09 43.73 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.8 p -113.01 139.25 39.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-O 121.003 0.43 . . . . 0.0 110.752 -174.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -119.85 120.3 36.07 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.794 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.3 t -100.72 115.97 64.72 Favored Pre-proline 0 C--N 1.315 -0.93 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.591 -177.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -81.08 125.97 5.49 Favored 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 121.887 1.725 . . . . 0.0 112.522 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 47.1 t -90.47 125.07 43.32 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 20.5 m -107.03 138.94 42.24 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 120.887 0.375 . . . . 0.0 110.183 -175.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.575 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.3 tt -124.68 127.56 72.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 178.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.6 m -130.6 164.76 24.23 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 122.333 0.253 . . . . 0.0 110.711 -176.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.5 mm100 65.06 14.99 9.74 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.069 1.348 . . . . 0.0 114.237 177.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 7.1 p -94.02 104.92 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.807 0 C-N-CA 119.886 -0.726 . . . . 0.0 110.528 178.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 15.7 p -115.38 -17.12 11.35 Favored 'General case' 0 N--CA 1.441 -0.897 0 CA-C-O 121.692 0.758 . . . . 0.0 109.805 174.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.9 m -89.38 135.74 30.79 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 175.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.586 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 40.0 Cg_exo -58.79 123.52 13.71 Favored 'Trans proline' 0 C--N 1.352 0.745 0 C-N-CA 121.342 1.362 . . . . 0.0 111.733 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -87.92 142.66 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -118.3 -31.4 1.54 Allowed Glycine 0 N--CA 1.435 -1.399 0 C-N-CA 120.178 -1.011 . . . . 0.0 113.851 -176.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.3 tt -141.52 117.98 10.87 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.445 0.622 . . . . 0.0 110.258 -176.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 60.1 mt -121.24 119.58 59.6 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 174.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 45.4 t -128.78 137.76 51.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.0 ptp -157.65 139.32 13.93 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 123.274 0.63 . . . . 0.0 110.519 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -115.62 115.16 25.94 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.92 127.2 54.32 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.377 -171.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 11.4 m -110.18 126.58 54.25 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -127.86 171.08 12.09 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -77.79 117.44 19.17 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.53 -11.47 59.88 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -174.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 m -89.99 -36.53 14.91 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -82.8 -50.85 8.23 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.406 -0.815 . . . . 0.0 113.164 -177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -108.66 140.39 42.13 Favored 'General case' 0 CA--C 1.492 -1.263 0 CA-C-O 121.491 0.663 . . . . 0.0 112.777 -171.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 8.9 m -120.64 110.16 16.08 Favored 'General case' 0 C--N 1.289 -2.038 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 175.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.4 p -77.01 132.9 31.96 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.412 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtpm? -88.9 -62.39 1.5 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 174.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -169.32 177.12 4.86 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 -174.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -127.76 142.87 42.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.41 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 72.7 mt -102.53 113.42 65.89 Favored Pre-proline 0 C--N 1.287 -2.116 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.46 141.45 25.38 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.42 1.414 . . . . 0.0 109.54 176.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -75.06 107.67 7.29 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 175.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 1.4 p -71.46 -5.84 35.97 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 124.721 1.208 . . . . 0.0 112.737 -175.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -74.96 -34.64 62.07 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 176.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.57 -57.82 2.1 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.774 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' THR . 25.5 t -88.19 102.36 12.59 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.056 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -178.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.532 ' HD3' ' H ' ' A' ' 61' ' ' LYS . 0.0 OUTLIER -95.18 173.9 7.32 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.649 -179.567 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . 0.278 1.9 p30 23.48 68.13 0.04 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 O-C-N 125.626 1.828 . . . . 0.0 114.837 178.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.56 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 17.2 p -61.72 -20.06 63.08 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -171.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -69.73 -19.66 63.54 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.998 0.427 . . . . 0.0 111.315 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 56.3 m-80 -82.74 11.17 6.23 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 121.789 -0.569 . . . . 0.0 111.033 178.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.305 64.9 m-85 66.71 52.71 0.95 Allowed 'General case' 0 CA--C 1.488 -1.427 0 C-N-CA 124.524 1.13 . . . . 0.0 113.987 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.56 ' OG ' ' HA ' ' A' ' 63' ' ' THR . 3.7 p -92.13 -21.21 20.55 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 167.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.0 t80 -110.71 110.78 21.58 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 113.275 -1.784 . . . . 0.0 108.337 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -124.32 107.71 19.06 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 175.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 89.1 t -126.46 110.78 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-O 121.472 0.653 . . . . 0.0 109.981 176.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -103.34 124.81 49.38 Favored 'General case' 0 C--N 1.296 -1.726 0 N-CA-C 107.381 -1.34 . . . . 0.0 107.381 178.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.3 m -75.54 108.3 8.26 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.3 t -81.15 175.76 10.36 Favored 'General case' 0 N--CA 1.426 -1.666 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.499 -172.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.0 m -46.96 134.69 8.49 Favored Pre-proline 0 CA--C 1.542 0.67 0 C-N-CA 126.1 1.76 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -34.82 112.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.388 2.612 1 C-N-CA 125.399 4.066 . . . . 0.0 114.046 -172.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.87 0.59 36.33 Favored Glycine 0 N--CA 1.428 -1.843 0 CA-C-N 114.757 -1.11 . . . . 0.0 112.875 -177.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 37.4 mtmt -134.92 159.06 42.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 118.358 1.079 . . . . 0.0 112.899 177.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 12.3 mt -134.25 129.12 53.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.7 m -103.9 111.1 23.49 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 176.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 65.7 mt -114.21 131.71 65.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 121.186 0.517 . . . . 0.0 110.352 -175.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 36.0 m -138.88 123.4 18.42 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -112.7 108.34 17.34 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 174.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.8 t -135.85 120.37 18.16 Favored 'General case' 0 C--N 1.275 -2.673 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.67 119.75 54.92 Favored Pre-proline 0 C--N 1.292 -1.923 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.197 -170.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -83.93 -3.7 10.45 Favored 'Trans proline' 0 CA--C 1.546 1.112 0 C-N-CA 122.713 2.275 . . . . 0.0 113.078 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.427 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -109.77 19.67 18.89 Favored 'General case' 0 CA--C 1.547 0.849 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -175.721 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.7 pp -56.94 -19.54 18.54 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 115.957 1.836 . . . . 0.0 115.957 -175.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.32 -26.43 35.64 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 110.233 177.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.427 ' HB2' HG22 ' A' ' 86' ' ' THR . 36.7 m-80 -91.97 -41.1 10.75 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.369 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -126.15 101.66 28.39 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 176.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -85.42 120.26 2.11 Favored 'Trans proline' 0 N--CA 1.436 -1.887 0 C-N-CA 121.65 1.567 . . . . 0.0 110.49 176.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.7 mt -77.68 90.94 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -126.66 17.16 7.5 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 -173.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.7 m -125.93 158.03 35.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.575 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.6 p-10 -106.47 169.83 8.28 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 121.069 0.461 . . . . 0.0 111.682 -177.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 157.38 -135.94 4.64 Favored Glycine 0 N--CA 1.435 -1.388 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.417 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 49.3 mm -88.93 141.61 14.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 55.0 tp -96.3 -48.46 5.6 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.003 0.43 . . . . 0.0 110.256 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -159.02 165.53 33.8 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.739 -178.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.417 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 90.8 m-85 -121.12 124.27 44.35 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 176.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.99 116.63 29.08 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -105.8 111.05 23.57 Favored 'General case' 0 C--O 1.254 1.318 0 CA-C-O 121.215 0.531 . . . . 0.0 111.201 -175.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -121.83 137.06 54.92 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.265 -176.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.0 mt -91.74 127.26 44.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 106.46 -1.681 . . . . 0.0 106.46 172.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 42.6 mt -85.87 130.77 35.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 46.2 t-20 -70.46 152.52 43.94 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.8 t -76.41 -21.44 55.97 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 175.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -80.79 -11.69 59.57 Favored 'General case' 0 CA--C 1.542 0.647 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.299 178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -61.61 126.36 27.07 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.391 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -85.71 160.68 19.48 Favored 'General case' 0 N--CA 1.424 -1.764 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.544 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.74 158.71 25.43 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.432 -174.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.78 -179.49 17.25 Favored Glycine 0 N--CA 1.428 -1.867 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -72.69 123.75 23.91 Favored 'General case' 0 N--CA 1.422 -1.85 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.0 m -122.19 93.46 3.99 Favored 'General case' 0 C--N 1.276 -2.612 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 141' ' ' LYS . . . -91.7 141.62 28.49 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.845 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 28.6 mt -92.56 112.88 24.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 104.528 -2.397 . . . . 0.0 104.528 176.265 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.7 m -93.43 123.33 36.65 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -174.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 44.9 t -103.93 132.13 51.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.442 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 25.9 t70 -76.03 120.06 79.99 Favored Pre-proline 0 C--N 1.316 -0.854 0 O-C-N 123.759 0.662 . . . . 0.0 111.12 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 17.2 Cg_exo -68.74 -27.39 31.78 Favored 'Trans proline' 0 C--N 1.356 0.969 0 C-N-CA 122.819 2.346 . . . . 0.0 112.913 -179.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.96 -27.95 67.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.069 0.461 . . . . 0.0 111.2 -177.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.9 p -105.96 8.32 32.45 Favored 'General case' 0 C--N 1.306 -1.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.533 176.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -97.55 108.3 20.98 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.5 mt -127.98 128.15 68.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.471 ' HB ' ' CG ' ' A' ' 134' ' ' LYS . 83.7 t -134.57 99.7 2.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 175.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.64 149.98 38.87 Favored 'General case' 0 N--CA 1.426 -1.64 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.755 -176.36 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -87.35 -164.13 1.04 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.049 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -71.68 -20.95 61.86 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 178.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -89.68 4.33 49.88 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.9 t70 59.83 36.81 22.04 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 126.109 1.764 . . . . 0.0 111.726 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 46.1 mmtm -100.38 127.43 46.7 Favored 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 177.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -74.71 111.71 10.19 Favored 'General case' 0 C--O 1.242 0.697 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.522 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 25.2 pt -126.8 38.34 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.131 -170.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.471 ' CG ' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.44 136.76 44.41 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 117.611 2.449 . . . . 0.0 117.611 -172.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -95.65 103.77 15.66 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 164.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -121.01 120.0 34.14 Favored 'General case' 0 C--N 1.285 -2.226 0 C-N-CA 117.958 -1.497 . . . . 0.0 113.031 -171.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -117.44 112.72 21.04 Favored 'General case' 0 N--CA 1.414 -2.269 0 N-CA-C 104.194 -2.521 . . . . 0.0 104.194 170.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 48.9 m -134.99 105.65 6.46 Favored 'General case' 0 N--CA 1.42 -1.948 0 CA-C-O 122.456 1.122 . . . . 0.0 111.753 -177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.63 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.4 t-20 -167.77 80.05 0.18 Allowed 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 113.089 -1.869 . . . . 0.0 107.145 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -72.7 118.57 6.6 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 115' ' ' ALA . 36.6 ttpt -107.35 128.98 54.95 Favored 'General case' 0 C--N 1.28 -2.449 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.195 -173.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 61.2 mt -112.67 122.81 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 9.2 m -92.5 108.5 20.01 Favored 'General case' 0 C--N 1.277 -2.552 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 96.7 t -83.48 121.39 36.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 18.3 p -77.79 134.13 38.09 Favored 'General case' 0 N--CA 1.426 -1.653 0 O-C-N 123.946 0.779 . . . . 0.0 111.977 -178.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -87.75 65.02 3.6 Favored Glycine 0 N--CA 1.441 -0.977 0 CA-C-N 115.388 -0.823 . . . . 0.0 113.688 -177.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -130.25 -48.44 1.09 Allowed 'General case' 0 C--N 1.297 -1.686 0 O-C-N 122.552 -0.381 . . . . 0.0 109.986 175.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 69.19 155.14 0.15 Allowed Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.78 1.632 . . . . 0.0 111.313 -178.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -67.26 -22.01 47.06 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.53 1.487 . . . . 0.0 110.475 177.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.2 m 61.3 72.5 0.51 Allowed 'General case' 0 N--CA 1.431 -1.398 0 CA-C-O 123.096 1.427 . . . . 0.0 108.955 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.413 -2.275 0 CA-C-N 112.919 -1.946 . . . . 0.0 106.252 -179.122 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.164 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 40.1 m -81.65 126.39 31.71 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -141.55 131.2 24.06 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 21.2 t 68.36 21.94 8.14 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.549 1.14 . . . . 0.0 109.941 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 90.8 t -87.23 139.01 18.0 Favored 'Isoleucine or valine' 0 C--O 1.245 0.829 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.678 -177.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -92.49 129.08 38.52 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . 0.252 18.4 m120 73.64 80.92 0.13 Allowed 'General case' 0 CA--C 1.5 -0.948 0 C-N-CA 125.484 1.513 . . . . 0.0 110.407 -174.113 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' HG3' ' HB3' ' A' ' 31' ' ' SER . 3.0 mm-40 -109.08 153.7 23.3 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 112.352 -2.204 . . . . 0.0 110.337 -175.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.3 m -73.27 105.37 4.65 Favored 'General case' 0 N--CA 1.423 -1.791 0 O-C-N 123.948 0.78 . . . . 0.0 109.006 178.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.3 t -87.66 115.09 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.056 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.14 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HG2' ' OD2' ' A' ' 135' ' ' ASP . 57.2 mttm -87.42 122.12 30.76 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.267 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -93.54 113.62 25.78 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 171.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 31.6 t -122.0 149.44 43.48 Favored 'General case' 0 N--CA 1.42 -1.954 0 O-C-N 124.284 0.99 . . . . 0.0 110.072 -173.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.96 163.2 24.69 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 C-N-CA 124.68 1.192 . . . . 0.0 108.012 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.53 -171.84 12.63 Favored Glycine 0 N--CA 1.42 -2.393 0 C-N-CA 119.358 -1.401 . . . . 0.0 111.302 -179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 38.9 m -111.35 129.83 55.88 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -177.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.9 m -122.95 159.27 26.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 -178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -114.57 149.67 36.17 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 110.529 -0.174 . . . . 0.0 110.529 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.45 178.28 26.13 Favored Glycine 0 N--CA 1.438 -1.206 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 26.0 m-80 -124.23 148.83 58.99 Favored Pre-proline 0 C--N 1.308 -1.196 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.57 116.95 3.95 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 122.471 2.114 . . . . 0.0 111.228 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 104.21 -20.76 39.49 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -178.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -89.71 157.53 17.94 Favored 'General case' 0 C--N 1.315 -0.901 0 C-N-CA 123.47 0.708 . . . . 0.0 110.628 -176.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 17.0 m -96.2 132.49 41.58 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -119.83 149.23 22.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.8 tppt? -118.02 119.05 33.61 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.5 t -102.37 112.64 65.72 Favored Pre-proline 0 C--N 1.311 -1.087 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -83.62 126.98 4.2 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.095 1.864 . . . . 0.0 113.783 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.8 t -90.63 125.1 43.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 N-CA-C 106.406 -1.701 . . . . 0.0 106.406 175.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.0 m -108.64 133.67 52.42 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-O 120.941 0.4 . . . . 0.0 110.777 -173.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.1 tt -112.05 119.91 61.18 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 176.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.5 m -126.47 153.42 45.11 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.388 -173.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 26.9 mt-30 63.27 15.54 8.71 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 125.082 1.353 . . . . 0.0 113.486 177.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 9.3 p -75.93 144.34 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.6 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 176.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.409 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 37.7 t -150.49 -41.37 0.13 Allowed 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -174.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.1 m -85.37 134.99 39.37 Favored Pre-proline 0 N--CA 1.418 -2.056 0 CA-C-N 114.991 -1.004 . . . . 0.0 108.294 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.543 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.1 Cg_exo -57.1 125.64 19.59 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 123.126 2.551 . . . . 0.0 111.768 178.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 14.7 p -88.11 138.53 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.83 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -110.01 -41.06 1.34 Allowed Glycine 0 N--CA 1.441 -1.005 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.002 -177.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 58.5 mt -124.3 112.89 17.54 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 -178.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 48.9 mt -118.59 121.15 66.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 173.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 38.6 t -130.02 141.18 50.76 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 174.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.4 ptm -154.22 146.59 23.93 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -131.77 121.6 24.44 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -103.22 125.46 57.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -176.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 18.6 m -117.12 123.71 47.42 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 175.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 29.3 p90 -139.93 174.15 10.8 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 -176.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.04 111.33 9.1 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -68.6 -20.04 64.48 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -174.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.2 m -94.12 -19.46 20.79 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.907 0.384 . . . . 0.0 111.251 -177.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -95.33 -32.66 12.86 Favored 'General case' 0 N--CA 1.428 -1.527 0 CA-C-N 116.606 -0.27 . . . . 0.0 111.212 -175.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -129.08 155.84 44.8 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 21.7 m -133.08 110.01 9.9 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 12.9 p -76.94 134.82 27.94 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? -97.91 -55.51 2.77 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.808 0.814 . . . . 0.0 109.037 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 4.6 p-10 -156.76 178.0 10.84 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 114.098 -1.41 . . . . 0.0 108.696 -173.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.96 144.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 175.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 91.0 mt -106.62 112.91 63.46 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -75.9 145.33 28.34 Favored 'Trans proline' 0 N--CA 1.444 -1.405 0 C-N-CA 121.451 1.434 . . . . 0.0 109.411 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -78.64 105.21 9.77 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.646 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 9.5 t -70.08 -2.8 13.91 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.673 -175.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -74.88 -30.74 61.4 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 173.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.8 mt -101.61 -70.52 0.74 Allowed 'General case' 0 N--CA 1.438 -1.059 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.054 177.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' A' ' 57' ' ' THR . 6.5 t -85.96 101.4 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.766 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -178.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.433 ' HD3' ' CE1' ' A' ' 90' ' ' TYR . 61.7 tttm -112.6 153.11 28.09 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 -174.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.448 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 6.1 m-20 54.04 65.47 1.5 Allowed 'General case' 0 CA--C 1.494 -1.193 0 O-C-N 124.697 1.248 . . . . 0.0 110.45 -178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.424 ' HA ' ' OG ' ' A' ' 67' ' ' SER . 21.3 p -69.38 -8.57 47.64 Favored 'General case' 0 N--CA 1.44 -0.93 0 CA-C-N 114.235 -1.348 . . . . 0.0 113.25 -172.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.9 -14.48 61.48 Favored 'General case' 0 C--O 1.217 -0.632 0 C-N-CA 125.219 1.407 . . . . 0.0 111.231 178.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.448 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 40.8 m-80 -89.68 19.79 4.45 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 112.243 0.46 . . . . 0.0 112.243 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 58.9 t80 68.88 26.17 5.94 Favored 'General case' 0 C--O 1.211 -0.945 0 CA-C-O 122.434 1.111 . . . . 0.0 110.081 179.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.629 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.7 p -83.21 -13.53 55.18 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 122.525 1.155 . . . . 0.0 109.175 174.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -118.36 112.66 20.3 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.051 -177.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -124.83 114.4 40.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 70.8 t -123.34 115.15 44.65 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.036 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 175.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.445 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 23.3 t30 -93.9 110.92 22.57 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 176.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.0 m -81.92 92.53 6.75 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.8 m -67.3 174.16 3.46 Favored 'General case' 0 N--CA 1.419 -2.006 0 C-N-CA 125.053 1.341 . . . . 0.0 110.176 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.4 m -59.78 136.55 90.06 Favored Pre-proline 0 CA--C 1.562 1.427 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 176.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -34.55 128.27 0.21 Allowed 'Trans proline' 0 C--N 1.385 2.497 0 C-N-CA 125.273 3.982 . . . . 0.0 114.542 -175.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.71 -18.68 34.48 Favored Glycine 0 N--CA 1.439 -1.118 0 CA-C-N 115.089 -0.959 . . . . 0.0 112.329 -175.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.5 mttm -124.33 148.43 47.48 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 117.439 0.619 . . . . 0.0 111.766 175.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 17.9 mt -137.32 110.31 7.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 175.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 21.4 m -99.29 113.93 26.49 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 60.5 mt -115.87 143.65 25.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-O 120.977 0.418 . . . . 0.0 110.324 -175.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.6 m -142.1 122.9 14.36 Favored 'General case' 0 N--CA 1.424 -1.752 0 C-N-CA 123.105 0.562 . . . . 0.0 109.678 175.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -113.59 113.84 25.63 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.629 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.1 t -137.36 118.99 14.95 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 175.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -111.27 119.55 45.16 Favored Pre-proline 0 C--N 1.298 -1.646 0 C-N-CA 119.853 -0.739 . . . . 0.0 111.141 -176.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.35 -5.37 16.55 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.528 2.152 . . . . 0.0 112.011 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.433 HG22 ' HB2' ' A' ' 89' ' ' ASN . 0.2 OUTLIER -112.74 23.69 13.22 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 123.048 0.539 . . . . 0.0 110.818 -176.969 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.7 pp -57.89 -17.7 18.18 Favored 'General case' 0 N--CA 1.498 1.93 0 N-CA-C 114.887 1.439 . . . . 0.0 114.887 -175.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.23 -24.38 26.07 Favored 'General case' 0 N--CA 1.439 -1.019 0 CA-C-O 120.929 0.395 . . . . 0.0 110.249 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.453 HD22 ' N ' ' A' ' 89' ' ' ASN . 0.7 OUTLIER -94.6 -43.03 8.49 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.368 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HD3' ' A' ' 61' ' ' LYS . 28.6 m-85 -100.42 104.54 30.95 Favored Pre-proline 0 CA--C 1.487 -1.454 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 174.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -77.86 89.61 1.32 Allowed 'Trans proline' 0 N--CA 1.415 -3.095 0 N-CA-C 115.363 1.255 . . . . 0.0 115.363 -169.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 21.3 mt -88.87 88.03 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.895 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 172.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -157.28 16.96 0.28 Allowed 'General case' 0 C--N 1.287 -2.113 0 CA-C-N 113.638 -1.619 . . . . 0.0 108.022 178.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.1 m -122.24 143.87 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.791 -177.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -85.77 155.88 20.83 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.195 0.521 . . . . 0.0 112.194 -173.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 152.29 -142.67 9.57 Favored Glycine 0 N--CA 1.424 -2.101 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.438 HG21 ' CZ ' ' A' ' 100' ' ' TYR . 44.1 mm -90.89 136.87 22.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 61.7 tp -91.79 -49.68 6.14 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 177.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.55 161.42 40.88 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.252 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.438 ' CZ ' HG21 ' A' ' 97' ' ' ILE . 98.2 m-85 -117.59 118.15 31.36 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 176.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 60.4 mt -86.71 132.38 33.88 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.534 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 22.7 t70 -105.93 117.25 33.54 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 120.61 0.243 . . . . 0.0 111.096 -177.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -128.94 125.54 37.72 Favored 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.902 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.8 mt -89.64 126.26 42.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 170.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 41.3 mt -81.11 133.93 28.25 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.41 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.0 t-20 -65.57 147.79 52.82 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.4 m -76.71 -14.89 59.91 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-O 121.847 0.832 . . . . 0.0 109.859 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -93.28 1.9 56.82 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.663 177.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.41 ' HB2' ' HB3' ' A' ' 106' ' ' ASN . . . -86.53 138.35 31.8 Favored 'General case' 0 N--CA 1.435 -1.183 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.66 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 12.9 t -95.17 175.1 6.74 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.083 -177.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.25 158.54 26.17 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.327 -176.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 131.71 158.87 9.23 Favored Glycine 0 N--CA 1.433 -1.522 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.743 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -73.95 130.88 40.76 Favored 'General case' 0 N--CA 1.429 -1.5 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.0 m -131.43 115.71 16.56 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.61 139.84 30.31 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 121.415 0.626 . . . . 0.0 112.604 -176.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 25.1 mt -97.91 119.57 36.76 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 6.7 m -88.46 114.34 24.99 Favored 'General case' 0 C--N 1.291 -1.977 0 C-N-CA 121.166 -0.213 . . . . 0.0 110.723 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 40.9 t -96.65 118.34 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.255 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 172.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.426 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 15.1 t70 -69.08 118.8 65.18 Favored Pre-proline 0 C--N 1.308 -1.23 0 O-C-N 123.598 0.561 . . . . 0.0 111.103 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 6.3 Cg_exo -69.19 -20.5 37.47 Favored 'Trans proline' 0 C--N 1.365 1.429 0 C-N-CA 123.424 2.749 . . . . 0.0 114.051 -176.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -85.63 -34.56 21.34 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.254 0.55 . . . . 0.0 109.912 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 7.6 m -82.2 -12.79 57.91 Favored 'General case' 0 N--CA 1.424 -1.745 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.4 tm? -79.9 107.86 13.02 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 175.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -121.28 124.3 71.7 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.541 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 53.5 t -133.01 97.02 2.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -109.11 138.15 45.9 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 114.865 -1.061 . . . . 0.0 108.937 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.532 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.4 p-10 -82.54 -168.16 1.9 Allowed 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -66.91 -20.79 65.97 Favored 'General case' 0 CA--C 1.548 0.882 0 O-C-N 122.211 -0.306 . . . . 0.0 111.737 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -87.25 4.82 41.15 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 123.564 0.746 . . . . 0.0 109.504 176.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 34.7 t70 70.87 15.65 6.75 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 125.114 1.366 . . . . 0.0 111.773 174.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 75.0 mmtt -97.54 130.25 44.62 Favored 'General case' 0 C--N 1.313 -1.002 0 O-C-N 121.019 -1.051 . . . . 0.0 111.652 -175.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 19.7 t70 -75.4 106.3 6.87 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 12.8 pt -123.59 46.17 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.521 -173.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -107.89 131.06 54.91 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 115.456 1.65 . . . . 0.0 115.456 -171.501 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.438 ' OD2' ' HG2' ' A' ' 7' ' ' LYS . 24.8 t70 -96.74 103.39 15.3 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 165.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -120.32 120.93 37.45 Favored 'General case' 0 C--N 1.286 -2.164 0 C-N-CA 118.98 -1.088 . . . . 0.0 112.993 -172.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.23 112.35 7.31 Favored 'General case' 0 N--CA 1.417 -2.087 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 168.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 69.8 m -141.0 105.72 4.91 Favored 'General case' 0 N--CA 1.412 -2.329 0 CA-C-O 122.634 1.207 . . . . 0.0 111.979 -177.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -140.31 85.07 1.99 Allowed 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 174.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.39 144.31 38.81 Favored Glycine 0 CA--C 1.479 -2.198 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 33.7 ttpt -132.03 129.26 39.83 Favored 'General case' 0 C--N 1.282 -2.341 0 C-N-CA 118.025 -1.47 . . . . 0.0 111.565 -174.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 62.9 mt -105.51 117.65 51.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 16.9 m -91.88 105.73 17.93 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.7 t -80.27 110.9 16.36 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 17.3 p -99.99 120.31 39.61 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -166.43 119.18 0.84 Allowed Glycine 0 N--CA 1.417 -2.613 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -177.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.6 m -71.28 -28.32 64.05 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 123.318 0.647 . . . . 0.0 109.663 179.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -158.66 119.13 1.83 Allowed Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 176.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -62.18 -33.22 82.17 Favored 'Trans proline' 0 C--N 1.359 1.107 0 C-N-CA 122.159 1.906 . . . . 0.0 110.586 177.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 t -150.17 136.35 18.74 Favored 'General case' 0 N--CA 1.406 -2.671 0 N-CA-C 105.802 -1.925 . . . . 0.0 105.802 175.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.426 -1.667 0 O-C-N 123.058 0.224 . . . . 0.0 110.929 -178.324 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.498 -1.009 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 18.5 m -97.17 171.72 8.27 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 -179.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 71.0 -84.59 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 125.429 1.492 . . . . 0.0 112.631 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.9 m 58.3 24.15 11.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.521 1.128 . . . . 0.0 112.15 179.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.1 t -82.78 -42.33 18.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.6 mtpt -140.07 -175.79 4.36 Favored 'General case' 0 C--O 1.251 1.134 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.353 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.482 HD21 ' HB3' ' A' ' 129' ' ' ASN . 12.2 m120 71.24 95.34 0.07 Allowed 'General case' 0 C--O 1.246 0.887 0 C-N-CA 124.931 1.292 . . . . 0.0 111.254 177.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.52 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 9.2 mm-40 -91.4 -177.38 4.82 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.486 -1.234 . . . . 0.0 112.317 -175.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.2 m -102.93 105.04 15.31 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 172.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.9 t -99.85 117.64 45.31 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 CA-C-O 120.917 0.389 . . . . 0.0 110.324 -175.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -88.63 118.78 28.53 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -100.66 111.96 24.27 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.768 -1.938 . . . . 0.0 105.768 177.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.409 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 61.3 m -117.38 158.33 24.63 Favored 'General case' 0 N--CA 1.414 -2.263 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.216 -174.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 18.8 m -138.21 162.0 31.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 177.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.4 -176.58 14.43 Favored Glycine 0 N--CA 1.425 -2.067 0 C-N-CA 118.397 -1.859 . . . . 0.0 113.591 -176.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.8 m -110.61 122.05 46.82 Favored 'General case' 0 N--CA 1.411 -2.377 0 CA-C-N 114.759 -0.72 . . . . 0.0 109.343 -177.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -118.91 164.26 15.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.5 m -123.98 152.65 42.3 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.389 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -157.32 174.53 34.83 Favored Glycine 0 N--CA 1.43 -1.74 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.758 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.0 m-80 -125.46 150.51 67.97 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 123.058 0.543 . . . . 0.0 110.378 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_exo -56.55 125.86 20.41 Favored 'Trans proline' 0 C--O 1.251 1.135 0 C-N-CA 122.924 2.416 . . . . 0.0 111.268 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.68 -23.89 34.04 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 111.699 -0.56 . . . . 0.0 111.699 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -90.12 148.16 23.16 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.699 0.285 . . . . 0.0 110.554 -177.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 14.8 m -83.1 129.68 35.05 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.69 133.5 57.13 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 -178.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -118.93 116.42 26.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.7 t -100.7 120.85 54.69 Favored Pre-proline 0 C--N 1.305 -1.358 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.342 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.59 129.12 2.16 Favored 'Trans proline' 0 N--CA 1.439 -1.719 0 C-N-CA 122.122 1.882 . . . . 0.0 113.682 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 80.5 t -90.38 117.12 33.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 174.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 24.9 m -98.6 131.99 44.36 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-O 121.179 0.514 . . . . 0.0 110.801 -173.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.46 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.0 tt -115.98 128.66 73.19 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.961 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 176.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 18.0 m -130.88 152.39 50.26 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 111.643 0.238 . . . . 0.0 111.643 -176.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 28.6 mt-30 67.27 15.37 9.96 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 125.466 1.507 . . . . 0.0 114.257 177.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.5 p -77.48 133.71 30.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.3 t -138.93 -47.86 0.49 Allowed 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.4 m -76.12 134.67 70.75 Favored Pre-proline 0 N--CA 1.424 -1.737 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 172.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 51.4 Cg_exo -57.52 125.35 18.5 Favored 'Trans proline' 0 C--N 1.356 0.962 0 C-N-CA 122.227 1.951 . . . . 0.0 113.021 -178.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.2 p -87.38 147.81 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -138.65 -3.37 1.81 Allowed Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 118.564 -1.779 . . . . 0.0 115.18 -176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -138.92 112.19 8.08 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.2 mp -125.41 115.85 44.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 53.7 t -121.33 131.74 54.38 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 177.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -153.71 124.51 7.24 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -108.44 114.46 28.32 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 38.8 mt -100.96 135.99 34.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.634 -173.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.419 ' OG ' ' HE2' ' A' ' 77' ' ' LYS . 19.3 m -119.23 132.17 55.9 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 174.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -144.3 179.04 7.49 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 120.872 -0.331 . . . . 0.0 111.02 -177.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 35.0 t0 -86.1 111.41 20.31 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.92 -0.86 57.76 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -176.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.6 t -94.23 -31.53 14.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.506 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 3.9 ttmp? -94.45 -33.69 13.02 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.286 -177.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -127.89 160.9 30.41 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 96.2 m -144.3 116.96 8.66 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 175.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.5 p -70.65 135.13 28.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.871 0.367 . . . . 0.0 110.276 178.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -86.19 -59.95 2.14 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 175.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -170.25 177.49 4.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 -175.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 31.4 m -125.21 144.44 35.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 85.8 mt -110.46 118.58 48.7 Favored Pre-proline 0 C--N 1.291 -1.939 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.72 139.9 14.37 Favored 'Trans proline' 0 N--CA 1.438 -1.747 0 C-N-CA 121.157 1.238 . . . . 0.0 109.718 176.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -75.35 105.01 6.16 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 175.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 12.7 t -77.78 2.79 15.94 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.166 -174.028 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -77.37 -30.45 53.76 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 170.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.7 mt -97.52 -69.44 0.76 Allowed 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.477 177.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 57' ' ' THR . 41.1 t -70.29 115.13 9.06 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 179.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.56 ' HG2' ' CG ' ' A' ' 90' ' ' TYR . 27.6 tptt -112.86 140.94 47.23 Favored 'General case' 0 N--CA 1.414 -2.257 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.997 -168.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.4 ' HB3' ' ND2' ' A' ' 65' ' ' ASN . 1.2 m-20 49.89 65.5 1.4 Allowed 'General case' 0 C--O 1.247 0.97 0 O-C-N 124.943 1.402 . . . . 0.0 111.916 177.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.49 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.9 p -58.95 -21.15 57.8 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 113.398 -1.728 . . . . 0.0 115.311 -172.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -77.6 -2.78 37.51 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-O 121.449 0.642 . . . . 0.0 111.339 -175.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.4 ' ND2' ' HB3' ' A' ' 62' ' ' ASP . 55.8 m-80 -88.7 28.38 1.15 Allowed 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 122.8 0.44 . . . . 0.0 110.15 175.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 36.5 t80 62.8 38.2 11.82 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.636 1.174 . . . . 0.0 109.63 -178.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.644 ' HA ' ' O ' ' A' ' 83' ' ' THR . 40.0 t -90.02 -27.8 19.5 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 122.305 1.05 . . . . 0.0 108.23 175.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 88.6 t80 -101.08 105.94 17.16 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.62 -1.173 . . . . 0.0 109.641 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.56 107.46 20.16 Favored 'Isoleucine or valine' 0 C--O 1.237 0.403 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 176.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 85.3 t -125.13 110.89 25.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-O 121.378 0.609 . . . . 0.0 110.154 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.17 115.69 28.31 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 177.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.4 m -86.58 89.48 7.93 Favored 'General case' 0 N--CA 1.417 -2.086 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 m -64.17 174.78 1.46 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 126.414 1.886 . . . . 0.0 111.576 -177.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -48.66 134.94 13.58 Favored Pre-proline 0 CA--C 1.557 1.214 0 C-N-CA 124.212 1.005 . . . . 0.0 109.111 175.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -38.86 124.94 0.98 Allowed 'Trans proline' 0 C--N 1.384 2.405 0 C-N-CA 124.42 3.414 . . . . 0.0 113.63 -175.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 108.05 -14.83 37.07 Favored Glycine 0 N--CA 1.434 -1.459 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.064 -174.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.419 ' HE2' ' OG ' ' A' ' 42' ' ' SER . 65.5 mttt -127.28 152.79 46.97 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 174.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.4 mt -140.58 111.41 3.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 177.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -97.71 110.69 23.21 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 62.6 mt -109.02 135.42 47.97 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 -177.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.407 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 24.6 m -142.62 121.99 13.13 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-O 121.535 0.683 . . . . 0.0 109.811 176.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -110.29 109.17 19.52 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.644 ' O ' ' HA ' ' A' ' 67' ' ' SER . 53.0 p -113.26 117.12 30.96 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 105.903 -1.888 . . . . 0.0 105.903 174.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -113.14 119.6 42.06 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 119.845 -0.742 . . . . 0.0 112.861 -169.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.31 -15.36 5.38 Favored 'Trans proline' 0 CA--C 1.554 1.506 0 C-N-CA 122.687 2.258 . . . . 0.0 113.195 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.41 -3.36 58.85 Favored 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.149 1.38 . . . . 0.0 114.194 -169.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.9 pp -51.6 -21.54 2.64 Favored 'General case' 0 CA--C 1.556 1.19 0 N-CA-C 117.277 2.325 . . . . 0.0 117.277 -176.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.86 -34.99 15.9 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 121.488 -0.758 . . . . 0.0 109.931 179.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -77.24 -37.89 52.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.992 178.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.56 ' CG ' ' HG2' ' A' ' 61' ' ' LYS . 70.3 m-85 -126.97 103.16 23.84 Favored Pre-proline 0 C--N 1.308 -1.224 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -80.12 123.11 4.95 Favored 'Trans proline' 0 N--CA 1.443 -1.471 0 C-N-CA 121.59 1.527 . . . . 0.0 113.355 -176.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.411 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 54.1 mt -79.85 90.99 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 172.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 28.3 p -126.08 8.89 7.37 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.319 -173.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 24.9 m -123.94 145.63 30.72 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.1 p30 -85.94 177.23 7.67 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.123 -178.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.03 -140.13 10.93 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.6 mp -96.03 131.27 43.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 51.1 tp -87.62 -47.25 8.83 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.156 0.503 . . . . 0.0 109.984 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.55 153.57 36.02 Favored 'General case' 0 N--CA 1.44 -0.943 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.773 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -111.28 123.31 49.94 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 46.1 mt -91.9 117.8 30.14 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -108.95 109.4 20.46 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.152 0.501 . . . . 0.0 110.587 -172.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -119.44 155.27 32.34 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.9 -176.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 77.3 mt -104.84 135.56 42.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.829 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 170.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.54 126.93 43.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 175.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 36.7 t30 -62.94 146.76 52.29 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 123.603 0.761 . . . . 0.0 110.636 -178.307 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.0 p -68.48 -27.38 66.1 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.662 0.744 . . . . 0.0 110.746 179.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 59.9 t30 -94.21 18.73 10.39 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-O 122.215 1.007 . . . . 0.0 109.654 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.506 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -81.63 142.81 32.42 Favored 'General case' 0 CA--C 1.507 -0.706 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.4 m -87.77 150.34 23.63 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -76.83 151.15 36.01 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 109.487 -0.561 . . . . 0.0 109.487 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.49 171.3 12.62 Favored Glycine 0 C--N 1.289 -2.077 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -176.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 5.9 p-10 -91.68 144.28 25.68 Favored 'General case' 0 N--CA 1.422 -1.849 0 CA-C-N 117.463 0.632 . . . . 0.0 110.834 -179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 54.5 m -137.88 134.56 35.2 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 175.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.83 154.79 19.62 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.647 0.737 . . . . 0.0 111.727 -177.173 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 64.6 mt -111.36 113.58 26.14 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.746 -1.576 . . . . 0.0 106.746 176.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 91.7 m -88.11 114.16 24.45 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-O 120.576 0.227 . . . . 0.0 111.127 -175.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 45.0 t -101.67 119.31 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 174.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.426 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 14.9 t70 -63.5 116.46 26.06 Favored Pre-proline 0 C--N 1.315 -0.922 0 O-C-N 124.09 0.869 . . . . 0.0 111.402 -175.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -70.86 -21.73 28.0 Favored 'Trans proline' 0 C--N 1.365 1.426 0 C-N-CA 122.781 2.321 . . . . 0.0 113.753 -177.231 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.68 -38.28 58.84 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.218 0.532 . . . . 0.0 110.533 -177.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 p -95.78 6.26 49.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.677 178.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.443 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.0 tt -89.82 111.3 22.27 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 177.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 72.5 mt -131.51 128.38 60.8 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.45 ' HB ' ' HG2' ' A' ' 134' ' ' LYS . 75.4 t -131.43 98.05 3.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -105.22 137.7 42.58 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 114.782 -1.099 . . . . 0.0 111.008 -176.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -64.55 -179.71 0.52 Allowed 'General case' 0 C--N 1.294 -1.843 0 C-N-CA 126.544 1.938 . . . . 0.0 109.844 177.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -70.06 -22.94 63.02 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.73 0.776 . . . . 0.0 108.968 176.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . 0.482 ' HB3' HD21 ' A' ' 3' ' ' ASN . 66.8 t30 -87.76 11.75 14.61 Favored 'General case' 0 CA--C 1.555 1.139 0 CA-C-N 114.836 -1.075 . . . . 0.0 109.957 177.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 17.2 t70 70.24 5.94 5.55 Favored 'General case' 0 N--CA 1.51 2.54 0 C-N-CA 125.799 1.64 . . . . 0.0 112.145 173.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.5 mmtm -88.45 122.47 31.97 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.784 -0.573 . . . . 0.0 109.949 -176.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -70.31 117.16 11.51 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.52 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 27.6 pt -127.81 32.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.972 -172.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.8 pptp? -105.45 131.72 52.52 Favored 'General case' 0 N--CA 1.427 -1.606 0 N-CA-C 114.732 1.382 . . . . 0.0 114.732 -174.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -96.72 109.48 22.12 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 103.361 -2.829 . . . . 0.0 103.361 164.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -131.06 132.04 44.65 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.408 -1.317 . . . . 0.0 114.117 -171.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -125.02 112.96 17.16 Favored 'General case' 0 N--CA 1.416 -2.152 0 N-CA-C 105.618 -1.993 . . . . 0.0 105.618 171.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -132.65 104.73 6.8 Favored 'General case' 0 N--CA 1.409 -2.486 0 CA-C-O 122.969 1.366 . . . . 0.0 112.475 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -155.41 89.92 1.22 Allowed 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 104.721 -2.326 . . . . 0.0 104.721 174.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -77.03 173.97 54.67 Favored Glycine 0 CA--C 1.487 -1.696 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.696 -175.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -149.87 133.93 17.1 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 118.11 0.955 . . . . 0.0 110.251 -178.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 66.2 mt -116.61 119.48 62.11 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 175.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 18.1 m -96.77 106.78 19.14 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 48.2 t -80.39 113.97 20.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.7 p -77.23 -46.13 24.2 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-O 121.437 0.637 . . . . 0.0 111.542 -176.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 85.61 26.38 35.71 Favored Glycine 0 N--CA 1.427 -1.918 0 CA-C-N 115.196 -0.911 . . . . 0.0 111.768 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 14.0 m -76.56 -41.64 45.71 Favored 'General case' 0 N--CA 1.44 -0.975 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -117.36 109.69 41.89 Favored Pre-proline 0 C--N 1.317 -0.805 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -92.3 37.46 0.25 Allowed 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.361 2.708 . . . . 0.0 113.176 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.3 m 70.69 109.94 0.06 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 124.513 1.125 . . . . 0.0 110.671 -178.238 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.6 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.215 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.635 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.0 m -104.85 174.68 5.77 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 122.684 -0.303 . . . . 0.0 110.755 -177.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 69.52 77.55 0.21 Allowed 'General case' 0 C--O 1.241 0.657 0 C-N-CA 125.508 1.523 . . . . 0.0 113.995 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -135.16 31.09 3.25 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 171.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.8 m -92.01 175.74 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.054 0 CA-C-N 114.244 -1.344 . . . . 0.0 111.748 -174.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -104.92 -164.53 1.05 Allowed 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.508 ' HB3' HG21 ' A' ' 133' ' ' ILE . 19.6 m120 76.1 113.8 0.07 Allowed 'General case' 0 C--O 1.245 0.834 0 C-N-CA 124.597 1.159 . . . . 0.0 112.872 174.076 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -88.59 -167.24 1.82 Allowed 'General case' 0 N--CA 1.427 -1.605 0 CA-C-N 114.789 -1.096 . . . . 0.0 109.624 176.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.1 m -108.04 105.42 15.18 Favored 'General case' 0 C--N 1.288 -2.096 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 176.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 81.0 t -96.56 113.37 30.74 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 CA-C-O 121.995 0.902 . . . . 0.0 110.435 -173.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -89.73 130.04 36.06 Favored 'General case' 0 C--N 1.277 -2.571 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.341 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -108.56 117.47 34.25 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 106.071 -1.826 . . . . 0.0 106.071 176.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.6 t -121.66 157.06 31.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-O 121.844 0.83 . . . . 0.0 110.925 -172.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.404 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.5 m -140.03 162.55 25.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 C-N-CA 125.734 1.614 . . . . 0.0 106.905 -179.733 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.67 -169.22 11.89 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 119.3 -1.429 . . . . 0.0 112.584 -177.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 60.5 m -111.46 130.57 55.67 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 122.992 0.517 . . . . 0.0 110.587 -176.205 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 27.5 m -129.09 165.09 29.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 C-N-CA 123.921 0.888 . . . . 0.0 108.736 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.0 m -119.47 150.04 40.89 Favored 'General case' 0 C--N 1.306 -1.326 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.61 178.28 29.01 Favored Glycine 0 N--CA 1.438 -1.169 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 32.5 m-80 -140.53 155.8 69.6 Favored Pre-proline 0 C--N 1.314 -0.952 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -62.77 121.01 8.76 Favored 'Trans proline' 0 C--N 1.353 0.765 0 C-N-CA 121.868 1.712 . . . . 0.0 110.222 175.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.91 -17.44 58.22 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -90.39 143.56 26.64 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 123.542 0.737 . . . . 0.0 110.651 -176.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.1 m -83.16 131.77 35.11 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 p -121.03 143.19 34.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 -177.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -130.37 116.5 18.38 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 120.798 0.332 . . . . 0.0 110.821 -177.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 30.7 t -100.86 117.04 63.33 Favored Pre-proline 0 C--N 1.316 -0.877 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.542 -179.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -82.3 129.52 5.95 Favored 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 121.78 1.654 . . . . 0.0 112.253 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 59.4 t -90.07 120.86 39.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.4 m -107.03 128.27 54.21 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.15 0.5 . . . . 0.0 111.069 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.508 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 16.2 tt -111.31 132.93 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 175.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -135.41 154.36 51.49 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -175.053 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 65.46 15.31 9.96 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 126.234 1.814 . . . . 0.0 113.161 178.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 6.5 p -83.9 112.11 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.69 0 CA-C-O 121.48 0.657 . . . . 0.0 110.129 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.7 t -119.26 -36.21 3.43 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 176.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 18.0 m -66.01 122.19 79.84 Favored Pre-proline 0 N--CA 1.442 -0.828 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 172.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.512 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 31.1 Cg_exo -59.0 122.43 11.6 Favored 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 121.008 1.138 . . . . 0.0 111.191 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 10.4 p -89.32 148.8 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.572 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.258 178.316 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -130.98 -9.27 2.8 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 119.579 -1.296 . . . . 0.0 113.429 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 4.3 tt -144.17 112.61 6.5 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.1 mp -121.18 114.45 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 174.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 45.7 t -121.16 133.81 55.21 Favored 'General case' 0 C--N 1.277 -2.573 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 -179.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.5 ptm -155.12 144.69 21.32 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.205 0.457 . . . . 0.0 110.362 -178.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -123.25 118.04 26.67 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.968 0.413 . . . . 0.0 110.001 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -100.34 115.3 41.36 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.599 -175.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 15.4 m -100.71 129.58 46.63 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 176.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -144.0 179.7 7.03 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 -176.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -83.57 110.4 18.2 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.605 -1.258 . . . . 0.0 107.605 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.86 -8.22 59.66 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -173.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.1 t -91.27 -37.46 13.28 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 177.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.664 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 39.7 ttmt -82.78 -37.47 24.5 Favored 'General case' 0 N--CA 1.438 -1.037 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.43 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 -117.07 139.35 50.81 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.242 0.544 . . . . 0.0 111.157 -177.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 17.8 m -120.61 110.12 16.05 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.8 p -76.06 135.97 25.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-O 120.865 0.364 . . . . 0.0 111.207 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? -91.01 -61.93 1.56 Allowed 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 175.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -167.68 176.71 6.24 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -175.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 32.9 m -124.8 135.24 64.62 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.6 mt -94.42 113.1 60.09 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -177.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -80.41 143.75 15.66 Favored 'Trans proline' 0 N--CA 1.449 -1.145 0 C-N-CA 121.953 1.769 . . . . 0.0 110.935 178.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.4 t30 -83.89 109.25 17.44 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.578 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.0 p -68.55 -11.67 60.23 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 113.535 0.939 . . . . 0.0 113.535 -176.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.03 -32.71 72.41 Favored 'General case' 0 C--O 1.222 -0.369 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 173.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 98' ' ' LEU . 56.2 mt -97.9 -62.79 1.2 Allowed 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.639 178.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 57' ' ' THR . 12.1 t -87.96 102.43 12.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 20.5 ttmm -109.89 147.13 33.95 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 120.687 -0.405 . . . . 0.0 110.145 -172.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t0 51.53 63.45 2.24 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 125.387 1.475 . . . . 0.0 110.332 -176.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.8 p -57.57 -20.05 29.67 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-N 113.81 -1.541 . . . . 0.0 114.5 -174.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -70.18 -11.57 60.99 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 124.037 0.935 . . . . 0.0 112.607 -176.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 -82.59 20.18 1.16 Allowed 'General case' 0 N--CA 1.479 0.989 0 O-C-N 121.829 -0.545 . . . . 0.0 110.799 179.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 46.8 t80 69.0 32.9 3.62 Favored 'General case' 0 C--O 1.211 -0.954 0 C-N-CA 125.37 1.468 . . . . 0.0 108.033 -178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.8 m -84.78 -15.76 43.85 Favored 'General case' 0 N--CA 1.437 -1.081 0 CA-C-N 114.138 -1.392 . . . . 0.0 109.282 178.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 92.7 t80 -114.21 108.23 16.67 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-N 114.865 -1.062 . . . . 0.0 109.769 -177.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.3 mp -124.44 119.02 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.126 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -128.44 114.87 35.6 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 174.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -114.32 132.48 56.17 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.16 0.505 . . . . 0.0 110.011 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.5 p -86.71 104.02 15.71 Favored 'General case' 0 N--CA 1.409 -2.52 0 CA-C-O 121.729 0.775 . . . . 0.0 110.854 178.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 49.8 m -83.59 177.85 8.23 Favored 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.361 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.6 m -46.17 134.26 7.18 Favored Pre-proline 0 CA--C 1.557 1.24 0 C-N-CA 124.399 1.08 . . . . 0.0 110.284 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -35.01 120.72 0.16 Allowed 'Trans proline' 0 C--N 1.388 2.627 0 C-N-CA 125.297 3.998 . . . . 0.0 114.478 -173.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.65 -7.43 39.11 Favored Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 114.948 -1.024 . . . . 0.0 112.946 -177.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -126.72 122.48 34.99 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.897 0.848 . . . . 0.0 112.659 178.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 25.6 mt -110.6 115.3 49.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.9 m -100.41 111.09 23.32 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.4 mt -112.43 139.99 34.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.259 -175.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.406 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 29.6 m -141.11 121.82 14.32 Favored 'General case' 0 N--CA 1.419 -2.016 0 CA-C-O 121.175 0.512 . . . . 0.0 109.97 177.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -110.48 108.89 19.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 175.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.614 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -143.43 119.63 10.81 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 178.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -108.29 125.0 32.93 Favored Pre-proline 0 C--N 1.293 -1.884 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.876 -175.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -77.07 -4.26 14.65 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.081 2.521 . . . . 0.0 111.904 177.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -101.19 17.69 21.85 Favored 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 123.898 0.879 . . . . 0.0 108.799 -178.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.4 pp -56.94 -18.12 12.23 Favored 'General case' 0 N--CA 1.482 1.167 0 N-CA-C 116.294 1.961 . . . . 0.0 116.294 -174.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.25 -21.21 33.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.589 0.709 . . . . 0.0 109.923 178.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -100.36 -41.19 7.14 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.311 -178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -117.47 101.78 52.41 Favored Pre-proline 0 N--CA 1.441 -0.879 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 174.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -96.55 128.95 0.33 Allowed 'Trans proline' 0 N--CA 1.432 -2.133 0 C-N-CA 121.826 1.684 . . . . 0.0 112.141 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.512 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 47.0 mt -86.12 90.43 3.08 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 173.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.5 p -122.14 12.13 10.28 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.846 -175.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.3 m -126.53 158.89 36.46 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.508 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 8.3 p-10 -100.51 -179.92 4.25 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 121.059 0.457 . . . . 0.0 111.671 -175.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.98 -148.56 20.08 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.9 mp -87.49 130.56 37.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 176.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.401 ' HA ' HD12 ' A' ' 59' ' ' LEU . 58.1 tp -86.14 -49.35 7.82 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.149 0.499 . . . . 0.0 110.112 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -155.51 163.33 40.15 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.554 -178.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -116.69 126.96 53.94 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 177.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 71.3 mt -88.77 110.45 21.02 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -100.4 105.66 17.17 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.559 0.695 . . . . 0.0 110.581 -174.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -118.86 146.57 44.78 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.527 -177.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.68 125.46 54.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 168.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.2 mt -76.5 131.29 35.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 174.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 109' ' ' ALA . 48.8 t-20 -56.42 144.25 31.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 123.412 0.685 . . . . 0.0 109.793 -174.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.3 m -67.23 -24.3 65.81 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.442 0.639 . . . . 0.0 109.81 176.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -104.5 24.75 11.16 Favored 'General case' 0 CA--C 1.554 1.103 0 CA-C-O 122.295 1.045 . . . . 0.0 109.034 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.664 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.75 154.96 20.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.094 178.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 m -94.21 141.73 28.22 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.43 149.41 27.65 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-N 115.828 -0.623 . . . . 0.0 109.423 178.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.98 163.19 11.51 Favored Glycine 0 N--CA 1.419 -2.464 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -75.03 115.41 14.61 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 m -125.58 119.4 28.01 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.004 0.43 . . . . 0.0 111.778 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.19 149.79 20.97 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.039 0.447 . . . . 0.0 110.588 177.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.422 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 42.4 mt -102.37 156.01 17.87 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 173.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.1 m -125.08 107.29 10.64 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 118.27 0.486 . . . . 0.0 109.951 -178.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 138' ' ' SER . 43.6 t -91.92 128.79 43.37 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.477 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 13.6 t70 -76.0 110.33 10.69 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.654 0.596 . . . . 0.0 110.291 -176.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 4.1 Cg_exo -77.93 -10.73 16.72 Favored 'Trans proline' 0 C--N 1.357 1.007 0 C-N-CA 123.246 2.63 . . . . 0.0 113.61 -176.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -83.59 -38.41 21.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.975 0.417 . . . . 0.0 110.712 -175.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.9 p -97.26 7.59 46.27 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-O 121.913 0.863 . . . . 0.0 110.236 176.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 5.3 tt -90.0 127.95 36.16 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 104.927 -2.249 . . . . 0.0 104.927 175.054 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 58.5 mt -132.38 122.58 48.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.793 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.535 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 76.6 t -121.15 96.39 4.17 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 174.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.49 138.94 50.99 Favored 'General case' 0 N--CA 1.422 -1.863 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.371 -174.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.539 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 3.0 p-10 -82.49 -169.53 2.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 179.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . 0.253 0.0 OUTLIER -73.74 -10.08 59.31 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -179.247 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.0 t30 -93.48 3.04 56.19 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 174.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 26.6 t70 73.19 10.39 5.18 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 126.524 1.929 . . . . 0.0 112.49 176.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.9 mmmt -84.1 126.14 32.8 Favored 'General case' 0 C--N 1.317 -0.824 0 O-C-N 120.941 -1.1 . . . . 0.0 109.992 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.535 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 11.6 t70 -76.82 127.58 33.0 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.508 HG21 ' HB3' ' A' ' 3' ' ' ASN . 2.6 pt -128.41 26.95 2.03 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.634 -174.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.508 ' O ' ' HD2' ' A' ' 134' ' ' LYS . 1.7 pptp? -104.83 131.4 52.35 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 115.196 1.554 . . . . 0.0 115.196 -174.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.6 m-20 -97.25 104.12 16.11 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 161.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -115.79 120.14 38.32 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 118.925 -1.11 . . . . 0.0 111.858 -175.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.99 112.11 18.33 Favored 'General case' 0 N--CA 1.416 -2.17 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 171.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.46 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 60.0 m -139.35 104.33 4.95 Favored 'General case' 0 N--CA 1.407 -2.578 0 C-N-CA 118.54 -1.264 . . . . 0.0 112.955 -173.442 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.422 ' HA ' ' O ' ' A' ' 116' ' ' LEU . 18.3 m120 -139.85 82.67 1.88 Allowed 'General case' 0 N--CA 1.392 -3.372 0 CA-C-N 113.123 -1.853 . . . . 0.0 106.077 172.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -66.83 131.78 31.34 Favored Glycine 0 CA--C 1.48 -2.125 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 178.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 4.7 tmmm? -121.38 129.7 53.19 Favored 'General case' 0 C--N 1.283 -2.323 0 C-N-CA 117.759 -1.576 . . . . 0.0 111.324 -172.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 59.3 mt -113.78 113.81 44.96 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.717 0 CA-C-N 114.45 -1.25 . . . . 0.0 108.504 -177.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.0 m -86.26 105.67 16.8 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 175.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 25.5 t -84.84 104.66 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.4 p -81.55 -58.54 2.97 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.255 0.55 . . . . 0.0 111.372 -175.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 95.33 65.86 0.98 Allowed Glycine 0 N--CA 1.417 -2.587 0 C-N-CA 120.348 -0.929 . . . . 0.0 111.366 178.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 16.4 m -70.32 -22.41 62.82 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.199 0.523 . . . . 0.0 109.725 177.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.55 124.83 90.75 Favored Pre-proline 0 N--CA 1.436 -1.147 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 172.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.28 -28.83 72.59 Favored 'Trans proline' 0 C--N 1.347 0.463 0 C-N-CA 122.304 2.003 . . . . 0.0 113.531 -175.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.1 m -146.31 140.08 26.18 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 177.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 69.7 m . . . . . 0 C--N 1.295 -1.794 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.135 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.496 -1.118 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.7 t -158.98 105.8 1.78 Allowed 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 176.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -76.83 146.18 37.94 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 175.027 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 20.2 m -75.95 54.44 0.83 Allowed 'General case' 0 CA--C 1.554 1.119 0 CA-C-O 122.208 1.004 . . . . 0.0 113.322 -175.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 55.1 t -105.09 -42.78 7.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 170.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.0 mtmp? -93.86 174.43 7.17 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 171.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.7 m120 59.17 73.87 0.46 Allowed 'General case' 0 CA--C 1.501 -0.936 0 O-C-N 124.264 0.977 . . . . 0.0 110.352 176.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.11 168.12 9.43 Favored 'General case' 0 C--N 1.284 -2.279 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.76 -174.093 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 135' ' ' ASP . 0.2 OUTLIER -79.77 105.27 10.93 Favored 'General case' 0 N--CA 1.408 -2.554 0 CA-C-O 121.905 0.86 . . . . 0.0 110.091 -176.47 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.407 HG13 ' HB ' ' A' ' 30' ' ' VAL . 93.7 t -83.32 117.77 29.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 114.548 -1.205 . . . . 0.0 109.632 -177.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 67.0 mttm -81.42 116.27 21.15 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.91 0.386 . . . . 0.0 111.418 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 45.9 tp -93.33 115.79 28.35 Favored 'General case' 0 N--CA 1.427 -1.577 0 N-CA-C 106.168 -1.789 . . . . 0.0 106.168 172.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.6 t -119.2 164.0 16.25 Favored 'General case' 0 N--CA 1.426 -1.663 0 CA-C-O 121.654 0.74 . . . . 0.0 111.267 -172.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.536 HG21 ' H ' ' A' ' 139' ' ' ASN . 19.2 m -135.7 162.71 36.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 C-N-CA 125.573 1.549 . . . . 0.0 108.489 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.5 173.9 21.52 Favored Glycine 0 N--CA 1.441 -0.988 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.718 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 21.7 m -110.47 128.72 55.74 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.3 m -124.92 164.51 23.58 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.8 m -128.52 148.95 50.78 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.67 -179.08 29.63 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 49.1 m-80 -126.86 156.7 73.49 Favored Pre-proline 0 C--N 1.305 -1.33 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -177.048 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.63 121.53 9.32 Favored 'Trans proline' 0 C--N 1.359 1.088 0 C-N-CA 122.362 2.041 . . . . 0.0 111.064 176.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 101.6 -18.53 53.0 Favored Glycine 0 C--O 1.243 0.702 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -177.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 19.3 t70 -90.44 146.11 24.4 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 123.834 0.854 . . . . 0.0 110.114 -179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.6 m -90.95 127.34 36.36 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -178.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -111.72 151.38 13.79 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 37.1 ttpt -128.37 126.66 41.13 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.287 -178.317 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 41.7 t -111.39 121.55 39.95 Favored Pre-proline 0 C--N 1.312 -1.061 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.34 126.75 1.97 Allowed 'Trans proline' 0 N--CA 1.444 -1.411 0 C-N-CA 122.281 1.987 . . . . 0.0 113.585 179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.8 t -90.57 116.37 31.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 175.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.1 m -102.77 139.69 38.02 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.656 0.265 . . . . 0.0 110.765 -172.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.9 tt -123.0 127.61 74.8 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.1 m -142.33 165.71 26.69 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 122.091 -0.381 . . . . 0.0 111.79 -177.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 68.4 15.23 9.23 Favored 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 126.121 1.768 . . . . 0.0 112.469 179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.9 p -89.56 121.39 39.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-O 120.835 0.35 . . . . 0.0 110.283 -178.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 m -124.99 -25.46 3.87 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-O 121.436 0.636 . . . . 0.0 110.426 175.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.4 m -95.02 133.37 26.4 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 177.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 28.5 Cg_endo -62.31 124.24 13.94 Favored 'Trans proline' 0 C--N 1.357 1.013 0 C-N-CA 122.492 2.128 . . . . 0.0 115.524 -174.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.7 p -87.54 137.13 21.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 CA-C-N 114.641 -1.163 . . . . 0.0 108.952 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -124.47 -16.45 3.11 Favored Glycine 0 N--CA 1.439 -1.165 0 C-N-CA 120.047 -1.073 . . . . 0.0 113.506 -177.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -135.96 116.0 13.3 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 120.999 0.428 . . . . 0.0 110.082 -176.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.433 HG21 HD21 ' A' ' 98' ' ' LEU . 72.4 mt -126.05 119.92 55.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 179.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.521 ' HB2' ' HB ' ' A' ' 124' ' ' ILE . 67.7 m -127.24 130.51 49.76 Favored 'General case' 0 C--N 1.289 -2.059 0 C-N-CA 125.069 1.348 . . . . 0.0 109.27 -178.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.1 ptp -157.86 154.34 27.81 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 122.307 0.243 . . . . 0.0 110.756 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -127.9 119.06 24.78 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -100.61 113.78 37.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -176.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 16.4 m -97.05 144.66 26.71 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -151.72 167.42 28.27 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 -176.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -80.13 114.55 19.12 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.69 69.92 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 114.359 1.244 . . . . 0.0 114.359 -173.101 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.5 t -93.98 -23.03 18.2 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-O 121.038 0.447 . . . . 0.0 110.62 -177.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.4 tttt -88.44 -38.92 14.65 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.541 -175.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -124.88 135.56 52.99 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.901 -178.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 19.9 m -119.92 110.37 16.64 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 178.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.403 ' HB ' ' CE1' ' A' ' 103' ' ' PHE . 7.6 p -78.46 132.93 31.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 120.882 0.372 . . . . 0.0 110.11 -179.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.3 mtmp? -97.62 -56.88 2.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.557 0.694 . . . . 0.0 109.767 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.513 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 7.6 p-10 -153.27 168.36 26.27 Favored 'General case' 0 N--CA 1.426 -1.631 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.892 -172.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.2 m -128.64 140.83 48.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 175.412 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 96.0 mt -108.36 112.68 60.94 Favored Pre-proline 0 C--N 1.288 -2.101 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -79.73 145.72 18.3 Favored 'Trans proline' 0 N--CA 1.442 -1.552 0 C-N-CA 121.883 1.722 . . . . 0.0 110.568 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 48.3 t30 -80.04 103.11 9.7 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 11.6 t -73.27 -8.85 57.61 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 121.643 0.735 . . . . 0.0 111.364 -175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.72 -40.57 88.42 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 170.042 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 71.9 mt -92.86 -61.19 1.63 Allowed 'General case' 0 N--CA 1.437 -1.104 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.833 179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 21.3 t -79.46 117.53 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -176.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.1 tppt? -107.22 154.03 21.82 Favored 'General case' 0 N--CA 1.418 -2.063 0 CA-C-O 121.212 0.53 . . . . 0.0 111.95 -175.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.3 t70 40.29 70.58 0.23 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 127.362 2.265 . . . . 0.0 112.544 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.7 p -68.25 -15.66 63.66 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -171.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -69.24 -31.78 70.57 Favored 'General case' 0 CA--C 1.518 -0.286 0 O-C-N 123.041 0.213 . . . . 0.0 111.29 -179.436 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 19.9 m-80 -83.89 29.67 0.54 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -179.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 48.2 t80 75.52 32.45 0.71 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.308 1.043 . . . . 0.0 111.722 171.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.504 ' HA ' ' O ' ' A' ' 83' ' ' THR . 3.8 m -80.63 -26.41 37.73 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 122.226 1.012 . . . . 0.0 108.759 172.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -101.1 106.52 17.79 Favored 'General case' 0 N--CA 1.437 -1.118 0 CA-C-N 114.132 -1.395 . . . . 0.0 108.684 -178.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.0 mp -118.75 107.68 22.24 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.1 t -131.41 112.36 21.04 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -106.74 107.19 18.09 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.7 m -76.68 95.03 3.89 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 176.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.4 m -70.82 175.85 4.71 Favored 'General case' 0 N--CA 1.421 -1.895 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.021 -177.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -47.48 129.65 10.42 Favored Pre-proline 0 C--O 1.25 1.131 0 C-N-CA 124.153 0.981 . . . . 0.0 108.959 177.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -35.2 128.88 0.26 Allowed 'Trans proline' 0 C--N 1.384 2.429 1 C-N-CA 125.322 4.015 . . . . 0.0 115.046 -170.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.5 -7.32 36.66 Favored Glycine 0 N--CA 1.437 -1.289 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.916 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -142.36 132.64 24.85 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 117.481 0.64 . . . . 0.0 112.197 176.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 20.0 mt -120.4 114.66 44.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.949 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 175.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 12.1 m -96.25 111.7 23.68 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 57.0 mt -115.72 138.28 46.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 110.971 -174.592 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 98.5 m -141.12 129.75 22.77 Favored 'General case' 0 N--CA 1.42 -1.968 0 C-N-CA 123.396 0.678 . . . . 0.0 109.516 175.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -120.6 116.44 25.34 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 175.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.504 ' O ' ' HA ' ' A' ' 67' ' ' SER . 9.1 t -137.42 119.67 15.69 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 175.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -94.67 121.53 62.84 Favored Pre-proline 0 C--N 1.296 -1.736 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.627 -172.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -82.21 -3.2 11.48 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.174 2.583 . . . . 0.0 111.895 178.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.66 14.54 28.24 Favored 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 -177.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.0 pp -56.07 -23.14 31.79 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.11 -32.84 59.38 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.997 0.427 . . . . 0.0 110.91 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -94.76 -28.75 15.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.273 -179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 73.0 m-85 -131.34 103.58 15.1 Favored Pre-proline 0 C--N 1.314 -0.966 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 177.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -88.16 117.58 1.06 Allowed 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.79 1.66 . . . . 0.0 112.242 179.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 39.4 mt -79.1 90.36 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 177.779 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 30.1 p -131.12 18.79 4.95 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-O 121.483 0.658 . . . . 0.0 110.794 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 m -118.19 151.07 20.26 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.672 179.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 5.5 p-10 -90.3 176.64 6.66 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 121.254 0.55 . . . . 0.0 111.717 -174.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 142.09 -144.19 13.88 Favored Glycine 0 N--CA 1.423 -2.193 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.439 HG21 ' CE1' ' A' ' 100' ' ' TYR . 47.1 mm -98.27 142.53 14.43 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.883 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 177.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.433 HD21 HG21 ' A' ' 37' ' ' ILE . 63.5 tp -92.83 -48.96 6.3 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-O 120.985 0.421 . . . . 0.0 110.361 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.9 154.5 33.98 Favored 'General case' 0 N--CA 1.44 -0.94 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.015 -179.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.439 ' CE1' HG21 ' A' ' 97' ' ' ILE . 57.9 m-85 -112.79 118.15 34.16 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.194 -1.409 . . . . 0.0 107.194 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 66.9 mt -90.21 129.37 36.48 Favored 'General case' 0 C--N 1.308 -1.218 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 10.0 t70 -110.33 113.59 26.38 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.423 0.452 . . . . 0.0 110.787 -176.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . 0.403 ' CE1' ' HB ' ' A' ' 50' ' ' VAL . 97.1 m-85 -126.43 139.19 53.44 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 71.0 mt -94.59 127.94 46.2 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.779 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 170.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.8 mt -80.54 122.09 35.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 45.2 t-20 -62.19 139.61 58.48 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.5 m -72.78 -18.04 61.53 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-O 121.306 0.574 . . . . 0.0 110.723 179.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -90.2 -0.35 57.57 Favored 'General case' 0 CA--C 1.548 0.89 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.755 178.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -84.15 153.85 23.46 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.981 -0.45 . . . . 0.0 110.586 -178.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -86.84 152.8 22.16 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.06 158.75 23.65 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.649 0.261 . . . . 0.0 110.362 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 135.3 169.65 11.92 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 111.399 -0.681 . . . . 0.0 111.399 -177.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -78.74 117.78 20.2 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-O 121.649 0.738 . . . . 0.0 110.034 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.0 m -121.66 126.93 50.17 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.74 152.79 19.29 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-O 121.592 0.71 . . . . 0.0 112.82 -175.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 71.2 mt -110.62 113.54 26.23 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 105.79 -1.93 . . . . 0.0 105.79 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.6 m -94.39 106.98 18.96 Favored 'General case' 0 C--N 1.279 -2.473 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.349 -173.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 36.5 t -85.08 123.57 39.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 175.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 19.8 t70 -70.19 113.57 18.89 Favored Pre-proline 0 C--N 1.308 -1.212 0 O-C-N 123.786 0.679 . . . . 0.0 110.972 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 16.9 Cg_exo -68.03 -26.57 37.02 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.776 2.318 . . . . 0.0 113.599 -176.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -72.2 -38.26 69.06 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.076 0.465 . . . . 0.0 110.772 -177.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 p -97.29 16.76 19.05 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.47 0.652 . . . . 0.0 111.493 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.439 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.5 tt -102.83 115.31 30.33 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 178.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.521 ' HB ' ' HB2' ' A' ' 38' ' ' CYS . 86.7 mt -133.73 126.05 50.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.407 0 N-CA-C 107.933 -1.136 . . . . 0.0 107.933 -176.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.4 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.1 t -134.25 104.49 5.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -116.01 144.25 44.36 Favored 'General case' 0 N--CA 1.421 -1.903 0 CA-C-N 114.916 -1.038 . . . . 0.0 112.912 -173.033 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.35 173.59 1.51 Allowed 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 113.486 -1.688 . . . . 0.0 110.124 173.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -63.74 -22.01 66.69 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.221 0.534 . . . . 0.0 111.84 178.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 9.8 t30 -82.51 2.47 32.75 Favored 'General case' 0 CA--C 1.551 1.013 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.762 176.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 35.0 t70 68.45 32.55 4.43 Favored 'General case' 0 N--CA 1.48 1.06 0 CA-C-O 123.243 1.497 . . . . 0.0 111.642 175.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt -110.5 122.54 47.98 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.274 -0.891 . . . . 0.0 110.685 174.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.35 122.32 17.67 Favored 'General case' 0 C--N 1.32 -0.694 0 O-C-N 124.326 1.016 . . . . 0.0 110.117 -179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.51 ' O ' ' HA ' ' A' ' 5' ' ' THR . 12.1 pt -135.14 28.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 CA-C-N 115.874 -0.603 . . . . 0.0 112.056 -174.469 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.4 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -105.64 137.4 43.55 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 117.319 -1.753 . . . . 0.0 113.967 -174.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.522 ' HB2' HG22 ' A' ' 5' ' ' THR . 32.3 t70 -94.95 104.17 16.04 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 171.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -122.86 129.61 51.86 Favored 'General case' 0 C--N 1.291 -1.955 0 C-N-CA 119.303 -0.959 . . . . 0.0 113.48 -171.39 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -124.91 112.98 17.25 Favored 'General case' 0 C--N 1.285 -2.222 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 168.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 41.4 m -132.7 105.89 7.45 Favored 'General case' 0 N--CA 1.418 -2.048 0 C-N-CA 118.644 -1.222 . . . . 0.0 112.415 -173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.536 ' H ' HG21 ' A' ' 10' ' ' VAL . 26.0 t-20 -167.46 93.45 0.42 Allowed 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 106.232 -1.766 . . . . 0.0 106.232 177.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -85.72 166.24 39.27 Favored Glycine 0 CA--C 1.49 -1.523 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 35.3 ttpt -142.39 136.13 29.25 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 118.634 -1.226 . . . . 0.0 111.921 -178.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 80.2 mt -109.97 119.99 60.13 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 CA-C-N 114.584 -1.189 . . . . 0.0 107.792 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 31.2 m -95.22 105.96 17.94 Favored 'General case' 0 C--N 1.284 -2.267 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.3 t -81.03 108.27 14.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 177.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 13.9 p -77.74 -50.53 12.21 Favored 'General case' 0 C--N 1.299 -1.612 0 O-C-N 123.146 0.279 . . . . 0.0 111.751 -175.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.51 123.29 3.35 Favored Glycine 0 N--CA 1.424 -2.115 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.4 m -70.43 -43.67 69.46 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 122.926 0.49 . . . . 0.0 111.184 -175.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -144.38 130.97 10.09 Favored Pre-proline 0 N--CA 1.428 -1.525 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.21 93.37 0.19 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.757 2.305 . . . . 0.0 111.336 176.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 88.7 m -150.49 102.73 3.07 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 30.4 t . . . . . 0 N--CA 1.424 -1.745 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 -179.348 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.2 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 37.9 m 67.68 -69.68 0.13 Allowed 'General case' 0 N--CA 1.476 0.858 0 C-N-CA 125.161 1.384 . . . . 0.0 111.14 -178.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -97.13 -175.89 3.37 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 172.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 53.2 p 53.97 34.04 18.77 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 124.025 0.93 . . . . 0.0 112.197 -179.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.1 p -80.71 -31.56 12.53 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.076 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -99.73 147.52 25.36 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 174.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.607 ' HB3' HG21 ' A' ' 133' ' ' ILE . 16.0 m120 68.7 93.51 0.08 Allowed 'General case' 0 C--O 1.24 0.605 0 O-C-N 124.476 1.11 . . . . 0.0 110.71 -179.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.413 ' OE2' ' HB3' ' A' ' 31' ' ' SER . 0.4 OUTLIER -94.35 169.24 10.37 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.389 -173.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.4 m -72.1 106.51 4.36 Favored 'General case' 0 N--CA 1.432 -1.333 0 C-N-CA 124.467 1.107 . . . . 0.0 112.092 -175.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.8 t -88.39 113.49 25.38 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -88.54 123.94 33.54 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.805 -177.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -105.87 113.7 27.41 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 173.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.2 m -119.82 147.05 45.13 Favored 'General case' 0 N--CA 1.409 -2.484 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.977 -177.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 20.2 m -137.68 162.01 32.72 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.63 -163.66 10.08 Favored Glycine 0 N--CA 1.429 -1.827 0 C-N-CA 118.764 -1.684 . . . . 0.0 113.453 -176.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -114.78 120.92 41.67 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-O 121.476 0.655 . . . . 0.0 110.209 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.3 m -118.08 164.35 14.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.136 -0.938 . . . . 0.0 108.752 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.7 m -117.59 156.76 27.57 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -154.43 167.23 32.43 Favored Glycine 0 N--CA 1.426 -1.994 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.804 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.413 ' O ' ' HB3' ' A' ' 19' ' ' ASP . 24.9 m-80 -120.95 161.35 40.77 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -65.12 124.81 13.55 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 121.925 1.75 . . . . 0.0 110.445 174.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.0 -9.68 77.14 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.413 ' HB3' ' O ' ' A' ' 16' ' ' ASN . 16.5 t70 -90.44 141.73 28.44 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 124.013 0.925 . . . . 0.0 109.973 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.7 m -95.25 127.64 41.45 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.42 143.93 24.15 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 36.2 ttpt -120.38 118.89 31.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.689 -178.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.2 t -100.9 113.05 65.72 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -87.06 126.69 2.44 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 121.818 1.678 . . . . 0.0 112.967 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.33 120.11 38.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 N-CA-C 106.595 -1.631 . . . . 0.0 106.595 176.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 15.7 m -102.58 123.74 46.86 Favored 'General case' 0 C--N 1.293 -1.879 0 CA-C-O 121.103 0.477 . . . . 0.0 110.135 -175.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.558 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 11.2 tt -105.95 136.38 40.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 178.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 19.3 m -144.18 162.92 35.09 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 122.372 -0.205 . . . . 0.0 110.692 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 67.94 15.89 9.55 Favored 'General case' 0 N--CA 1.481 1.075 0 N-CA-C 115.361 1.615 . . . . 0.0 115.361 172.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.532 HG12 ' HB3' ' A' ' 95' ' ' ASP . 11.9 p -87.11 140.3 16.0 Favored 'Isoleucine or valine' 0 C--O 1.251 1.155 0 O-C-N 122.249 -0.282 . . . . 0.0 110.379 178.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.413 ' HB3' ' OE2' ' A' ' 4' ' ' GLU . 33.5 t -136.16 -43.32 0.64 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 22.0 m -75.54 125.97 88.01 Favored Pre-proline 0 CA--C 1.542 0.643 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 173.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 17.1 Cg_endo -58.05 124.47 16.02 Favored 'Trans proline' 0 C--N 1.356 0.968 0 C-N-CA 122.225 1.95 . . . . 0.0 113.909 -175.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 8.4 p -88.45 129.01 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.576 178.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.93 -2.31 11.3 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.39 -0.909 . . . . 0.0 112.539 -177.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 73.3 mt -137.56 112.06 8.71 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-O 120.85 0.357 . . . . 0.0 110.379 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.468 ' O ' ' HA ' ' A' ' 81' ' ' THR . 4.3 mp -128.59 118.42 47.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.8 t -127.56 130.35 48.93 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 178.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.9 ptm -157.29 133.4 9.58 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 179.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.9 t70 -112.46 133.86 54.31 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -106.11 110.2 30.57 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.011 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 22.4 m -96.6 116.99 30.02 Favored 'General case' 0 N--CA 1.423 -1.8 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.9 p90 -135.82 177.39 7.86 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.27 -173.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -88.5 110.01 20.51 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 176.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.21 -16.65 60.97 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -175.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.8 m -86.54 -25.72 24.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.617 0.723 . . . . 0.0 110.116 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 40.0 ttmt -91.74 -39.56 11.74 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.344 -178.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -120.92 139.34 53.36 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.11 0.481 . . . . 0.0 110.345 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 39.4 m -120.25 111.63 18.05 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 175.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.12 129.15 37.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 CA-C-O 121.43 0.633 . . . . 0.0 110.621 -178.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.9 mtpm? -83.97 -61.79 1.73 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -165.62 176.51 8.03 Favored 'General case' 0 N--CA 1.42 -1.954 0 CA-C-N 113.862 -1.517 . . . . 0.0 107.263 -175.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.6 m -126.47 143.89 38.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.045 0 N-CA-C 107.637 -1.245 . . . . 0.0 107.637 175.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 70.1 mt -104.28 119.3 54.47 Favored Pre-proline 0 C--N 1.282 -2.33 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -80.31 139.58 13.21 Favored 'Trans proline' 0 N--CA 1.438 -1.749 0 C-N-CA 121.317 1.345 . . . . 0.0 109.756 175.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -78.45 109.32 12.51 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 176.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.592 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 21.8 p -71.07 -4.16 23.64 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 124.237 1.015 . . . . 0.0 113.156 -174.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -76.41 -23.95 54.03 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 45.8 mt -112.45 -63.49 1.43 Allowed 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.423 178.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 57' ' ' THR . 3.6 t -95.5 102.61 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.791 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 -179.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttm -114.04 156.87 23.34 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -173.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 56.32 44.38 24.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 122.417 1.103 . . . . 0.0 111.151 179.749 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.44 ' HB ' ' HB2' ' A' ' 68' ' ' PHE . 6.7 p -61.14 -22.79 65.02 Favored 'General case' 0 N--CA 1.441 -0.922 0 CA-C-N 112.846 -1.979 . . . . 0.0 113.815 -173.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -69.11 -11.94 61.24 Favored 'General case' 0 C--N 1.314 -0.952 0 C-N-CA 124.267 1.027 . . . . 0.0 111.656 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -92.07 23.2 3.88 Favored 'General case' 0 C--O 1.244 0.801 0 CA-C-O 120.839 0.352 . . . . 0.0 111.236 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 52.7 t80 75.19 24.98 1.37 Allowed 'General case' 0 C--O 1.206 -1.236 0 C-N-CA 125.011 1.325 . . . . 0.0 110.304 176.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' THR . 2.1 m -77.55 -24.65 49.84 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 107.248 -1.389 . . . . 0.0 107.248 172.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.44 ' HB2' ' HB ' ' A' ' 63' ' ' THR . 76.7 t80 -102.78 106.45 17.06 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 113.282 -1.781 . . . . 0.0 107.983 179.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.05 107.79 23.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.9 t -122.47 110.29 26.48 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.409 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 26.0 t30 -97.8 109.95 22.61 Favored 'General case' 0 C--N 1.283 -2.288 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 178.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 4.1 m -81.04 104.79 11.78 Favored 'General case' 0 N--CA 1.41 -2.46 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 178.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.6 t -84.57 175.04 9.52 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.033 -177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 5.8 m -48.06 139.54 9.69 Favored Pre-proline 0 CA--C 1.556 1.21 0 C-N-CA 125.291 1.436 . . . . 0.0 108.853 177.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -34.16 118.09 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.09 1 C-N-CA 125.315 4.01 . . . . 0.0 115.147 -174.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.566 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.27 -1.33 33.01 Favored Glycine 0 N--CA 1.427 -1.927 0 CA-C-N 114.753 -1.112 . . . . 0.0 114.586 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 28.3 mtpp -138.2 132.1 31.33 Favored 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 118.612 1.206 . . . . 0.0 110.795 172.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 28.2 mt -120.8 110.09 27.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 175.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.409 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 9.2 m -91.62 110.32 21.64 Favored 'General case' 0 C--N 1.291 -1.972 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 -177.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 61.1 mt -111.54 138.74 38.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 O-C-N 121.932 -0.48 . . . . 0.0 110.887 -175.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.468 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 47.8 m -141.09 125.82 17.97 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 175.688 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -111.7 113.07 25.2 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 174.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 67' ' ' SER . 8.9 t -146.33 120.34 9.4 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 175.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -98.38 128.5 32.98 Favored Pre-proline 0 C--N 1.293 -1.869 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.527 -172.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.87 -22.97 41.83 Favored 'Trans proline' 0 C--N 1.36 1.147 0 C-N-CA 122.962 2.441 . . . . 0.0 112.562 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -103.66 32.02 4.1 Favored 'General case' 0 N--CA 1.425 -1.688 0 C-N-CA 123.655 0.782 . . . . 0.0 111.267 -178.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -57.15 -15.73 6.28 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 -176.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -81.33 -21.88 38.87 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.917 0.389 . . . . 0.0 110.225 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -104.1 -41.08 5.93 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 123.598 0.759 . . . . 0.0 110.889 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -112.0 101.0 50.77 Favored Pre-proline 0 N--CA 1.445 -0.689 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 175.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -103.44 126.55 0.08 OUTLIER 'Trans proline' 0 N--CA 1.436 -1.878 0 C-N-CA 122.207 1.938 . . . . 0.0 113.121 178.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 51.1 mt -85.6 89.48 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 174.299 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 10.3 p -121.84 8.39 9.95 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 122.102 0.953 . . . . 0.0 109.849 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.9 m -122.21 155.78 27.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 114.565 -1.198 . . . . 0.0 107.967 177.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.558 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 2.0 p30 -113.06 -176.29 2.86 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -176.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 141.33 -130.21 4.34 Favored Glycine 0 N--CA 1.442 -0.923 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -177.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.41 HG21 ' CE1' ' A' ' 100' ' ' TYR . 49.9 mm -92.61 136.42 24.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.636 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 175.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.412 HD21 HG21 ' A' ' 37' ' ' ILE . 59.4 tp -88.2 -54.53 4.16 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.382 0.61 . . . . 0.0 109.602 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.38 158.78 42.0 Favored 'General case' 0 N--CA 1.433 -1.276 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.357 -178.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 53.4 m-85 -115.45 126.14 53.97 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 177.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 32.3 mt -92.49 120.47 32.99 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -108.17 104.92 14.44 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 121.471 0.653 . . . . 0.0 110.586 -174.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -119.0 136.91 53.87 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.103 -176.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 80.4 mt -90.37 125.71 43.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.2 mt -82.76 126.8 40.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 174.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 108' ' ' ASN . 57.1 t30 -63.72 149.99 45.47 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.419 0.449 . . . . 0.0 109.864 -177.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.4 p -71.49 -27.53 63.29 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-O 122.046 0.927 . . . . 0.0 109.857 178.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.447 ' HB3' ' ND2' ' A' ' 106' ' ' ASN . 10.4 t30 -89.03 7.81 32.92 Favored 'General case' 0 CA--C 1.557 1.243 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.983 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -71.32 140.18 50.17 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.92 -179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.7 m -78.01 139.65 39.14 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -82.87 132.8 35.15 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.828 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.24 172.72 23.96 Favored Glycine 0 C--N 1.287 -2.173 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -177.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -78.46 119.39 21.7 Favored 'General case' 0 N--CA 1.425 -1.682 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.6 m -119.08 117.94 30.07 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.533 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.57 142.13 27.74 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.164 -177.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 20.8 mt -107.78 113.82 27.34 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 177.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.3 m -83.43 116.89 22.71 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.2 t -87.4 116.23 29.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.746 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 40' ' ' ASP . 9.9 t70 -54.79 106.78 0.71 Allowed Pre-proline 0 C--N 1.32 -0.688 0 C-N-CA 126.413 1.885 . . . . 0.0 110.416 -175.196 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.12 -13.18 19.24 Favored 'Trans proline' 0 C--N 1.351 0.672 0 C-N-CA 122.852 2.368 . . . . 0.0 113.227 -176.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -79.11 -38.5 36.02 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 11.1 m -90.49 -6.71 54.49 Favored 'General case' 0 N--CA 1.422 -1.843 0 CA-C-N 115.162 -0.926 . . . . 0.0 110.229 179.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.444 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -82.06 108.63 15.69 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -179.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 63.0 mt -136.33 124.53 35.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.569 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 89.1 t -130.64 103.79 8.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -122.69 145.71 48.14 Favored 'General case' 0 N--CA 1.419 -2.02 0 CA-C-N 114.983 -1.008 . . . . 0.0 112.474 -171.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.524 ' OD2' ' HB3' ' A' ' 129' ' ' ASN . 0.0 OUTLIER -70.32 173.75 6.45 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 114.106 -1.406 . . . . 0.0 109.865 176.114 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.35 -9.46 53.5 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 119.055 0.843 . . . . 0.0 112.74 -176.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . 0.524 ' HB3' ' OD2' ' A' ' 127' ' ' ASP . 41.4 t30 -98.46 16.88 20.35 Favored 'General case' 0 CA--C 1.572 1.794 0 C-N-CA 124.812 1.245 . . . . 0.0 108.461 175.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . 0.273 2.1 p30 58.67 19.23 6.58 Favored 'General case' 0 N--CA 1.506 2.359 0 C-N-CA 127.974 2.51 . . . . 0.0 114.685 178.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 33.8 mmtp -88.26 115.04 25.47 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 122.005 -0.434 . . . . 0.0 110.009 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -70.78 129.95 40.45 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.607 HG21 ' HB3' ' A' ' 3' ' ' ASN . 3.6 pt -140.2 38.57 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.31 -174.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.7 pptp? -104.66 131.42 52.11 Favored 'General case' 0 N--CA 1.433 -1.319 0 N-CA-C 116.12 1.896 . . . . 0.0 116.12 -173.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -95.96 103.4 15.28 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 104.925 -2.25 . . . . 0.0 104.925 165.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.63 120.6 29.91 Favored 'General case' 0 C--N 1.281 -2.408 0 C-N-CA 118.83 -1.148 . . . . 0.0 113.175 -173.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.86 113.18 20.66 Favored 'General case' 0 N--CA 1.417 -2.109 0 N-CA-C 103.008 -2.96 . . . . 0.0 103.008 169.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.5 m -137.74 106.5 5.91 Favored 'General case' 0 N--CA 1.414 -2.23 0 CA-C-O 122.53 1.157 . . . . 0.0 113.101 -172.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -155.11 100.68 2.19 Favored 'General case' 0 N--CA 1.416 -2.153 0 N-CA-C 105.59 -2.004 . . . . 0.0 105.59 174.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -82.03 129.62 9.17 Favored Glycine 0 CA--C 1.481 -2.045 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -118.88 129.07 55.0 Favored 'General case' 0 C--N 1.278 -2.524 0 C-N-CA 118.156 -1.418 . . . . 0.0 110.613 -176.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.9 mt -115.65 116.05 51.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 21.7 m -88.75 105.8 17.94 Favored 'General case' 0 N--CA 1.414 -2.272 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 44.8 t -81.8 116.42 26.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 176.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.7 p -77.47 -50.4 12.74 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 121.175 0.512 . . . . 0.0 111.698 -175.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 88.52 13.82 62.62 Favored Glycine 0 N--CA 1.429 -1.805 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -177.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 7.3 p -81.16 -6.82 59.27 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -177.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -101.57 110.85 62.9 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.09 100.75 1.33 Allowed 'Trans proline' 0 N--CA 1.451 -0.997 0 C-N-CA 122.328 2.019 . . . . 0.0 113.332 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 8.9 t -171.15 138.67 1.27 Allowed 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 176.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 46.0 m . . . . . 0 C--N 1.301 -1.504 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.31 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.079 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 55.8 m -133.78 138.18 45.57 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.433 0.616 . . . . 0.0 112.005 -177.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -131.43 115.16 15.83 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 174.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 12.6 p -90.24 -87.67 0.18 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 113.801 1.038 . . . . 0.0 113.801 -172.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p -87.22 -27.56 5.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.34 0.59 . . . . 0.0 110.772 -176.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.16 124.35 48.94 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.418 ' HB3' HG21 ' A' ' 133' ' ' ILE . 17.4 m120 70.61 169.31 0.31 Allowed 'General case' 0 N--CA 1.47 0.567 0 O-C-N 124.612 1.195 . . . . 0.0 112.537 178.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.472 ' O ' ' HB ' ' A' ' 133' ' ' ILE . 69.3 mm-40 -108.08 -174.93 2.64 Favored 'General case' 0 N--CA 1.427 -1.594 0 CA-C-O 121.157 0.503 . . . . 0.0 110.156 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 40.0 m -122.14 104.75 9.7 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 173.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.35 116.8 30.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.458 -172.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 135' ' ' ASP . 30.2 mtpp -88.38 132.48 34.42 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 122.979 0.174 . . . . 0.0 110.667 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.76 113.92 27.51 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 173.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 23.6 t -121.79 144.04 49.05 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.565 -174.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 24.3 m -136.37 163.19 34.31 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.97 -178.83 15.87 Favored Glycine 0 N--CA 1.436 -1.326 0 C-N-CA 118.616 -1.754 . . . . 0.0 113.89 -174.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 49.3 m -110.73 125.7 53.78 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 123.377 0.671 . . . . 0.0 109.65 -175.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.4 m -124.77 164.52 23.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.492 -178.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 36.8 m -120.86 159.21 25.97 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-O 120.584 0.23 . . . . 0.0 110.988 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -156.82 -176.88 29.4 Favored Glycine 0 N--CA 1.421 -2.313 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.128 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -125.47 153.85 72.48 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -176.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -67.04 111.8 2.32 Favored 'Trans proline' 0 C--N 1.352 0.712 0 C-N-CA 121.7 1.6 . . . . 0.0 110.749 177.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.57 -10.72 35.66 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 111.867 -0.493 . . . . 0.0 111.867 -177.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -89.71 153.98 20.29 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 124.061 0.944 . . . . 0.0 111.104 -178.24 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.3 m -101.67 125.83 48.4 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.5 p -115.38 149.77 17.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -175.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 38.0 ttpt -126.47 125.34 41.95 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 120.7 0.286 . . . . 0.0 110.547 -178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.5 t -106.92 120.13 49.09 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.773 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -84.17 124.22 3.26 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.229 1.953 . . . . 0.0 113.471 178.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.0 t -91.12 116.39 32.24 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.289 -1.374 . . . . 0.0 107.289 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.2 m -100.83 136.53 40.54 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 121.19 0.519 . . . . 0.0 111.093 -175.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.1 tt -115.59 130.81 69.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.9 m -140.09 163.63 32.19 Favored 'General case' 0 C--N 1.312 -1.036 0 O-C-N 121.959 -0.463 . . . . 0.0 111.621 -177.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 61.41 25.1 15.1 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 125.312 1.445 . . . . 0.0 112.739 178.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.4 p -95.13 135.6 28.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.408 ' HB3' ' HG3' ' A' ' 4' ' ' GLU . 35.9 t -141.86 -37.13 0.41 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 6.8 m -73.71 127.73 88.04 Favored Pre-proline 0 N--CA 1.438 -1.035 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 172.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -57.92 124.72 16.63 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.242 1.961 . . . . 0.0 111.49 179.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -87.45 139.62 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.749 0 CA-C-N 115.077 -0.965 . . . . 0.0 109.631 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.07 -24.73 2.67 Favored Glycine 0 N--CA 1.431 -1.64 0 C-N-CA 119.68 -1.248 . . . . 0.0 113.129 -178.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -128.36 112.57 14.57 Favored 'General case' 0 CA--C 1.498 -1.022 0 CA-C-O 120.731 0.301 . . . . 0.0 111.477 -177.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.472 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 36.1 mt -126.46 120.14 55.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 176.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 44.5 t -130.63 137.78 49.78 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 176.045 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.3 ptp -155.62 143.07 19.47 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -121.41 120.46 35.05 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -101.06 109.35 25.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 20.2 m -98.13 128.49 44.66 Favored 'General case' 0 C--N 1.292 -1.935 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 177.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 27.6 p90 -143.32 173.24 11.78 Favored 'General case' 0 C--N 1.311 -1.101 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.949 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -76.76 106.76 8.61 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 107.967 -1.124 . . . . 0.0 107.967 177.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.72 -0.75 56.05 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.1 m -94.35 -37.84 11.28 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-O 121.262 0.553 . . . . 0.0 109.832 177.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.407 ' HG3' ' HB1' ' A' ' 109' ' ' ALA . 4.5 ttmp? -88.78 -32.74 17.73 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.892 -179.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.469 ' CZ ' ' HB ' ' A' ' 142' ' ' ILE . 17.4 m-85 -126.03 157.27 38.35 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -179.399 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 29.6 m -144.93 116.92 8.3 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 175.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.5 p -80.71 141.09 15.7 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 120.811 0.339 . . . . 0.0 110.944 -178.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 51' ' ' LYS . 46.9 mtmt -91.9 -61.96 1.52 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 173.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -165.9 177.38 7.17 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.41 HG22 HG21 ' A' ' 70' ' ' VAL . 12.5 m -121.85 148.24 25.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 91.1 mt -104.22 114.56 64.2 Favored Pre-proline 0 C--N 1.287 -2.131 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -77.58 141.27 19.64 Favored 'Trans proline' 0 N--CA 1.441 -1.607 0 C-N-CA 121.501 1.468 . . . . 0.0 110.265 179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.0 t30 -72.15 111.09 7.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 17.2 p -66.41 -15.02 62.98 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 124.347 1.059 . . . . 0.0 112.825 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -69.85 -32.49 70.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 69.9 mt -102.47 -52.93 3.0 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.34 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 30.7 t -83.69 123.85 39.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 -177.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 165.31 25.46 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.809 -176.442 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 18.4 t70 57.44 36.05 26.61 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 124.738 1.274 . . . . 0.0 109.593 173.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.9 p -51.19 -42.53 60.93 Favored 'General case' 0 C--O 1.254 1.305 0 N-CA-C 115.483 1.66 . . . . 0.0 115.483 -172.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -70.87 -22.22 62.31 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 123.361 0.664 . . . . 0.0 111.915 -175.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -84.15 28.73 0.6 Allowed 'General case' 0 C--N 1.31 -1.139 0 C-N-CA 122.937 0.495 . . . . 0.0 111.593 -175.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 67.2 t80 70.23 53.55 0.34 Allowed 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 124.693 1.197 . . . . 0.0 110.016 179.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 83' ' ' THR . 22.7 t -114.22 -34.35 5.36 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-N 114.812 -1.085 . . . . 0.0 109.264 176.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -106.0 106.47 16.99 Favored 'General case' 0 N--CA 1.438 -1.057 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.425 -178.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.1 mp -120.93 117.97 54.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 -179.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.41 HG21 HG22 ' A' ' 53' ' ' VAL . 95.2 t -132.55 110.64 16.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -103.11 119.3 38.61 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 3.0 p -79.36 95.22 5.67 Favored 'General case' 0 N--CA 1.42 -1.933 0 CA-C-O 122.099 0.952 . . . . 0.0 109.899 176.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.6 m -79.93 175.35 10.71 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.365 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.4 m -47.81 133.3 11.28 Favored Pre-proline 0 C--O 1.248 1.02 0 C-N-CA 123.946 0.898 . . . . 0.0 109.351 178.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -35.1 123.24 0.2 Allowed 'Trans proline' 0 C--N 1.387 2.567 0 C-N-CA 125.013 3.808 . . . . 0.0 114.384 -173.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.92 -9.66 37.17 Favored Glycine 0 N--CA 1.427 -1.953 0 CA-C-N 114.628 -1.169 . . . . 0.0 112.789 -177.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -127.24 125.58 41.22 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 118.213 1.007 . . . . 0.0 113.025 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 15.5 mt -114.34 110.05 30.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.6 m -98.58 111.11 23.58 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -178.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 54.5 mt -114.27 137.84 46.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 120.86 0.362 . . . . 0.0 110.136 -175.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 27.7 m -137.15 125.48 23.3 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.472 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 92.1 m-85 -115.31 109.24 17.63 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 174.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.458 ' O ' ' HD3' ' A' ' 85' ' ' PRO . 28.3 p -107.4 123.85 48.98 Favored 'General case' 0 C--N 1.283 -2.299 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 176.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -95.32 105.85 22.52 Favored Pre-proline 0 C--N 1.306 -1.301 0 C-N-CA 121.074 -0.251 . . . . 0.0 110.745 -175.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 83' ' ' THR . 84.4 Cg_endo -85.45 -9.87 7.91 Favored 'Trans proline' 0 CA--C 1.541 0.87 0 C-N-CA 122.789 2.326 . . . . 0.0 113.307 178.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 26.2 m -123.42 23.32 9.02 Favored 'General case' 0 CA--C 1.552 1.023 0 CA-C-O 121.4 0.619 . . . . 0.0 110.152 -170.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.7 pp -60.29 -20.76 60.45 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 114.554 1.316 . . . . 0.0 114.554 -176.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -76.96 -31.14 56.36 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-O 120.873 0.368 . . . . 0.0 111.014 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 -105.03 -41.89 5.46 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.04 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 4.8 m-85 -124.75 101.56 32.99 Favored Pre-proline 0 C--N 1.315 -0.923 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -95.76 136.72 0.65 Allowed 'Trans proline' 0 N--CA 1.432 -2.129 0 C-N-CA 121.577 1.518 . . . . 0.0 113.19 -178.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 58.8 mt -82.43 90.17 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 170.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.5 p -132.32 13.13 4.61 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.153 -175.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.7 m -126.62 154.02 35.97 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.036 -179.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -90.99 168.66 11.5 Favored 'General case' 0 C--N 1.309 -1.18 0 O-C-N 123.494 0.496 . . . . 0.0 111.785 -174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 147.06 -157.13 27.31 Favored Glycine 0 N--CA 1.432 -1.609 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -88.54 133.5 30.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 175.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 54.9 tp -86.23 -49.65 7.55 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.097 0.475 . . . . 0.0 109.897 -179.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.83 156.0 38.19 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.012 -179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -112.27 124.51 52.62 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 177.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 41.5 mt -89.8 116.19 27.71 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -104.57 105.49 15.61 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-O 121.637 0.732 . . . . 0.0 110.342 -175.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -108.27 139.67 42.62 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.305 -175.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.4 mt -94.08 129.61 44.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 171.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 57.2 mt -87.59 133.12 31.12 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.042 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 175.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -64.12 148.65 49.4 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.812 0.845 . . . . 0.0 109.569 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 33.2 t -70.26 -23.0 62.82 Favored 'General case' 0 CA--C 1.547 0.834 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 174.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -92.89 20.36 6.7 Favored 'General case' 0 CA--C 1.557 1.238 0 C-N-CA 124.607 1.163 . . . . 0.0 108.613 -179.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.407 ' HB1' ' HG3' ' A' ' 47' ' ' LYS . . . -86.41 133.64 33.76 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 121.498 -0.751 . . . . 0.0 110.95 -179.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 10.7 m -88.78 157.85 18.35 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.424 ' HB2' ' HA2' ' A' ' 146' ' ' GLY . . . -73.49 138.15 44.92 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.771 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 147.62 158.43 7.89 Favored Glycine 0 N--CA 1.405 -3.398 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -176.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -91.93 139.02 31.07 Favored 'General case' 0 C--N 1.278 -2.502 0 CA-C-O 121.376 0.608 . . . . 0.0 110.347 179.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 65.6 m -131.33 134.08 45.97 Favored 'General case' 0 C--N 1.283 -2.286 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -86.46 143.72 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.276 -174.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 42.7 mt -104.25 112.99 26.24 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 176.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.2 m -93.56 104.26 16.39 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -175.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.6 t -85.2 107.87 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.675 0 N-CA-C 103.998 -2.593 . . . . 0.0 103.998 173.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 12.2 t70 -64.08 109.25 2.49 Favored Pre-proline 0 C--N 1.302 -1.476 0 O-C-N 124.641 1.213 . . . . 0.0 111.699 -168.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_exo -71.0 -21.01 28.3 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.047 2.498 . . . . 0.0 113.23 -176.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.69 -33.83 46.61 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.093 0.473 . . . . 0.0 110.322 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.3 m -89.56 -12.67 39.21 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-O 121.43 0.633 . . . . 0.0 109.863 178.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.1 tt -79.3 120.25 23.5 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -176.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 70.3 mt -126.61 127.72 70.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.487 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 77.0 t -132.6 96.71 2.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -112.49 143.14 44.15 Favored 'General case' 0 N--CA 1.421 -1.883 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.395 -178.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.1 p-10 -81.9 -168.55 1.97 Allowed 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.055 -177.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -63.37 -25.62 68.37 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 176.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -93.55 14.22 19.5 Favored 'General case' 0 CA--C 1.551 0.984 0 CA-C-O 121.487 0.661 . . . . 0.0 109.926 177.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.5 p30 63.03 22.27 13.36 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 127.005 2.122 . . . . 0.0 115.345 173.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 61.7 mmtt -100.89 128.78 46.78 Favored 'General case' 0 C--N 1.31 -1.127 0 C-N-CA 119.075 -1.05 . . . . 0.0 110.952 -178.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.486 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.0 t70 -74.04 113.21 10.97 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 178.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.472 ' HB ' ' O ' ' A' ' 4' ' ' GLU . 17.1 pt -125.31 34.57 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.284 -2.255 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.639 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.487 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 1.6 pptp? -105.02 135.06 47.06 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -173.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' LYS . 25.9 t70 -96.4 104.67 16.66 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 168.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.26 123.94 39.25 Favored 'General case' 0 C--N 1.285 -2.202 0 C-N-CA 118.849 -1.14 . . . . 0.0 112.164 -175.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -134.84 112.62 10.84 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 104.322 -2.473 . . . . 0.0 104.322 170.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.8 m -140.08 106.13 5.21 Favored 'General case' 0 N--CA 1.406 -2.658 0 CA-C-O 122.199 0.999 . . . . 0.0 112.158 -172.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -142.75 95.62 2.81 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 174.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -83.59 164.79 41.78 Favored Glycine 0 CA--C 1.482 -1.978 0 N-CA-C 108.53 -1.828 . . . . 0.0 108.53 -179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -150.49 133.77 16.29 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-N 118.589 1.195 . . . . 0.0 110.815 -178.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.469 ' HB ' ' CZ ' ' A' ' 48' ' ' PHE . 67.3 mt -111.48 123.78 67.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 45.1 m -102.76 108.26 19.43 Favored 'General case' 0 N--CA 1.423 -1.806 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.47 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 60.0 t -81.04 119.43 30.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 N-CA-C 105.388 -2.078 . . . . 0.0 105.388 172.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 31.6 p -68.14 -64.96 0.76 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 114.262 1.208 . . . . 0.0 114.262 -170.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.424 ' HA2' ' HB2' ' A' ' 111' ' ' ALA . . . 138.13 34.38 0.18 Allowed Glycine 0 CA--C 1.479 -2.215 0 C-N-CA 119.975 -1.107 . . . . 0.0 111.548 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.6 p -82.89 -17.19 44.62 Favored 'General case' 0 N--CA 1.424 -1.768 0 C-N-CA 123.786 0.835 . . . . 0.0 109.983 177.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 70.3 160.31 0.15 Allowed Pre-proline 0 C--N 1.359 1.009 0 C-N-CA 125.643 1.577 . . . . 0.0 111.785 178.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -72.8 48.16 1.32 Allowed 'Trans proline' 0 CA--C 1.556 1.62 0 C-N-CA 123.162 2.575 . . . . 0.0 112.126 175.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 39.4 m 71.97 -66.16 0.32 Allowed 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 126.061 1.744 . . . . 0.0 111.67 -178.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 63.1 m . . . . . 0 C--N 1.31 -1.13 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -179.571 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.501 -0.797 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.8 t -65.29 -38.25 89.64 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 117.193 0.496 . . . . 0.0 111.018 -177.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -81.99 84.9 6.82 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.232 0.539 . . . . 0.0 110.323 -179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 48.4 m -133.69 72.99 1.49 Allowed 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.626 178.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.7 m -96.97 168.7 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 176.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 35.6 mmtp -123.8 157.86 33.12 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.118 0.485 . . . . 0.0 110.327 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -110.14 110.71 21.68 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 172.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -101.92 154.86 18.55 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.057 -174.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.5 m -79.88 109.98 14.81 Favored 'General case' 0 N--CA 1.427 -1.612 0 CA-C-N 115.197 -0.91 . . . . 0.0 111.345 -171.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.8 t -73.54 117.42 17.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.039 -0.982 . . . . 0.0 108.976 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -88.67 112.12 22.74 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.1 tp -95.29 128.05 41.82 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.505 ' HB2' ' HB ' ' A' ' 26' ' ' THR . 66.7 m -121.93 149.69 43.07 Favored 'General case' 0 N--CA 1.412 -2.344 0 CA-C-O 121.957 0.885 . . . . 0.0 112.376 -174.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.484 HG21 ' H ' ' A' ' 139' ' ' ASN . 16.6 m -120.55 163.18 18.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.534 179.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.71 166.48 24.26 Favored Glycine 0 N--CA 1.429 -1.807 0 C-N-CA 119.815 -1.183 . . . . 0.0 111.102 -179.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.4 m -111.27 119.89 40.42 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -177.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.0 163.56 17.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.2 p -116.37 161.7 18.65 Favored 'General case' 0 N--CA 1.415 -2.179 0 N-CA-C 111.573 0.212 . . . . 0.0 111.573 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.53 178.16 39.17 Favored Glycine 0 N--CA 1.436 -1.313 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -130.36 156.98 78.68 Favored Pre-proline 0 C--N 1.316 -0.89 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -62.04 112.24 1.47 Allowed 'Trans proline' 0 C--N 1.359 1.085 0 C-N-CA 122.1 1.867 . . . . 0.0 110.794 176.336 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 111.32 -12.91 28.43 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 121.178 -0.534 . . . . 0.0 111.916 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.12 146.14 25.0 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -177.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.0 m -92.17 120.7 33.0 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.8 p -111.11 140.59 29.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-O 121.157 0.503 . . . . 0.0 110.364 -174.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 100' ' ' TYR . 37.9 ttpt -121.02 119.27 32.02 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.438 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 18.3 t -101.79 112.29 65.08 Favored Pre-proline 0 C--N 1.316 -0.885 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -79.77 125.73 6.24 Favored 'Trans proline' 0 CA--C 1.545 1.05 0 C-N-CA 122.073 1.849 . . . . 0.0 112.659 177.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -90.81 124.33 43.34 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 107.271 -1.381 . . . . 0.0 107.271 177.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 9' ' ' SER . 4.7 m -100.15 130.92 46.34 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 120.903 0.383 . . . . 0.0 109.986 -174.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -116.65 138.46 47.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 177.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.0 m -146.43 153.46 40.48 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 118.181 0.446 . . . . 0.0 112.149 -178.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 52.3 mt-30 65.72 25.08 11.48 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 115.402 1.63 . . . . 0.0 115.402 173.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.482 HG12 ' HB3' ' A' ' 95' ' ' ASP . 5.5 p -83.19 107.02 14.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-O 121.8 0.809 . . . . 0.0 110.327 175.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.2 t -105.3 -35.32 7.58 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.345 177.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.3 m -73.94 127.72 87.74 Favored Pre-proline 0 N--CA 1.448 -0.546 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 176.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.72 123.04 11.35 Favored 'Trans proline' 0 C--O 1.245 0.849 0 CA-C-N 120.557 1.235 . . . . 0.0 110.159 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 7.6 p -88.85 139.67 17.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.261 -177.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -115.41 -24.47 4.09 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.494 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.0 tt -142.57 112.02 6.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 117.614 0.707 . . . . 0.0 109.865 -178.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 81' ' ' THR . 63.5 mt -112.16 115.07 48.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 108.625 -0.879 . . . . 0.0 108.625 175.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 43.4 t -115.97 137.93 51.67 Favored 'General case' 0 C--N 1.28 -2.427 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 22.4 ptp -152.21 154.4 35.71 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 176.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -136.32 113.62 10.72 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 -179.167 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.7 mp -101.84 122.99 54.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.251 -173.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 34.3 t -107.68 143.4 36.23 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 174.415 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 54.5 p90 -152.3 170.95 18.8 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 110.406 -0.22 . . . . 0.0 110.406 -177.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -77.68 113.94 16.04 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -82.79 -6.54 59.47 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 113.109 0.781 . . . . 0.0 113.109 -174.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -85.98 -37.55 18.88 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 93.3 mttt -82.71 -44.05 16.11 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 115.173 -0.921 . . . . 0.0 112.526 178.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -119.65 154.56 33.83 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.881 0.848 . . . . 0.0 112.026 -173.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 33.4 m -140.07 112.43 7.79 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.3 137.37 23.06 Favored 'Isoleucine or valine' 0 C--O 1.245 0.865 0 C-N-CA 120.454 -0.499 . . . . 0.0 109.702 179.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.459 ' HD3' HD11 ' A' ' 104' ' ' ILE . 10.2 mtmp? -100.34 -56.64 2.3 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 174.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -163.78 170.76 16.48 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 -174.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.41 147.6 32.21 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 76.9 mt -102.82 118.87 57.3 Favored Pre-proline 0 C--N 1.285 -2.207 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -83.03 150.18 13.83 Favored 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 121.673 1.582 . . . . 0.0 112.048 179.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.595 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 14.6 t-20 -73.27 118.2 15.93 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 171.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 43.9 p -82.41 2.34 32.99 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.43 0.633 . . . . 0.0 112.1 -174.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.435 ' HB2' ' OD1' ' A' ' 56' ' ' ASN . 15.3 m-20 -89.92 -41.03 12.01 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.533 0.682 . . . . 0.0 109.247 178.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.595 ' HG ' ' OD1' ' A' ' 56' ' ' ASN . 17.3 mt -87.78 -64.62 1.12 Allowed 'General case' 0 N--CA 1.429 -1.508 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.555 179.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.31 107.8 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -120.15 161.05 21.68 Favored 'General case' 0 C--N 1.293 -1.887 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.637 -175.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 t70 62.68 31.13 16.83 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 125.039 1.336 . . . . 0.0 110.556 176.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.2 p -49.21 -32.84 11.26 Favored 'General case' 0 C--O 1.245 0.82 0 C-N-CA 126.386 1.874 . . . . 0.0 115.573 -172.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -71.97 -12.58 61.31 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -175.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 39.1 m-80 -90.34 23.66 2.85 Favored 'General case' 0 C--N 1.316 -0.873 0 O-C-N 121.685 -0.634 . . . . 0.0 111.143 177.032 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 18.0 t80 69.7 32.84 3.14 Favored 'General case' 0 C--O 1.211 -0.963 0 C-N-CA 125.545 1.538 . . . . 0.0 109.628 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 83' ' ' THR . 6.8 m -83.62 -17.38 41.76 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.454 1.121 . . . . 0.0 108.158 173.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 69.6 t80 -107.77 106.59 16.97 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 113.9 -1.5 . . . . 0.0 107.972 179.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.7 mp -116.0 108.27 24.74 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.139 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -178.158 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 86.6 t -122.69 112.31 33.64 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.899 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 174.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -100.58 109.97 22.09 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.922 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 11.2 m -73.36 96.37 2.32 Favored 'General case' 0 N--CA 1.422 -1.856 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 176.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.4 t -81.63 174.81 11.04 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-N 114.69 -1.141 . . . . 0.0 109.855 -174.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.3 m -49.64 136.94 18.15 Favored Pre-proline 0 C--N 1.31 -1.12 0 C-N-CA 125.778 1.631 . . . . 0.0 109.678 178.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -35.16 115.39 0.1 Allowed 'Trans proline' 0 C--N 1.383 2.388 0 C-N-CA 124.728 3.619 . . . . 0.0 114.073 -177.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 107.23 2.47 35.78 Favored Glycine 0 N--CA 1.43 -1.727 0 CA-C-N 114.651 -1.159 . . . . 0.0 112.506 -177.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -140.27 147.16 39.54 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 174.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -135.52 119.27 24.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 174.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.9 m -104.58 110.97 23.48 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 66.3 mt -114.65 134.4 57.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 CA-C-O 120.879 0.371 . . . . 0.0 110.173 -175.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 37' ' ' ILE . 25.8 m -138.52 124.09 19.61 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 177.064 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -109.03 108.6 19.38 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 175.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 67' ' ' SER . 10.5 t -147.33 119.61 8.35 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.381 0.61 . . . . 0.0 109.663 179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -102.95 128.9 26.73 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.015 -177.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 69.4 Cg_endo -75.73 -3.42 13.84 Favored 'Trans proline' 0 CA--C 1.547 1.147 0 C-N-CA 123.445 2.764 . . . . 0.0 113.516 -178.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.06 40.24 3.61 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 123.696 0.798 . . . . 0.0 110.609 -178.381 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.6 pp -53.92 -22.47 10.21 Favored 'General case' 0 N--CA 1.486 1.331 0 N-CA-C 115.852 1.797 . . . . 0.0 115.852 -174.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -72.06 -29.24 63.94 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.551 0.691 . . . . 0.0 110.423 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -97.36 -41.48 8.21 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.265 -176.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -122.28 101.08 41.46 Favored Pre-proline 0 N--CA 1.442 -0.869 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -103.62 158.3 0.24 Allowed 'Trans proline' 0 N--CA 1.436 -1.862 0 C-N-CA 121.65 1.566 . . . . 0.0 112.886 177.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.513 HG23 ' HB3' ' A' ' 59' ' ' LEU . 35.7 mt -108.63 91.23 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.703 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 167.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 7.9 p -113.08 -5.09 13.75 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.641 -176.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -121.78 165.34 17.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 -179.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 6.5 p-10 -116.01 -170.56 1.82 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 138.04 -129.47 4.61 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.782 -1.727 . . . . 0.0 108.782 -175.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.38 138.58 19.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 174.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.7 tp -93.04 -51.01 5.25 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.351 0.596 . . . . 0.0 110.386 179.381 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.18 165.93 33.7 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.471 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.434 ' HB3' ' CG ' ' A' ' 22' ' ' LYS . 73.7 m-85 -122.0 121.15 36.38 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 63.1 mt -87.44 113.16 22.9 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 179.006 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -104.8 107.0 17.72 Favored 'General case' 0 C--O 1.26 1.623 0 CA-C-O 121.424 0.63 . . . . 0.0 110.246 -174.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -116.6 148.21 41.14 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.918 -176.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.459 HD11 ' HD3' ' A' ' 51' ' ' LYS . 73.2 mt -95.21 128.9 46.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 168.436 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 50.0 mt -84.81 125.92 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 173.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -61.81 143.72 55.88 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 -178.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.8 m -70.46 -18.71 62.99 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-O 121.395 0.616 . . . . 0.0 109.863 177.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -90.4 -1.99 57.94 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.03 178.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -70.67 133.65 46.84 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.8 m -85.09 154.38 22.09 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -68.84 156.8 37.77 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.122 0.487 . . . . 0.0 110.847 -179.161 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 133.16 154.31 7.43 Favored Glycine 0 N--CA 1.42 -2.403 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -178.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 143' ' ' THR . 9.7 p-10 -76.04 116.76 17.06 Favored 'General case' 0 N--CA 1.418 -2.03 0 CA-C-O 121.904 0.859 . . . . 0.0 109.916 179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 15.6 m -114.75 122.28 45.92 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.879 -174.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -92.97 143.53 26.15 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 112.616 0.598 . . . . 0.0 112.616 -174.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.445 ' O ' ' HA ' ' A' ' 139' ' ' ASN . 57.1 mt -97.58 113.93 25.75 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 176.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 5.0 m -83.45 104.0 13.25 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.968 -0.56 . . . . 0.0 109.902 -176.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 21.3 t -101.13 119.56 49.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 178.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.411 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.6 t70 -71.82 119.02 71.88 Favored Pre-proline 0 C--N 1.318 -0.802 0 O-C-N 123.794 0.684 . . . . 0.0 111.429 -175.063 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 8.1 Cg_endo -76.39 -10.21 18.96 Favored 'Trans proline' 0 C--N 1.361 1.212 0 C-N-CA 122.656 2.237 . . . . 0.0 114.074 -175.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -88.64 -36.39 16.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 121.323 0.582 . . . . 0.0 109.712 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 5.4 m -82.43 -12.78 57.64 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.941 0.877 . . . . 0.0 108.949 176.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.455 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -86.31 116.36 24.44 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 177.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 65.8 mt -133.94 124.28 46.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 -176.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 99.3 t -117.4 95.83 4.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -106.92 132.87 52.38 Favored 'General case' 0 N--CA 1.425 -1.709 0 CA-C-N 114.733 -1.121 . . . . 0.0 109.857 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 6.6 p-10 -85.97 -163.8 0.93 Allowed 'General case' 0 C--N 1.287 -2.145 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.963 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -59.91 -32.84 71.14 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 121.339 0.59 . . . . 0.0 110.814 175.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -86.53 8.04 23.67 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 124.999 1.319 . . . . 0.0 109.485 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.7 p30 55.2 25.96 7.87 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 126.719 2.008 . . . . 0.0 114.063 177.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 44.6 mmtm -101.68 134.15 45.27 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.56 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 20.7 t70 -75.22 112.17 11.23 Favored 'General case' 0 C--N 1.309 -1.161 0 O-C-N 123.771 0.67 . . . . 0.0 110.643 179.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.1 pp -125.95 79.66 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.923 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.488 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.44 ' HD3' ' HB2' ' A' ' 136' ' ' ALA . 1.0 OUTLIER -147.68 140.33 24.7 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 114.687 1.366 . . . . 0.0 114.687 -176.95 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 34.2 m-20 -96.09 103.91 15.83 Favored 'General case' 0 CA--C 1.474 -1.967 0 N-CA-C 105.071 -2.196 . . . . 0.0 105.071 164.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 134' ' ' LYS . . . -110.76 119.91 40.66 Favored 'General case' 0 C--N 1.278 -2.532 0 C-N-CA 117.649 -1.62 . . . . 0.0 111.391 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -118.39 111.54 18.83 Favored 'General case' 0 N--CA 1.402 -2.849 0 N-CA-C 102.406 -3.183 . . . . 0.0 102.406 166.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.5 m -135.22 105.71 6.42 Favored 'General case' 0 N--CA 1.401 -2.899 0 CA-C-O 122.806 1.289 . . . . 0.0 111.52 -175.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.484 ' H ' HG21 ' A' ' 10' ' ' VAL . 21.8 t-20 -164.49 77.96 0.35 Allowed 'General case' 0 N--CA 1.415 -2.206 0 CA-C-N 112.695 -2.048 . . . . 0.0 106.238 178.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -74.06 149.4 40.96 Favored Glycine 0 CA--C 1.482 -1.98 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.124 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 36.4 ttpt -133.2 130.87 39.68 Favored 'General case' 0 C--N 1.28 -2.435 0 C-N-CA 118.133 -1.427 . . . . 0.0 111.96 -176.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 68.1 mt -102.99 115.66 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.048 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.511 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 23.3 m -91.86 105.34 17.63 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.297 -178.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.7 t -82.04 107.93 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.735 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 177.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 6.2 p -80.23 -47.11 15.13 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.825 -179.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 113.71 134.48 5.94 Favored Glycine 0 N--CA 1.411 -2.988 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.638 176.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 2.8 p -66.94 -32.85 74.37 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 122.393 1.092 . . . . 0.0 108.747 177.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -132.14 91.83 30.92 Favored Pre-proline 0 N--CA 1.42 -1.94 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 171.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -75.39 100.6 1.38 Allowed 'Trans proline' 0 N--CA 1.453 -0.908 0 C-N-CA 122.362 2.041 . . . . 0.0 112.233 -178.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 59.5 m -98.27 101.27 12.68 Favored 'General case' 0 N--CA 1.422 -1.869 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.159 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.158 -1.793 . . . . 0.0 106.158 175.384 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.297 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 15.2 m -73.07 101.47 3.28 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.346 0.593 . . . . 0.0 110.531 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -124.63 -164.91 1.31 Allowed 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 33.2 m -68.05 90.27 0.32 Allowed 'General case' 0 C--O 1.242 0.68 0 CA-C-O 122.269 1.033 . . . . 0.0 110.275 176.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.9 p -174.49 -34.13 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 C-N-CA 126.474 1.909 . . . . 0.0 105.925 -177.292 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.562 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 14.1 ttmm 62.76 -165.27 0.24 Allowed 'General case' 0 C--N 1.369 1.428 0 C-N-CA 125.717 1.607 . . . . 0.0 108.158 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.562 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 46.3 m-20 71.36 -164.39 0.14 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.523 1.129 . . . . 0.0 112.181 170.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.26 -173.44 2.72 Favored 'General case' 0 C--N 1.288 -2.094 0 C-N-CA 123.924 0.89 . . . . 0.0 108.778 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.2 m -97.87 105.67 17.85 Favored 'General case' 0 N--CA 1.418 -2.068 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 173.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG13 ' HB ' ' A' ' 30' ' ' VAL . 97.7 t -81.79 113.63 21.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -88.01 114.61 24.79 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.771 -176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 42.0 tp -97.9 132.09 43.8 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 13.9 t -132.92 172.15 12.98 Favored 'General case' 0 N--CA 1.413 -2.302 0 CA-C-O 121.86 0.838 . . . . 0.0 110.624 -172.047 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.592 HG21 ' H ' ' A' ' 139' ' ' ASN . 13.4 m -137.44 163.13 31.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 125.184 1.394 . . . . 0.0 108.599 -176.525 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.84 169.2 23.33 Favored Glycine 0 N--CA 1.415 -2.754 0 C-N-CA 119.644 -1.265 . . . . 0.0 112.346 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 53.4 m -113.86 123.08 48.92 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 29.0 m -124.13 160.49 28.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.334 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.5 p -109.09 147.92 31.65 Favored 'General case' 0 C--N 1.292 -1.905 0 C-N-CA 122.321 0.249 . . . . 0.0 111.195 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.86 175.77 29.69 Favored Glycine 0 N--CA 1.437 -1.281 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -132.77 152.78 80.49 Favored Pre-proline 0 C--N 1.316 -0.891 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -178.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -63.61 113.75 2.26 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 122.585 2.19 . . . . 0.0 111.341 177.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.67 -19.57 30.77 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 -178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -89.36 148.64 23.4 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.573 0.749 . . . . 0.0 110.439 -176.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.1 m -82.93 136.91 34.41 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.8 p -126.01 147.81 30.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -177.221 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 23.5 ttmm -123.72 125.23 44.39 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 -178.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.81 115.04 49.0 Favored Pre-proline 0 C--N 1.314 -0.953 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -83.61 126.7 4.13 Favored 'Trans proline' 0 N--CA 1.448 -1.154 0 C-N-CA 122.186 1.924 . . . . 0.0 113.339 179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 78.9 t -90.25 114.02 27.24 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.074 -1.824 . . . . 0.0 106.074 174.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 24.8 m -98.78 138.87 35.3 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.879 0.371 . . . . 0.0 110.7 -172.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 13.6 tt -125.86 137.1 58.79 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.1 m -137.93 157.25 46.78 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 122.099 -0.375 . . . . 0.0 111.068 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.7 mm100 72.8 14.38 4.95 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 125.244 1.418 . . . . 0.0 114.534 172.067 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.3 p -91.06 118.01 35.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.577 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -116.08 -30.92 5.86 Favored 'General case' 0 N--CA 1.426 -1.646 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.707 177.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 24.8 m -75.0 139.99 73.47 Favored Pre-proline 0 C--N 1.32 -0.693 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 173.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 23.8 Cg_exo -65.06 122.11 9.78 Favored 'Trans proline' 0 C--N 1.357 1.004 0 CA-C-N 120.35 1.161 . . . . 0.0 112.004 178.026 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 13.1 p -89.89 149.53 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-N 115.058 -0.973 . . . . 0.0 108.544 175.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -142.25 -15.54 0.35 Allowed Glycine 0 N--CA 1.444 -0.798 0 C-N-CA 118.859 -1.639 . . . . 0.0 114.463 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.412 HD23 HG22 ' A' ' 83' ' ' THR . 1.8 tt -131.91 111.95 12.01 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 117.994 0.897 . . . . 0.0 109.2 -176.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' ILE . 4.1 mp -129.26 141.64 46.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.178 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.422 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 48.8 t -144.52 143.88 31.06 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 175.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.1 ptp -157.39 152.95 26.49 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 118.134 0.424 . . . . 0.0 111.354 179.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.543 ' HB3' ' HB3' ' A' ' 119' ' ' ASP . 6.7 t70 -116.93 121.51 41.64 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp -108.09 108.65 25.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.623 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.235 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 50.9 m -95.59 125.03 39.9 Favored 'General case' 0 N--CA 1.423 -1.775 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -136.73 171.79 13.97 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -175.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -81.52 113.13 19.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -63.06 -29.6 70.94 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -175.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 p -89.09 -26.46 21.35 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -88.55 -33.72 17.63 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.926 -176.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -125.75 146.19 49.87 Favored 'General case' 0 CA--C 1.501 -0.917 0 CA-C-O 121.292 0.567 . . . . 0.0 111.095 -178.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 38.8 m -124.87 113.51 17.98 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 176.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.9 p -83.55 134.98 25.74 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-O 121.144 0.497 . . . . 0.0 109.909 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.45 ' HB2' ' HZ2' ' A' ' 51' ' ' LYS . 9.0 mtmp? -95.77 -58.21 2.16 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 122.018 0.914 . . . . 0.0 108.967 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -167.06 171.54 10.93 Favored 'General case' 0 N--CA 1.42 -1.969 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 -172.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -123.75 143.08 38.21 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 176.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -102.85 112.55 65.82 Favored Pre-proline 0 C--N 1.281 -2.392 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -77.13 144.98 24.09 Favored 'Trans proline' 0 N--CA 1.444 -1.385 0 C-N-CA 121.596 1.531 . . . . 0.0 110.607 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -76.82 109.89 10.98 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 176.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 3.3 p -72.1 -5.45 35.47 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 115.014 -0.994 . . . . 0.0 112.541 -175.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -77.96 -28.47 49.49 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 174.424 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -101.47 -62.59 1.23 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.112 178.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' THR . 29.1 t -82.01 115.17 24.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 -179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -123.28 140.1 53.36 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -175.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 46.9 t0 60.15 66.19 1.0 Allowed 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.91 1.382 . . . . 0.0 109.222 177.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.4 ' HA ' ' HB3' ' A' ' 67' ' ' SER . 9.5 p -61.15 -23.11 65.31 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 113.38 -1.736 . . . . 0.0 113.812 -173.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.405 ' C ' ' H ' ' A' ' 66' ' ' TYR . 30.2 t70 -65.21 -16.77 63.89 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.973 0.909 . . . . 0.0 112.786 -177.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -72.78 12.97 0.42 Allowed 'General case' 0 N--CA 1.502 2.162 0 C-N-CA 123.167 0.587 . . . . 0.0 112.11 178.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.405 ' H ' ' C ' ' A' ' 64' ' ' ASP . 30.6 t80 68.99 35.68 2.74 Favored 'General case' 0 C--O 1.218 -0.577 0 C-N-CA 125.356 1.463 . . . . 0.0 107.414 -174.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.566 ' HA ' ' O ' ' A' ' 83' ' ' THR . 32.7 t -86.07 -29.15 23.62 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.114 -1.403 . . . . 0.0 107.666 176.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -102.07 106.66 17.58 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.397 -0.82 . . . . 0.0 109.528 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.506 ' HB ' ' HB ' ' A' ' 81' ' ' THR . 4.7 mp -120.8 114.6 44.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.6 t -131.29 112.32 21.18 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 176.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.425 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 25.6 t30 -103.83 117.13 33.63 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 114.921 -1.036 . . . . 0.0 108.501 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.5 m -83.03 94.59 7.81 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 178.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.6 t -82.53 175.51 10.14 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 115.21 -0.905 . . . . 0.0 108.631 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 48.6 m -48.16 133.93 12.25 Favored Pre-proline 0 CA--C 1.551 0.989 0 C-N-CA 124.488 1.115 . . . . 0.0 110.344 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -40.9 131.45 2.84 Favored 'Trans proline' 0 C--N 1.382 2.34 0 C-N-CA 124.421 3.414 . . . . 0.0 113.233 -177.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 108.02 -18.13 34.3 Favored Glycine 0 N--CA 1.433 -1.528 0 CA-C-N 115.199 -0.91 . . . . 0.0 111.455 -175.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -134.4 138.06 44.55 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-O 121.41 0.624 . . . . 0.0 112.539 175.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 19.0 mt -119.26 130.06 74.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 173.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 17.6 m -107.5 110.75 22.75 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 59.0 mt -116.14 135.63 55.71 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.506 ' HB ' ' HB ' ' A' ' 69' ' ' ILE . 62.9 m -141.74 135.94 30.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 67' ' ' SER . 82.6 m-85 -127.11 108.12 10.63 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 176.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.566 ' O ' ' HA ' ' A' ' 67' ' ' SER . 81.9 p -130.75 119.37 22.22 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -111.46 116.55 50.55 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.592 -179.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -78.27 -2.55 12.61 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.216 2.611 . . . . 0.0 110.9 178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.76 22.25 16.17 Favored 'General case' 0 N--CA 1.418 -2.036 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.907 -174.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.2 pp -56.97 -17.58 10.27 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 115.488 1.662 . . . . 0.0 115.488 -175.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.42 -27.01 41.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.245 0.545 . . . . 0.0 110.392 176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -101.27 -31.05 11.17 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.589 -178.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -119.58 101.58 48.47 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 173.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -96.43 115.38 0.14 Allowed 'Trans proline' 0 N--CA 1.426 -2.475 0 C-N-CA 121.904 1.736 . . . . 0.0 112.335 179.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 45.7 mt -86.08 89.6 2.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 N-CA-C 105.801 -1.925 . . . . 0.0 105.801 173.189 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 12.8 p -122.58 14.61 10.23 Favored 'General case' 0 C--N 1.298 -1.655 0 CA-C-O 121.86 0.838 . . . . 0.0 110.91 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.8 m -126.45 159.76 35.13 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.013 177.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 4.2 p30 -106.55 -175.09 2.69 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -176.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 139.56 -134.41 6.64 Favored Glycine 0 N--CA 1.435 -1.416 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.0 mp -98.76 138.0 24.58 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 175.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 48.6 tp -86.76 -51.69 5.95 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -152.49 156.96 40.44 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.988 -179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -111.93 122.88 49.0 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 177.092 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 45.7 mt -85.91 118.46 25.4 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.59 105.24 14.09 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.671 0.748 . . . . 0.0 110.267 -174.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -112.9 155.13 25.25 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.817 -175.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 56.7 mt -104.12 132.62 50.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.014 0 N-CA-C 104.751 -2.315 . . . . 0.0 104.751 167.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 37.5 mt -87.94 136.75 22.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 -68.25 143.52 55.24 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 21.7 m -73.63 -19.02 60.97 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.599 0.714 . . . . 0.0 110.194 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 58.3 t30 -84.88 -2.36 57.71 Favored 'General case' 0 CA--C 1.55 0.972 0 CA-C-O 121.481 0.658 . . . . 0.0 109.98 178.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -72.92 148.62 44.15 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.219 -178.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 11.6 m -95.15 158.54 15.42 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.336 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -80.93 155.64 26.38 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 120.634 0.254 . . . . 0.0 110.554 -179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 128.71 173.68 13.5 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -177.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -75.19 136.68 41.0 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-O 121.487 0.661 . . . . 0.0 111.721 -178.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 2.4 m -127.5 110.76 13.06 Favored 'General case' 0 C--N 1.291 -1.941 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.425 ' HB1' HD21 ' A' ' 139' ' ' ASN . . . -91.27 139.07 31.08 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.39 0.614 . . . . 0.0 111.382 -176.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . . . . . . . . . 54.2 mt -102.83 113.99 27.89 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m -87.95 104.25 16.45 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -174.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.444 ' HB ' ' CB ' ' A' ' 138' ' ' SER . 38.3 t -92.03 119.85 40.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.57 ' O ' ' HB2' ' A' ' 123' ' ' LEU . 23.8 t70 -74.73 112.71 18.79 Favored Pre-proline 0 C--N 1.308 -1.225 0 O-C-N 123.922 0.764 . . . . 0.0 111.321 -175.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 7.1 Cg_exo -74.58 -14.25 22.25 Favored 'Trans proline' 0 C--N 1.358 1.056 0 C-N-CA 122.911 2.407 . . . . 0.0 113.859 -178.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.96 38.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.114 0.483 . . . . 0.0 111.199 -176.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 43.9 p -98.46 11.54 37.89 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 122.023 0.916 . . . . 0.0 109.963 176.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.57 ' HB2' ' O ' ' A' ' 119' ' ' ASP . 3.3 tt -93.97 123.58 37.43 Favored 'General case' 0 N--CA 1.424 -1.747 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.148 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 37' ' ' ILE . 55.5 mt -126.09 128.37 71.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.408 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -176.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 132' ' ' ASP . 87.0 t -130.75 96.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 173.604 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -116.66 139.36 50.62 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.037 -176.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.533 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 8.2 p-10 -91.22 -160.78 0.75 Allowed 'General case' 0 C--N 1.286 -2.177 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.48 -177.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -68.81 -18.79 64.24 Favored 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 122.89 0.476 . . . . 0.0 112.056 177.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -89.12 -1.12 57.95 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 174.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 24.6 t70 63.7 28.49 14.95 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.866 1.666 . . . . 0.0 110.282 177.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 126' ' ' ALA . 31.5 mmmt -103.1 129.8 50.06 Favored 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.128 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 12.4 t70 -77.17 105.59 8.35 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 8.3 pt -114.86 35.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.559 -172.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.451 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 24.8 pttm -104.23 135.97 44.71 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -172.046 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -96.53 103.81 15.75 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 162.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -126.43 120.73 30.52 Favored 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 118.7 -1.2 . . . . 0.0 112.867 -172.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -120.05 113.6 20.74 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 104.159 -2.534 . . . . 0.0 104.159 170.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.444 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 19.7 m -131.29 106.3 8.2 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-O 122.441 1.115 . . . . 0.0 112.925 -172.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.592 ' H ' HG21 ' A' ' 10' ' ' VAL . 3.0 t-20 -157.86 85.37 0.89 Allowed 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 113.95 -1.477 . . . . 0.0 107.134 175.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -70.86 159.61 53.86 Favored Glycine 0 CA--C 1.492 -1.364 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -143.75 129.72 19.52 Favored 'General case' 0 C--N 1.292 -1.931 0 C-N-CA 118.779 -1.168 . . . . 0.0 111.245 -176.259 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 69.8 mt -108.97 111.25 35.29 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 178.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.2 m -87.07 105.59 17.27 Favored 'General case' 0 C--N 1.28 -2.442 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 56.8 t -81.35 113.78 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.504 0 N-CA-C 105.73 -1.952 . . . . 0.0 105.73 176.292 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 21.5 p -79.62 -48.62 13.45 Favored 'General case' 0 C--N 1.291 -1.961 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -171.033 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 176.1 164.47 30.37 Favored Glycine 0 CA--C 1.481 -2.034 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.396 178.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -87.1 133.84 33.57 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -73.68 155.83 88.85 Favored Pre-proline 0 C--N 1.31 -1.118 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 174.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.06 113.89 1.54 Allowed 'Trans proline' 0 C--N 1.354 0.839 0 C-N-CA 122.517 2.145 . . . . 0.0 110.987 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 31.8 m 71.41 90.27 0.09 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.284 1.033 . . . . 0.0 111.171 -176.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 49.1 m . . . . . 0 C--N 1.304 -1.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.098 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.232 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 19.8 m -93.69 106.97 18.91 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 178.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -110.71 136.64 49.48 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.821 -179.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 30.0 t -90.16 79.87 6.37 Favored 'General case' 0 N--CA 1.427 -1.616 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 39.7 t -84.35 119.23 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 179.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -108.41 -172.67 2.1 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-O 121.367 0.603 . . . . 0.0 110.863 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 19.5 m120 79.14 165.56 0.2 Allowed 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 125.956 1.702 . . . . 0.0 115.314 169.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.572 ' HG3' ' O ' ' A' ' 29' ' ' GLN . 0.9 OUTLIER -116.89 -169.11 1.58 Allowed 'General case' 0 C--N 1.288 -2.098 0 CA-C-N 113.659 -1.609 . . . . 0.0 109.892 -174.659 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.3 m -107.5 104.9 14.56 Favored 'General case' 0 N--CA 1.418 -2.058 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 174.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.9 t -86.17 107.8 16.93 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.077 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.4 mtpp -88.35 131.8 34.68 Favored 'General case' 0 C--N 1.281 -2.396 0 CA-C-N 114.934 -1.03 . . . . 0.0 111.734 -174.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -105.25 123.69 48.27 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 168.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 42.4 t -124.61 149.52 46.97 Favored 'General case' 0 C--N 1.286 -2.172 0 O-C-N 123.665 0.603 . . . . 0.0 109.421 -176.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.491 HG21 ' H ' ' A' ' 139' ' ' ASN . 15.5 m -130.41 160.75 41.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.294 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -136.03 -173.25 12.91 Favored Glycine 0 N--CA 1.429 -1.791 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 141' ' ' LYS . 31.8 m -120.34 130.74 54.55 Favored 'General case' 0 C--N 1.29 -1.987 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 -178.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 31.3 m -124.87 158.21 32.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.9 p -104.29 150.38 24.49 Favored 'General case' 0 C--N 1.285 -2.226 0 CA-C-O 120.566 0.222 . . . . 0.0 110.713 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.94 164.66 30.04 Favored Glycine 0 N--CA 1.432 -1.604 0 C-N-CA 120.785 -0.721 . . . . 0.0 111.961 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 -132.91 148.95 71.48 Favored Pre-proline 0 C--N 1.317 -0.809 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 -179.116 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -56.81 118.37 5.2 Favored 'Trans proline' 0 C--N 1.364 1.391 0 C-N-CA 123.263 2.642 . . . . 0.0 112.928 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.08 -17.6 40.93 Favored Glycine 0 N--CA 1.441 -1.021 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.164 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -90.47 164.28 14.32 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.8 m -106.35 121.7 44.77 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 p -109.45 143.84 18.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-O 120.928 0.394 . . . . 0.0 110.356 -173.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 39.6 ttpt -119.75 122.09 40.64 Favored 'General case' 0 N--CA 1.433 -1.292 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.021 -177.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 26.2 t -109.03 117.65 53.18 Favored Pre-proline 0 C--N 1.312 -1.056 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -83.22 128.99 5.08 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 121.803 1.669 . . . . 0.0 113.252 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.7 t -91.01 123.75 43.28 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 175.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -107.33 139.09 42.35 Favored 'General case' 0 C--N 1.294 -1.839 0 CA-C-O 120.927 0.394 . . . . 0.0 110.7 -174.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HB2' ' A' ' 95' ' ' ASP . 12.4 tt -124.04 137.74 56.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 176.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.438 ' HA ' ' CB ' ' A' ' 95' ' ' ASP . 44.7 m -142.38 148.76 38.4 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -176.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . 0.572 ' O ' ' HG3' ' A' ' 4' ' ' GLU . 32.1 mt-30 74.09 14.72 3.83 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 126.999 2.12 . . . . 0.0 114.057 176.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.424 HG12 ' HB3' ' A' ' 95' ' ' ASP . 7.7 p -81.43 118.14 28.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.649 -179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.9 t -116.85 -38.93 3.34 Favored 'General case' 0 CA--C 1.541 0.608 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 m -75.55 131.5 77.15 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 172.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.623 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 50.5 Cg_exo -56.49 123.64 14.32 Favored 'Trans proline' 0 C--N 1.362 1.266 0 C-N-CA 121.487 1.458 . . . . 0.0 112.397 -176.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 15.0 p -88.22 134.12 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.558 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.933 178.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 83' ' ' THR . . . -130.1 -13.56 2.15 Favored Glycine 0 N--CA 1.436 -1.316 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.155 -176.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.91 111.88 17.63 Favored 'General case' 0 CA--C 1.49 -1.336 0 CA-C-N 117.035 0.417 . . . . 0.0 110.62 -178.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -137.47 122.87 25.39 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.901 178.245 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 40.7 t -133.34 134.96 44.45 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 175.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.6 ptm -153.8 134.03 13.36 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -115.53 120.89 40.99 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 39.2 mt -100.33 108.74 23.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -176.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 76' ' ' GLY . 16.0 m -90.38 113.26 25.13 Favored 'General case' 0 N--CA 1.416 -2.149 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 176.09 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.459 ' HB2' HD22 ' A' ' 116' ' ' LEU . 24.3 p90 -131.24 172.6 11.96 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.328 -176.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.9 t0 -83.44 108.99 16.97 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.4 -0.87 54.34 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -176.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.0 t -93.62 -36.95 12.12 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 39.8 ttmt -87.22 -39.93 15.02 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.423 -178.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -123.84 157.72 33.51 Favored 'General case' 0 C--O 1.216 -0.708 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 41.1 m -142.15 118.68 10.96 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 175.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 p -71.03 139.21 20.3 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.296 0.57 . . . . 0.0 110.823 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -94.98 -62.18 1.36 Allowed 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 172.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -166.51 161.25 16.03 Favored 'General case' 0 N--CA 1.422 -1.871 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -177.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 20.2 m -113.73 133.37 59.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 93.3 mt -88.93 122.42 68.98 Favored Pre-proline 0 C--N 1.294 -1.816 0 C-N-CA 120.596 -0.442 . . . . 0.0 109.834 -179.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.24 132.15 17.51 Favored 'Trans proline' 0 N--CA 1.435 -1.923 0 N-CA-C 107.573 -1.741 . . . . 0.0 107.573 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -71.74 107.93 4.8 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.722 179.106 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 16.4 p -67.13 -4.63 10.66 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 125.283 1.433 . . . . 0.0 113.221 -175.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -78.86 -27.07 44.06 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 174.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 43.2 mt -111.06 -59.84 1.91 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.32 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 57' ' ' THR . 21.1 t -81.96 104.66 10.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -113.34 136.98 52.17 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.902 -171.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 62.5 t0 57.49 74.39 0.42 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 125.143 1.527 . . . . 0.0 108.947 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.2 p -73.19 -3.5 27.07 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 114.395 -1.275 . . . . 0.0 113.344 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -82.81 -0.88 49.98 Favored 'General case' 0 CA--C 1.552 1.049 0 CA-C-O 121.387 0.613 . . . . 0.0 111.562 -175.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 53.2 m-80 -91.04 20.36 4.99 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 122.059 -0.401 . . . . 0.0 110.836 177.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 91.0 t80 71.67 22.88 3.88 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.668 1.223 . . . . 0.0 108.579 -176.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' THR . 1.4 m -74.2 -23.67 59.23 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.906 -178.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 53.7 t80 -127.7 110.86 13.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.245 -173.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.2 mp -124.55 124.85 69.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 58.0 t -121.64 110.41 27.54 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.415 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.9 t30 -91.88 112.6 24.59 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.237 -1.394 . . . . 0.0 107.237 179.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 5.8 m -82.07 88.82 6.41 Favored 'General case' 0 N--CA 1.428 -1.529 0 CA-C-O 122.051 0.929 . . . . 0.0 109.315 -178.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 38.8 m -73.06 176.14 6.06 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.463 -177.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.3 m -47.54 132.6 10.52 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.079 1.352 . . . . 0.0 109.651 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_exo -35.46 120.43 0.18 Allowed 'Trans proline' 0 C--N 1.383 2.366 0 C-N-CA 125.064 3.843 . . . . 0.0 114.236 -175.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 42' ' ' SER . . . 106.5 7.89 33.75 Favored Glycine 0 N--CA 1.422 -2.239 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.827 -176.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -136.1 144.15 44.98 Favored 'General case' 0 C--O 1.242 0.704 0 CA-C-O 121.001 0.429 . . . . 0.0 111.165 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.21 109.78 15.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 172.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.415 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 14.1 m -98.89 110.44 23.05 Favored 'General case' 0 C--N 1.29 -2.02 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 24.1 mt -105.97 136.11 41.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.98 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 34.4 m -136.82 121.1 17.99 Favored 'General case' 0 N--CA 1.412 -2.34 0 CA-C-O 121.348 0.594 . . . . 0.0 109.62 178.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 91.3 m-85 -112.56 108.8 18.02 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 176.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.575 ' HA ' ' O ' ' A' ' 35' ' ' GLY . 37.8 p -133.83 119.05 18.7 Favored 'General case' 0 C--N 1.284 -2.253 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 177.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -118.28 119.75 32.88 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 118.817 -1.153 . . . . 0.0 112.237 -175.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_endo -80.92 -2.64 11.91 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.549 2.833 . . . . 0.0 112.041 178.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.23 16.08 23.55 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.847 0.859 . . . . 0.0 110.308 -173.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.2 pp -59.23 -11.96 4.71 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.01 -25.79 25.77 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.116 0.484 . . . . 0.0 110.204 175.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 82.4 m-20 -96.9 -40.96 8.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.583 -178.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -116.06 101.8 53.9 Favored Pre-proline 0 C--N 1.314 -0.937 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -95.05 120.83 0.29 Allowed 'Trans proline' 0 N--CA 1.429 -2.289 0 C-N-CA 121.402 1.401 . . . . 0.0 113.142 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.623 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 50.9 mt -86.55 89.1 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 170.415 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 6.7 p -124.94 16.09 8.57 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.063 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.9 m -135.11 152.76 33.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.546 ' HB2' ' O ' ' A' ' 27' ' ' ILE . 3.0 p30 -105.11 -178.37 3.63 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 112.655 0.613 . . . . 0.0 112.655 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 148.48 -129.68 3.2 Favored Glycine 0 N--CA 1.422 -2.284 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.8 mm -96.82 136.0 29.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.434 HD21 HG21 ' A' ' 37' ' ' ILE . 58.9 tp -86.73 -53.34 4.99 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.51 160.6 42.56 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.329 -177.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -115.73 118.46 33.1 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 176.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.48 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 37.1 mt -86.17 116.61 24.47 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 -178.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -105.86 108.08 19.42 Favored 'General case' 0 C--O 1.254 1.337 0 CA-C-O 121.321 0.581 . . . . 0.0 110.233 -176.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -117.78 142.92 46.73 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.623 -178.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.2 mt -93.83 129.91 43.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 105.34 -2.096 . . . . 0.0 105.34 170.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 36.7 mt -87.7 126.96 41.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 175.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 43.7 t-20 -64.44 148.68 50.02 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 -176.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.4 t -80.28 -12.17 59.64 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.4 -3.87 58.25 Favored 'General case' 0 CA--C 1.551 1.001 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 176.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -71.86 153.9 41.6 Favored 'General case' 0 CA--C 1.514 -0.433 0 O-C-N 121.774 -0.579 . . . . 0.0 110.943 -178.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 6.4 m -105.47 154.75 19.93 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -77.19 148.29 35.98 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 150.83 160.26 9.29 Favored Glycine 0 N--CA 1.419 -2.493 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -178.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.456 ' OD1' ' HD2' ' A' ' 141' ' ' LYS . 31.5 t70 -76.45 117.3 17.97 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.9 m -126.14 108.59 11.47 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-O 121.266 0.555 . . . . 0.0 110.839 -175.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 142.88 26.8 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.494 179.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.459 HD22 ' HB2' ' A' ' 43' ' ' TYR . 20.1 mt -92.8 156.87 16.72 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 178.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.8 m -122.6 115.68 22.56 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.892 -0.723 . . . . 0.0 109.856 178.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 54.8 t -88.33 118.59 34.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.416 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.6 t70 -63.41 111.92 6.05 Favored Pre-proline 0 C--N 1.323 -0.565 0 O-C-N 124.102 0.876 . . . . 0.0 110.346 -175.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 11.8 Cg_exo -69.67 -21.91 33.22 Favored 'Trans proline' 0 C--N 1.363 1.326 0 C-N-CA 123.052 2.502 . . . . 0.0 113.842 -175.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.14 -34.83 61.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.131 0.491 . . . . 0.0 109.813 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 8.4 m -93.99 9.72 36.41 Favored 'General case' 0 N--CA 1.426 -1.636 0 CA-C-O 121.814 0.816 . . . . 0.0 109.789 178.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 2.3 tt -101.58 116.97 33.95 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 -178.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 87.3 mt -130.94 126.99 60.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -177.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HB ' ' HB3' ' A' ' 134' ' ' LYS . 97.3 t -136.31 101.96 2.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 176.231 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . . . . . . . . . . . -127.18 151.72 48.31 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-N 114.719 -1.128 . . . . 0.0 109.58 -176.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.496 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.0 p-10 -81.85 -169.47 2.37 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.518 -176.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.06 -30.9 69.52 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 122.934 0.493 . . . . 0.0 111.814 176.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -92.43 13.95 18.04 Favored 'General case' 0 CA--C 1.549 0.929 0 CA-C-O 121.054 0.454 . . . . 0.0 109.832 -179.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.3 p30 64.57 20.98 12.33 Favored 'General case' 0 N--CA 1.497 1.921 0 C-N-CA 126.953 2.101 . . . . 0.0 114.767 175.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 53.0 mmtt -90.96 116.89 29.11 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.619 -178.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -74.35 111.92 10.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.04 43.95 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.307 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.645 -171.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.511 ' HB3' ' HB ' ' A' ' 125' ' ' VAL . 25.7 pttm -104.74 133.32 49.77 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 114.583 1.327 . . . . 0.0 114.583 -169.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -95.68 103.61 15.49 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 166.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -116.11 121.36 41.94 Favored 'General case' 0 C--N 1.287 -2.13 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -170.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -129.01 112.63 14.23 Favored 'General case' 0 N--CA 1.42 -1.944 0 N-CA-C 103.176 -2.898 . . . . 0.0 103.176 167.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 50.2 m -142.15 107.15 4.92 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 122.297 1.046 . . . . 0.0 112.475 -172.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.491 ' H ' HG21 ' A' ' 10' ' ' VAL . 9.9 m120 -133.66 -77.52 0.48 Allowed 'General case' 0 N--CA 1.407 -2.618 0 CA-C-N 113.957 -1.474 . . . . 0.0 109.056 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.24 114.29 2.54 Favored Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 107.431 -2.268 . . . . 0.0 107.431 -175.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 113' ' ' ASP . 6.4 ttpm? -122.46 130.67 53.31 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 118.402 -1.319 . . . . 0.0 111.773 -173.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 55.8 mt -115.79 110.68 32.61 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 113' ' ' ASP . 32.0 m -91.18 106.91 18.84 Favored 'General case' 0 C--N 1.279 -2.49 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.031 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 40.5 t -80.1 110.82 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.324 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.1 p -76.91 -43.3 36.15 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 121.484 0.659 . . . . 0.0 110.373 179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 86.7 168.69 45.13 Favored Glycine 0 N--CA 1.422 -2.289 0 CA-C-N 114.915 -1.039 . . . . 0.0 111.812 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.1 m -74.65 -54.89 6.57 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 176.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 39.21 85.46 0.16 Allowed Pre-proline 0 C--N 1.357 0.907 0 C-N-CA 125.376 1.47 . . . . 0.0 113.701 177.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -77.3 39.78 0.77 Allowed 'Trans proline' 0 CA--C 1.549 1.246 0 C-N-CA 122.983 2.455 . . . . 0.0 112.273 -177.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.2 m -91.61 -30.98 16.06 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 123.763 0.825 . . . . 0.0 110.513 -176.538 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.438 -1.068 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.152 -176.414 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.499 -0.947 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 5.8 p -79.52 -31.71 42.21 Favored 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 122.907 0.483 . . . . 0.0 111.288 -178.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . -126.46 94.18 4.0 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 27.0 m -137.74 -0.69 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.342 178.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.5 p -122.75 118.75 56.02 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 178.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt 56.95 97.46 0.02 OUTLIER 'General case' 0 C--O 1.237 0.425 0 C-N-CA 125.504 1.522 . . . . 0.0 112.556 -176.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.405 HD22 ' HA ' ' A' ' 3' ' ' ASN . 13.6 m120 73.01 89.25 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 126.297 1.839 . . . . 0.0 112.308 -176.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -115.76 -163.06 0.87 Allowed 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.586 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.8 m -105.15 124.43 49.52 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 118.561 0.619 . . . . 0.0 109.726 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 92.5 t -99.41 122.22 50.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 121.348 0.594 . . . . 0.0 111.008 -178.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HG2' ' OD1' ' A' ' 135' ' ' ASP . 66.4 mttm -89.68 119.21 29.89 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.692 178.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -93.62 117.04 29.58 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 106.749 -1.575 . . . . 0.0 106.749 171.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.5 m -125.04 154.87 40.64 Favored 'General case' 0 N--CA 1.421 -1.902 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -174.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.463 HG21 ' H ' ' A' ' 139' ' ' ASN . 30.0 m -140.07 163.15 24.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 125.538 1.535 . . . . 0.0 107.212 179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -134.28 -177.56 15.03 Favored Glycine 0 C--N 1.295 -1.738 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.058 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 m -109.95 118.61 36.91 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.663 0.744 . . . . 0.0 109.362 -174.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.51 164.43 9.52 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.565 -177.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.1 m -130.59 158.57 39.63 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -164.29 177.5 39.95 Favored Glycine 0 N--CA 1.434 -1.454 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.7 m-80 -125.54 152.67 72.14 Favored Pre-proline 0 C--N 1.311 -1.091 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.75 113.47 1.99 Allowed 'Trans proline' 0 C--N 1.362 1.255 0 C-N-CA 122.343 2.028 . . . . 0.0 111.343 177.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 115.98 -22.79 11.22 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 -176.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -90.05 158.02 17.52 Favored 'General case' 0 C--N 1.307 -1.24 0 C-N-CA 123.816 0.847 . . . . 0.0 109.939 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.0 m -104.3 129.31 52.16 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.2 p -114.58 132.91 62.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.446 0.641 . . . . 0.0 109.982 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 7.2 ttpm? -110.35 121.46 45.34 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 23.9 t -101.78 113.45 65.84 Favored Pre-proline 0 C--N 1.305 -1.36 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -85.16 121.84 2.42 Favored 'Trans proline' 0 N--CA 1.446 -1.277 0 C-N-CA 122.013 1.809 . . . . 0.0 112.285 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 97.6 t -89.16 118.19 33.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.8 m -102.45 126.73 49.58 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 121.359 0.599 . . . . 0.0 111.307 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.7 tt -103.39 129.91 54.54 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 175.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 42.0 m -138.57 158.64 43.87 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.801 -0.562 . . . . 0.0 111.266 -176.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 15.9 mm100 69.18 15.17 8.66 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.982 1.313 . . . . 0.0 112.589 178.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.23 131.9 36.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.233 -179.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.3 t -135.4 -27.41 1.2 Allowed 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.904 177.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 87.4 m -88.61 136.73 30.86 Favored Pre-proline 0 N--CA 1.435 -1.22 0 C-N-CA 123.265 0.626 . . . . 0.0 109.594 176.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 47.7 Cg_exo -58.3 126.24 20.86 Favored 'Trans proline' 0 C--N 1.361 1.227 0 C-N-CA 122.677 2.252 . . . . 0.0 111.753 176.037 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 8.1 p -87.56 150.01 3.91 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.777 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.856 178.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -114.86 -39.43 0.97 Allowed Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.611 -0.804 . . . . 0.0 113.194 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.575 ' O ' ' HA ' ' A' ' 125' ' ' VAL . 77.5 mt -129.06 112.81 14.39 Favored 'General case' 0 C--O 1.203 -1.38 0 O-C-N 122.259 -0.553 . . . . 0.0 112.353 -176.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 47.5 mt -115.3 120.95 66.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.426 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 47.7 t -132.21 133.36 44.09 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 23.9 ptm -156.89 137.94 13.57 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -118.89 116.59 26.81 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 53.0 mt -100.25 123.94 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.769 -175.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 10.8 m -109.06 128.12 54.71 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.5 p90 -137.86 169.1 18.37 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 120.681 0.277 . . . . 0.0 110.509 -176.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -87.23 104.8 16.72 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.8 -10.46 59.39 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -171.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 p -87.53 -18.32 30.06 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 121.744 0.783 . . . . 0.0 110.082 177.074 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 38.9 ttmt -104.6 -44.66 4.83 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.645 -177.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -118.62 152.41 36.1 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 78.7 m -138.42 119.44 14.42 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 174.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.8 p -76.04 140.05 17.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-O 121.295 0.569 . . . . 0.0 110.926 -177.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.1 mtpt -85.67 -61.92 1.65 Allowed 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 174.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -171.75 173.49 4.56 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.106 -1.813 . . . . 0.0 106.106 176.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 30.5 m -110.13 125.46 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.845 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.453 ' HB2' ' HB2' ' A' ' 100' ' ' TYR . 62.6 mt -85.34 113.32 49.93 Favored Pre-proline 0 C--N 1.294 -1.809 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -177.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -79.03 134.36 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.419 0 C-N-CA 121.672 1.582 . . . . 0.0 110.727 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 25.0 t30 -70.59 115.09 9.35 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 176.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 15.4 p -64.33 -11.57 33.55 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 125.7 1.6 . . . . 0.0 113.807 -173.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -80.7 -35.28 33.81 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.436 0.636 . . . . 0.0 109.743 178.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 61' ' ' LYS . 82.5 mt -100.2 -56.86 2.25 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.213 -178.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 23.5 t -82.95 112.69 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.539 ' HZ1' HG13 ' A' ' 92' ' ' ILE . 0.0 OUTLIER -134.57 164.31 27.77 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.415 -171.774 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 52.78 33.88 15.11 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 124.589 1.181 . . . . 0.0 109.716 174.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 p -49.39 -44.89 45.38 Favored 'General case' 0 C--O 1.247 0.927 0 C-N-CA 127.015 2.126 . . . . 0.0 115.137 -169.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -59.68 -29.75 68.29 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 124.25 0.969 . . . . 0.0 112.741 -177.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -89.37 28.4 1.26 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.756 0.788 . . . . 0.0 110.829 -177.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . 0.445 74.3 m-85 70.66 54.41 0.28 Allowed 'General case' 0 N--CA 1.427 -1.623 0 N-CA-C 116.32 1.97 . . . . 0.0 116.32 176.083 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.4 t -105.19 -20.32 13.54 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 168.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -110.56 106.36 15.62 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.444 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.5 mp -123.26 107.8 19.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 175.7 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 97.6 t -131.08 118.55 41.65 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 177.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -108.4 122.78 47.72 Favored 'General case' 0 C--N 1.29 -2.006 0 N-CA-C 107.491 -1.299 . . . . 0.0 107.491 176.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 6.7 m -77.19 99.04 5.29 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 177.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 15.2 t -74.82 174.84 8.64 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 115.022 -0.99 . . . . 0.0 111.028 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.1 m -48.44 135.55 12.7 Favored Pre-proline 0 CA--C 1.551 1.0 0 C-N-CA 125.841 1.656 . . . . 0.0 108.789 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -33.96 113.0 0.07 OUTLIER 'Trans proline' 0 C--N 1.389 2.667 0 C-N-CA 125.252 3.968 . . . . 0.0 114.549 -171.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.48 9.45 31.14 Favored Glycine 0 N--CA 1.429 -1.767 0 CA-C-N 114.496 -1.229 . . . . 0.0 112.982 -178.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 59.6 mttm -141.02 149.45 41.74 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 117.419 0.609 . . . . 0.0 112.35 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 24.4 mt -135.31 112.37 14.16 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.8 m -96.89 111.26 23.54 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 64.2 mt -112.28 136.73 47.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.622 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 33.0 m -140.69 119.34 12.41 Favored 'General case' 0 N--CA 1.419 -2.0 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 174.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -110.65 112.08 23.73 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 175.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 38.0 p -106.91 133.97 50.76 Favored 'General case' 0 C--N 1.276 -2.623 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -110.37 94.73 19.59 Favored Pre-proline 0 C--N 1.297 -1.679 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -84.85 -7.79 9.34 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.188 1.925 . . . . 0.0 111.786 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 1.3 m -122.46 33.01 5.57 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 -170.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.3 pp -63.41 -17.01 62.2 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 114.217 1.192 . . . . 0.0 114.217 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -79.94 -42.23 24.46 Favored 'General case' 0 N--CA 1.441 -0.922 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.529 177.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 31.5 m-80 -83.98 -41.36 17.38 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 120.954 0.407 . . . . 0.0 111.859 179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.452 ' HB2' ' HZ2' ' A' ' 61' ' ' LYS . 6.5 m-85 -123.19 102.56 36.94 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 175.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -92.77 117.21 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 121.068 1.179 . . . . 0.0 113.303 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.539 HG13 ' HZ1' ' A' ' 61' ' ' LYS . 62.6 mt -74.25 99.87 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 171.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.6 p -151.49 14.61 0.67 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 -172.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 28.8 m -117.66 151.72 19.62 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -85.52 145.86 27.19 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 121.164 0.507 . . . . 0.0 111.019 -179.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 162.17 -148.84 16.5 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -178.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.73 134.81 29.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 60.4 tp -85.79 -52.95 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 177.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -150.49 152.94 34.99 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.54 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . 0.453 ' HB2' ' HB2' ' A' ' 54' ' ' LEU . 90.7 m-85 -108.46 121.79 45.68 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 26.0 mt -90.61 113.02 24.95 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -102.94 106.43 16.97 Favored 'General case' 0 C--O 1.255 1.344 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.646 -175.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -111.96 134.15 53.69 Favored 'General case' 0 CA--C 1.504 -0.806 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.724 -176.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.6 mt -88.64 128.09 41.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 172.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 34.7 mt -86.12 125.35 40.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -69.79 157.66 36.93 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.0 m -76.75 -13.76 60.0 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.887 0.851 . . . . 0.0 109.212 175.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -91.15 3.91 53.59 Favored 'General case' 0 CA--C 1.551 0.993 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.389 178.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -86.66 152.2 22.77 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.955 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 5.3 m -117.42 156.88 27.18 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -70.41 158.55 35.8 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 121.14 0.495 . . . . 0.0 112.145 -178.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 136.2 168.06 11.39 Favored Glycine 0 N--CA 1.442 -0.957 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.763 178.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -74.26 126.14 29.98 Favored 'General case' 0 N--CA 1.438 -1.042 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 14.3 m -129.28 113.54 15.13 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -177.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.27 138.28 31.79 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.44 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 40.5 mt -94.01 113.54 25.55 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 173.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 m -88.82 108.86 19.75 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -175.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 46.4 t -89.66 120.26 38.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 175.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.402 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 19.9 t70 -64.74 114.0 12.99 Favored Pre-proline 0 C--N 1.315 -0.929 0 O-C-N 124.059 0.849 . . . . 0.0 110.666 -176.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 2.9 Cg_exo -73.55 -15.43 24.6 Favored 'Trans proline' 0 C--N 1.357 1.01 0 C-N-CA 122.558 2.172 . . . . 0.0 113.339 -176.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -77.9 -38.8 44.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.949 0.404 . . . . 0.0 110.355 -178.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.0 p -95.24 2.55 54.91 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.585 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.8 tt -84.6 108.35 17.3 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 105.69 -1.967 . . . . 0.0 105.69 174.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 60.7 mt -131.09 135.8 59.14 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -174.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.578 ' CG1' ' HB3' ' A' ' 134' ' ' LYS . 9.3 p -144.09 109.16 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.599 0 CA-C-O 122.32 1.057 . . . . 0.0 110.709 174.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -106.67 140.6 39.28 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 114.355 -1.293 . . . . 0.0 110.118 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -79.17 -169.3 1.79 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 123.912 0.885 . . . . 0.0 110.808 -177.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -60.72 -30.69 70.13 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 123.38 0.672 . . . . 0.0 111.558 177.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 15.4 t30 -93.49 13.38 21.95 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.95 0.881 . . . . 0.0 110.021 178.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 12.7 t70 72.9 11.46 5.29 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 169.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HA ' ' HE3' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -100.22 154.18 18.67 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.473 -1.392 . . . . 0.0 110.675 -176.754 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.425 ' OD2' ' HG2' ' A' ' 134' ' ' LYS . 13.8 t70 -82.83 115.15 21.6 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.567 0.699 . . . . 0.0 110.46 -176.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . . . . . . . . . 1.2 mp -112.73 18.8 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.597 2.761 0 CA-C-O 122.109 0.956 . . . . 0.0 113.35 -169.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.578 ' HB3' ' CG1' ' A' ' 125' ' ' VAL . 24.9 pttm -104.97 133.27 50.03 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 116.774 2.139 . . . . 0.0 116.774 -167.445 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.419 ' OD1' ' HG2' ' A' ' 7' ' ' LYS . 2.7 p-10 -98.55 103.86 15.84 Favored 'General case' 0 C--O 1.254 1.319 0 N-CA-C 104.428 -2.434 . . . . 0.0 104.428 153.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . . . . . . . . . . . -111.17 133.68 53.34 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -170.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -141.63 113.55 7.92 Favored 'General case' 0 N--CA 1.432 -1.334 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 172.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 66.9 m -139.89 105.85 5.2 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-O 122.762 1.268 . . . . 0.0 112.4 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.463 ' H ' HG21 ' A' ' 10' ' ' VAL . 24.8 t-20 -143.59 93.04 2.42 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 176.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.44 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -78.02 101.95 1.75 Allowed Glycine 0 CA--C 1.49 -1.513 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -175.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -94.31 128.84 41.06 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 118.986 -1.086 . . . . 0.0 111.383 -177.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 60.6 mt -112.25 128.05 69.1 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 114.495 -1.229 . . . . 0.0 108.005 -179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.3 m -94.14 105.88 17.87 Favored 'General case' 0 C--N 1.275 -2.662 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 177.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 43.8 t -82.26 115.16 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 26.8 p -108.56 146.99 32.42 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.451 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -179.16 154.52 14.12 Favored Glycine 0 N--CA 1.429 -1.805 0 C-N-CA 119.576 -1.297 . . . . 0.0 112.827 178.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.9 t -126.75 13.35 7.43 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 176.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . 61.95 104.69 0.03 OUTLIER Pre-proline 0 C--N 1.356 0.863 0 C-N-CA 125.217 1.407 . . . . 0.0 111.879 -178.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_endo -59.24 -25.88 79.79 Favored 'Trans proline' 0 C--N 1.372 1.804 0 C-N-CA 122.929 2.42 . . . . 0.0 112.723 -178.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 25.4 m -129.63 -80.99 0.56 Allowed 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.556 -1.275 . . . . 0.0 107.556 174.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 73.1 m . . . . . 0 C--N 1.312 -1.045 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 176.293 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -3' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.5 -0.859 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -2' ' ' SER . . . . . . . . . . . . . 22.5 t -127.72 65.97 1.34 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.113 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' -1' ' ' ALA . . . . . . . . . . . . . . . 56.82 45.02 22.35 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -176.024 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 0' ' ' SER . . . . . . . . . . . . . 15.1 m -42.72 -58.36 2.36 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 125.986 1.714 . . . . 0.0 111.645 -174.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.4 m -112.53 -46.76 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.443 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.95 172.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.545 ' HG2' ' H ' ' A' ' 3' ' ' ASN . 38.6 tttt 53.71 -165.45 0.09 Allowed 'General case' 0 CA--C 1.555 1.152 0 C-N-CA 125.684 1.594 . . . . 0.0 108.049 -177.5 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.576 ' ND2' ' HB2' ' A' ' 131' ' ' LYS . 17.7 m120 50.4 91.29 0.02 OUTLIER 'General case' 0 C--O 1.243 0.738 0 N-CA-C 116.185 1.92 . . . . 0.0 116.185 164.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.42 147.73 22.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 11.9 t -73.19 107.59 5.6 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-O 122.389 1.09 . . . . 0.0 111.394 -177.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 134' ' ' LYS . 58.9 t -75.79 133.58 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 CA-C-N 113.849 -1.523 . . . . 0.0 109.837 -177.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -88.72 124.17 33.86 Favored 'General case' 0 C--N 1.289 -2.051 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.636 -178.206 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 29.4 tp -110.55 111.77 23.22 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 24.6 t -121.53 146.07 47.32 Favored 'General case' 0 N--CA 1.417 -2.114 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.703 -170.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.6 m -115.6 163.27 13.0 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.07 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.763 179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -133.14 171.68 21.73 Favored Glycine 0 N--CA 1.416 -2.659 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.414 HG23 ' HB3' ' A' ' 141' ' ' LYS . 33.9 m -111.04 132.26 54.38 Favored 'General case' 0 C--N 1.279 -2.476 0 CA-C-O 121.144 0.497 . . . . 0.0 110.676 -173.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.6 m -123.47 164.34 21.36 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 CA-C-N 115.268 -0.878 . . . . 0.0 108.881 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.9 p -115.28 146.57 41.35 Favored 'General case' 0 N--CA 1.411 -2.408 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 175.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 144' ' ' VAL . . . -142.5 159.88 27.26 Favored Glycine 0 N--CA 1.419 -2.453 0 C-N-CA 120.289 -0.958 . . . . 0.0 111.956 -178.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.41 ' HB3' ' OG ' ' A' ' 147' ' ' SER . 42.5 m-80 -128.25 146.25 58.83 Favored Pre-proline 0 C--N 1.295 -1.784 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -60.24 116.17 3.14 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.809 2.339 . . . . 0.0 112.097 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.97 -26.49 9.28 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 -178.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -90.33 154.07 19.97 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 -179.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -99.65 126.48 45.67 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 177.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.1 p -109.44 155.25 10.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -174.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 101' ' ' LEU . 38.1 ttpt -130.05 119.44 23.12 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.21 -177.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.8 t -101.93 117.74 60.87 Favored Pre-proline 0 C--N 1.314 -0.939 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -179.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -86.46 122.33 2.04 Favored 'Trans proline' 0 CA--C 1.547 1.157 0 C-N-CA 122.127 1.884 . . . . 0.0 112.831 178.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 61.4 t -90.65 113.09 25.96 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.915 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 176.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.0 m -96.88 141.22 30.33 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 121.048 0.451 . . . . 0.0 110.691 -173.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.6 tt -127.95 129.55 69.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.9 m -141.46 164.9 28.99 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 111.614 0.228 . . . . 0.0 111.614 -174.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 69.36 15.4 8.44 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 125.621 1.569 . . . . 0.0 113.926 174.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.448 ' HB ' HG13 ' A' ' 6' ' ' VAL . 6.8 p -84.14 135.78 24.12 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.691 -177.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 67.0 m -131.8 -36.49 1.21 Allowed 'General case' 0 N--CA 1.422 -1.828 0 C-N-CA 123.295 0.638 . . . . 0.0 110.247 173.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.517 HG23 ' HE2' ' A' ' 2' ' ' LYS . 27.6 m -77.07 128.52 80.89 Favored Pre-proline 0 N--CA 1.435 -1.181 0 N-CA-C 107.2 -1.408 . . . . 0.0 107.2 175.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 92' ' ' ILE . 29.2 Cg_endo -66.71 122.48 9.88 Favored 'Trans proline' 0 N--CA 1.452 -0.966 0 C-N-CA 120.648 0.899 . . . . 0.0 113.131 -175.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 127' ' ' ASP . 11.7 p -89.0 141.59 14.06 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 CA-C-N 114.384 -1.28 . . . . 0.0 109.286 179.041 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.75 -1.4 1.01 Allowed Glycine 0 C--N 1.306 -1.113 0 C-N-CA 119.874 -1.155 . . . . 0.0 112.51 177.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.2 mt -128.83 112.53 14.24 Favored 'General case' 0 CA--C 1.498 -1.023 0 CA-C-O 120.876 0.369 . . . . 0.0 110.024 -177.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 82' ' ' PHE . 4.2 mp -134.04 133.58 55.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 123' ' ' LEU . 42.8 t -138.49 141.36 39.41 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 21.7 ptp -157.75 155.2 29.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.127 0.489 . . . . 0.0 111.5 178.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 118' ' ' VAL . 5.8 t70 -122.02 114.8 21.45 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 177.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 77' ' ' LYS . 2.9 mp -100.77 108.55 23.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 -177.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.9 m -101.91 112.26 24.81 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 55.7 p90 -124.61 178.12 5.6 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.579 -176.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -76.35 119.44 20.23 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -72.75 -25.33 61.16 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.494 0.924 . . . . 0.0 113.494 -172.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 11.2 t -93.98 -28.93 15.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.517 -0.473 . . . . 0.0 110.745 -176.066 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -83.05 -42.98 16.83 Favored 'General case' 0 CA--C 1.507 -0.704 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.738 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -115.89 141.91 47.48 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.656 -0.818 . . . . 0.0 111.639 -172.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 23.2 m -130.91 110.12 11.05 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.0 p -80.76 132.44 31.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 9.7 mtmp? -88.47 -57.29 2.97 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 172.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.511 ' O ' ' HB3' ' A' ' 102' ' ' ASP . 6.5 p-10 -163.49 177.67 8.66 Favored 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 114.208 -1.36 . . . . 0.0 107.823 -173.233 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.2 m -127.37 144.44 37.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . . . . . . . . . 66.6 mt -98.86 111.45 60.58 Favored Pre-proline 0 C--N 1.294 -1.827 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -177.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -83.07 142.34 10.91 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 122.365 2.043 . . . . 0.0 111.799 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 21.1 t30 -82.34 116.45 21.84 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 120.948 0.404 . . . . 0.0 109.928 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 p -71.01 -17.5 62.63 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 124.429 1.092 . . . . 0.0 113.254 -176.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -68.85 -29.04 67.27 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.784 0.802 . . . . 0.0 109.072 176.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.454 ' O ' HG12 ' A' ' 92' ' ' ILE . 60.2 mt -98.97 -60.72 1.48 Allowed 'General case' 0 N--CA 1.427 -1.598 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.909 179.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 29.2 t -88.0 123.76 40.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.7 mptt -104.17 136.5 43.67 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 120.759 -0.377 . . . . 0.0 111.082 -178.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.8 t70 42.33 84.14 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 126.37 1.868 . . . . 0.0 113.69 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 23.6 p -67.02 -33.38 75.41 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.809 -174.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -67.8 -29.86 69.15 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -174.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 21.7 m-80 -78.61 30.39 0.19 Allowed 'General case' 0 N--CA 1.481 1.076 0 N-CA-C 114.938 1.459 . . . . 0.0 114.938 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 44.4 t80 78.48 28.84 0.45 Allowed 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 125.222 1.409 . . . . 0.0 111.074 173.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 83' ' ' THR . 30.9 t -88.47 -31.74 18.6 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 173.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 90.5 t80 -103.7 106.54 17.07 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.454 -1.248 . . . . 0.0 110.03 -178.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.83 107.13 20.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 83.8 t -126.43 110.06 22.62 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 176.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 79' ' ' SER . 6.3 t30 -100.44 111.61 23.89 Favored 'General case' 0 C--N 1.27 -2.872 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.758 -178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.9 m -74.47 105.24 5.51 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 178.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.8 t -86.47 176.51 7.81 Favored 'General case' 0 N--CA 1.423 -1.815 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.414 -175.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.9 m -48.08 135.87 11.52 Favored Pre-proline 0 CA--C 1.555 1.167 0 C-N-CA 124.907 1.283 . . . . 0.0 109.54 176.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -35.67 122.92 0.25 Allowed 'Trans proline' 0 C--N 1.384 2.444 0 C-N-CA 124.772 3.648 . . . . 0.0 113.923 -176.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 106.33 -11.75 43.64 Favored Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 115.02 -0.991 . . . . 0.0 112.87 -176.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 41' ' ' ILE . 56.1 mttm -132.23 148.34 52.45 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 113.591 0.96 . . . . 0.0 113.591 178.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 10.9 mt -131.19 130.85 63.68 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 172.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 71' ' ' ASN . 8.0 m -106.51 111.27 23.75 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 56.6 mt -116.64 129.99 72.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 C-N-CA 120.561 -0.455 . . . . 0.0 111.069 -177.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 28.0 m -134.01 124.81 26.9 Favored 'General case' 0 N--CA 1.421 -1.876 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 176.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' ILE . 87.3 m-85 -113.42 108.89 17.82 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 174.347 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.585 ' O ' ' HA ' ' A' ' 67' ' ' SER . 19.9 p -119.27 116.58 26.54 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 173.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -103.22 116.27 62.55 Favored Pre-proline 0 C--N 1.292 -1.893 0 C-N-CA 119.692 -0.803 . . . . 0.0 111.656 -173.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -83.87 -3.8 10.51 Favored 'Trans proline' 0 N--CA 1.441 -1.589 0 C-N-CA 122.331 2.021 . . . . 0.0 111.643 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -96.98 -3.09 42.23 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.614 -173.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 3.1 pp -52.14 -27.88 15.92 Favored 'General case' 0 N--CA 1.481 1.096 0 N-CA-C 116.438 2.014 . . . . 0.0 116.438 -173.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -80.65 -28.55 36.85 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 120.69 -0.404 . . . . 0.0 110.471 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -90.1 -41.27 11.76 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.58 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -136.03 106.97 9.6 Favored Pre-proline 0 C--N 1.312 -1.043 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -81.0 162.96 20.57 Favored 'Trans proline' 0 N--CA 1.45 -1.043 0 C-N-CA 121.569 1.513 . . . . 0.0 112.696 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 33' ' ' PRO . 17.5 mt -111.2 90.46 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 N-CA-C 105.951 -1.87 . . . . 0.0 105.951 170.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 44.4 p -131.69 15.81 4.85 Favored 'General case' 0 C--N 1.297 -1.685 0 CA-C-O 121.81 0.814 . . . . 0.0 110.331 -177.108 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 23.2 m -118.43 158.06 19.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.025 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -95.61 176.53 6.13 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -175.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 144.74 -147.85 19.29 Favored Glycine 0 N--CA 1.44 -1.071 0 N-CA-C 110.521 -1.032 . . . . 0.0 110.521 178.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.1 mp -99.58 135.14 36.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 176.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 57.6 tp -77.54 -55.92 4.96 Favored 'General case' 0 C--N 1.31 -1.127 0 CA-C-O 121.288 0.566 . . . . 0.0 109.581 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -153.5 153.38 32.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.633 179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' TYR . . . . . . . . . . . . . 82.0 m-85 -105.62 121.64 44.41 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 22' ' ' LYS . 61.1 mt -86.29 118.79 25.96 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.511 ' HB3' ' O ' ' A' ' 52' ' ' ASP . 16.1 t70 -96.54 114.52 26.19 Favored 'General case' 0 C--N 1.322 -0.593 0 O-C-N 123.345 0.403 . . . . 0.0 111.073 -178.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -125.64 120.14 29.94 Favored 'General case' 0 CA--C 1.503 -0.853 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.417 -179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.2 mt -81.27 120.85 33.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 173.462 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 51.8 mt -84.66 123.0 38.76 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.557 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.58 144.44 56.98 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 124.279 1.032 . . . . 0.0 109.872 -179.484 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.0 m -69.05 -15.99 63.59 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 123.17 0.588 . . . . 0.0 111.05 -179.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -100.97 19.15 17.9 Favored 'General case' 0 CA--C 1.552 1.024 0 CA-C-O 122.116 0.96 . . . . 0.0 110.14 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . . . . . . . . . . . -81.7 144.11 31.39 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 176.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.0 t -90.83 160.43 15.75 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.983 -0.687 . . . . 0.0 109.166 175.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -81.07 157.19 25.49 Favored 'General case' 0 C--N 1.288 -2.093 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.684 -177.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 132.15 168.41 12.06 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.554 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.457 ' OD2' ' HD3' ' A' ' 141' ' ' LYS . 8.0 m-20 -77.24 116.49 17.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 12.3 m -116.14 112.65 22.0 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -93.06 145.34 24.46 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.812 -178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 140' ' ' GLY . 50.5 mt -92.76 118.76 31.42 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 175.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.0 m -92.07 104.3 16.71 Favored 'General case' 0 C--N 1.292 -1.907 0 CA-C-O 120.863 0.363 . . . . 0.0 110.194 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 40' ' ' ASP . 87.6 t -97.07 120.66 46.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 177.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ASP . . . . . 0.436 ' HA ' ' HD3' ' A' ' 120' ' ' PRO . 17.8 t70 -61.81 118.59 39.88 Favored Pre-proline 0 N--CA 1.467 0.416 0 O-C-N 124.124 0.89 . . . . 0.0 111.363 -177.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 119' ' ' ASP . 22.6 Cg_exo -66.09 -29.17 48.38 Favored 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.244 2.629 . . . . 0.0 114.149 -177.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -75.16 -37.2 61.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.152 0.501 . . . . 0.0 110.436 -176.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.7 m -82.34 -12.31 58.05 Favored 'General case' 0 N--CA 1.421 -1.888 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.788 178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' CYS . 3.3 tt -85.66 108.69 18.13 Favored 'General case' 0 N--CA 1.439 -1.015 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 -179.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 67.1 mt -124.52 131.06 73.28 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 -179.093 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.6 t -130.19 97.83 3.5 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 175.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 131' ' ' LYS . . . -119.97 150.1 41.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.471 -174.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 5.7 p-10 -90.77 -166.61 1.62 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.428 -179.036 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -76.45 -1.05 25.18 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -106.25 12.26 30.23 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 171.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 p30 53.34 24.84 4.09 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 127.235 2.214 . . . . 0.0 114.716 178.013 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.576 ' HB2' ' ND2' ' A' ' 3' ' ' ASN . 75.7 mmtt -89.98 123.9 34.28 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.99 -0.444 . . . . 0.0 109.999 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -71.3 115.23 10.21 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.817 0.698 . . . . 0.0 109.582 178.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ILE . . . . . 0.498 HG21 ' HB3' ' A' ' 3' ' ' ASN . 6.9 pt -131.22 81.82 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.358 -175.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 2.3 pptp? -150.53 131.15 13.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.44 1.645 . . . . 0.0 115.44 -178.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -95.32 102.71 14.54 Favored 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 102.134 -3.284 . . . . 0.0 102.134 165.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ALA . . . . . 0.403 ' HB3' ' HD3' ' A' ' 134' ' ' LYS . . . -132.42 131.94 42.29 Favored 'General case' 0 C--N 1.28 -2.437 0 C-N-CA 119.161 -1.016 . . . . 0.0 112.016 -174.033 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -140.75 113.66 8.34 Favored 'General case' 0 C--N 1.278 -2.539 0 N-CA-C 106.603 -1.628 . . . . 0.0 106.603 173.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.455 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 47.6 t -123.37 105.99 10.29 Favored 'General case' 0 N--CA 1.398 -3.034 0 CA-C-O 122.408 1.099 . . . . 0.0 111.016 -178.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -133.22 40.74 3.17 Favored 'General case' 0 N--CA 1.414 -2.258 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 175.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.521 ' O ' ' HG ' ' A' ' 116' ' ' LEU . . . -42.27 110.06 0.23 Allowed Glycine 0 C--N 1.366 2.225 0 O-C-N 125.378 1.674 . . . . 0.0 111.916 -176.263 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' LYS . . . . . 0.457 ' HD3' ' OD2' ' A' ' 113' ' ' ASP . 34.1 ttmt -98.5 129.81 45.08 Favored 'General case' 0 C--N 1.286 -2.177 0 CA-C-O 121.388 0.613 . . . . 0.0 112.009 -169.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . . . . . . . . . 58.8 mt -111.65 105.83 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.339 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 173.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 58.0 m -84.64 105.97 15.84 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 15' ' ' GLY . 47.2 t -80.44 112.19 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 178.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 3.9 p -82.63 -55.68 4.31 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.993 -178.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 114.44 127.43 4.42 Favored Glycine 0 N--CA 1.429 -1.822 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.39 176.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 16' ' ' ASN . 19.2 m -90.98 13.57 16.28 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.208 0.527 . . . . 0.0 110.462 179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -104.79 122.14 44.42 Favored Pre-proline 0 N--CA 1.433 -1.306 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.08 140.09 27.74 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.836 2.357 . . . . 0.0 113.591 -177.042 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.1 p -80.89 -46.51 15.14 Favored 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' SER . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 175.118 . . . . . . . . 0 0 . 1 stop_ save_